

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>7</sup> :</b> <b>C07D 471/04, 401/14, A61K 31/4439, 31/444</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 00/43393</b> <b>(43) International Publication Date:</b> 27 July 2000 (27.07.00)
<b>(21) International Application Number:</b> PCT/US00/01006 <b>(22) International Filing Date:</b> 14 January 2000 (14.01.00)  <b>(30) Priority Data:</b> 60/116,596 20 January 1999 (20.01.99) US  <b>(71) Applicant (for all designated States except US):</b> MERCK & CO., INC. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065-0907 (US).  <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> FRALEY, Mark, E. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065-0907 (US). HUNGATE, Randall, W. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065-0907 (US). TEBBEN, Andrew, J. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065-0907 (US).  <b>(74) Common Representative:</b> MERCK & CO., INC.; 126 East Lincoln Avenue, Rahway, NJ 07065-0907 (US).		<b>(81) Designated States:</b> AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i>
<b>(54) Title:</b> NOVEL ANGIOGENESIS INHIBITORS  <b>(57) Abstract</b>  The present invention relates to compounds which inhibit tyrosine kinase enzymes, compositions which contain tyrosine kinase inhibiting compounds and methods of using tyrosine kinase inhibitors to treat tyrosine kinase-dependent diseases and conditions such as angiogenesis, cancer, atherosclerosis, diabetic retinopathy, and the like in mammals.		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

TITLE OF THE INVENTION

## NOVEL ANGIOGENESIS INHIBITORS

BACKGROUND OF THE INVENTION

5           The present invention relates to compounds which inhibit tyrosine kinase enzymes, compositions which contain tyrosine kinase inhibiting compounds and methods of using tyrosine kinase inhibitors to treat tyrosine kinase-dependent diseases and conditions such as neoangiogenesis, cancer, tumor growth, atherosclerosis, age related  
10   macular degeneration, diabetic retinopathy, inflammatory diseases, and the like in mammals.

          Aberrant vascularization is a key component in numerous disease states. For example, vascularization is a critical element of most solid tumors, such as cancers of the brain, genitourinary tract,  
15   lymphatic system, stomach, larynx and lung. These include histiocytic lymphoma, lung adenocarcinoma and small cell lung cancers. Additional examples include cancers in which overexpression or activation of Raf-activating oncogenes (e.g., K-ras, erb-B) is observed. More particularly, such cancers include pancreatic and breast  
20   carcinoma. Similarly, aberrant vascular growth in the retina can lead to visual degeneration which can culminate in blindness.

          Experimental evidence suggests that the growth factor VEGF plays a critical role in angiogenesis. Vascular endothelial growth factor (VEGF) binds the high affinity membrane-spanning  
25   tyrosine kinase receptors KDR and Flt-1. Cell culture and gene knockout experiments indicate that each receptor contributes to different aspects of angiogenesis. KDR mediates the mitogenic function of VEGF whereas Flt-1 appears to modulate non-mitogenic functions such as those associated with cellular adhesion. Inhibiting KDR thus modulates  
30   the level of mitogenic VEGF activity and would therefore disrupt angiogenesis, providing a treatment for angiogenesis-mediated

diseases, such as tumor proliferation, diabetic retinopathy, macular degeneration, inflammation, and the like.

VEGF accounts for most of the angiogenic activity produced in or near the retina in diabetic retinopathy. Ocular VEGF mRNA and protein are elevated by conditions such as retinal vein occlusion in  
5 primates and decreased  $pO_2$  levels in mice that lead to neovascularization. Intraocular injections of anti-VEGF monoclonal antibodies or VEGF receptor immunofusions inhibit ocular neovascularization in both primate and rodent models. Regardless of the cause of induction  
10 of VEGF in human diabetic retinopathy, inhibition of ocular VEGF is useful in treating the disease.

Expression of VEGF is also significantly increased in hypoxic regions of animal and human tumors adjacent to areas of necrosis. VEGF is also upregulated by the expression of the oncogenes  
15 ras, raf, src and mutant p53 (all of which are relevant to targeting cancer). Monoclonal anti-VEGF antibodies inhibit the growth of human tumors in nude mice. Although these same tumor cells continue to express VEGF in culture, the antibodies do not diminish their mitotic rate. Thus, tumor-derived VEGF does not function as  
20 an autocrine mitogenic factor. Therefore, VEGF contributes to tumor growth in vivo by promoting angiogenesis through its paracrine vascular endothelial cell chemotactic and mitogenic activities. These monoclonal antibodies also inhibit the growth of typically less well vascularized human colon cancers in athymic mice and decrease the  
25 number of tumors arising from inoculated cells. Viral expression of a VEGF-binding construct of Flk-1, Flt-1, the mouse KDR receptor homologue, truncated to eliminate the cytoplasmic tyrosine kinase domains but retaining a membrane anchor, virtually abolishes the growth of a transplantable glioblastoma in mice presumably by the  
30 dominant negative mechanism of heterodimer formation with membrane spanning endothelial cell VEGF receptors. Embryonic


stem cells, which normally grow as solid tumors in nude mice, do not produce detectable tumors if both VEGF alleles are knocked out. Taken together, these data indicate the role of VEGF in the growth of solid tumors.

5 Known heterocyclic kinase inhibitors are limited due to poor physical properties, pharmacokinetics, and selectivity against related kinases. The compounds of the instant invention represent novel structures which are unique and offer advantages over known KDR kinase inhibitors.

10

### SUMMARY OF THE INVENTION


The present invention relates to compounds of Formula I which inhibit tyrosine kinase enzymes, compositions which contain these tyrosine kinase inhibiting compounds and methods of using the disclosed tyrosine kinase inhibitors to treat tyrosine kinase-dependent  
15 diseases and conditions such as angiogenesis, cancer, atherosclerosis, diabetic retinopathy, and the like in mammals.



20

### DETAILED DESCRIPTION OF THE INVENTION

An embodiment of the present invention is a compound in  
25 accordance with formula I:



or a pharmaceutically acceptable salt or hydrate thereof,

5

wherein

W, X, Y and Z are independently CH or N;

10  $R^1$  is H,  $C_{1-10}$  alkyl,  $C_{3-6}$  cycloalkyl, aryl, halo,  $CF_3$ , heterocyclyl, said alkyl, aryl, and heterocyclyl optionally substituted with one to three substituents selected from  $R^a$ ;

15  $R^2$  is H,  $C_{1-6}$  alkyl, aryl, heteroaryl, or  $C_{3-6}$  cycloalkyl, said alkyl, aryl, heteroaryl or cycloalkyl optionally substituted with one to three substituents selected from  $R^a$ ;

20  $R^3$  is H, halo, CN,  $-C_{1-6}$  alkylene- $CO_2R$ ,  $C_{1-6}$  alkoxy,  $-C_{1-6}$  alkylene-O- $C_{1-6}$  alkyl,  $C_{1-6}$  alkyl, aryl, heteroaryl,  $C_{3-6}$  cycloalkyl or  $CO_2R$ , said alkyl, aryl, heteroaryl and cycloalkyl optionally substituted with one to three substituents selected from  $R^a$ ;

25  $R^a$  is  $C_{1-10}$  alkyl, halogen,  $CF_3$ ,  $NO_2$ , OR,  $NR^7R^8$ , aryl, heterocyclyl, said alkyl, aryl, and heterocyclyl optionally substituted with one or two substituents selected from  $NO_2$ , CN, halo, aryl,  $C_{1-6}$  alkoxy,  $-C_{1-6}$  alkylene-O- $C_{1-6}$  alkyl,  $C_{1-6}$  alkyl, and  $CF_3$ ;

R is H, or C<sub>1-6</sub> alkyl; and

R<sup>7</sup> and R<sup>8</sup> are independently H, C<sub>1-10</sub> alkyl, C<sub>3-6</sub> cycloalkyl, COR,  
-C<sub>1-6</sub> alkylene-O-C<sub>1-6</sub> alkyl, C<sub>1-6</sub> alkoxy, -C<sub>1-6</sub> alkylene-  
5 aryl, COOR, aryl, benzyl, or heterocyclyl,

or NR<sup>7</sup>R<sup>8</sup> are taken together to form a 5-10 membered  
saturated or unsaturated heterocyclic ring  
containing, in addition to the nitrogen atom attached  
10 to R<sup>7</sup> and R<sup>8</sup>, one or two additional heteroatoms  
selected from N, O, and S, said heterocyclic ring  
optionally substituted with CN, halo, or C<sub>1-6</sub> alkyl.

A second embodiment of the present invention is a  
15 compound of formula I, wherein

W is C-H or N;

X, Y and Z are CH or N, provided only one of X, Y and Z is N;

20 R<sup>1</sup> is H, C<sub>1-10</sub> alkyl, C<sub>3-6</sub> cycloalkyl, aryl, halo, CF<sub>3</sub>, or  
heterocyclyl, said alkyl, cycloalkyl aryl, and heterocyclyl  
are optionally substituted with one to three substituents  
selected from R<sup>a</sup>;

25 R<sup>2</sup> is H, C<sub>1-6</sub> alkyl, aryl, heteroaryl, or C<sub>3-6</sub> cycloalkyl, said alkyl,  
aryl, heteroaryl and cycloalkyl are optionally substituted  
with one to three substituents selected from R<sup>a</sup>;

$R^3$  is H, halo, CN,  $-C_{1-6}$  alkylene- $CO_2R$ ,  $C_{1-6}$  alkoxy,  $-C_{1-6}$  alkylene- $O-C_{1-6}$  alkyl,  $C_{1-6}$  alkyl, aryl, heteroaryl,  $C_{3-6}$  cycloalkyl or  $CO_2R$ , said alkyl, aryl, heteroaryl and cycloalkyl optionally substituted with one to three substituents selected from  $R^a$ ;

5

$R^a$  is  $C_{1-10}$  alkyl, halogen,  $CF_3$ ,  $NO_2$ , OR,  $NR^7R^8$ , aryl, heterocyclyl, said alkyl, aryl, and heterocyclyl optionally substituted with one or two substituents selected from  $NO_2$ , CN, halo, aryl,  $C_{1-6}$  alkoxy,  $-C_{1-6}$  alkylene- $O-C_{1-6}$  alkyl,  $C_{1-6}$  alkyl, and  $CF_3$ ;

10

$R$  is H or  $C_{1-6}$  alkyl; and

$R^7$  and  $R^8$  are independently H,  $C_{1-10}$  alkyl,  $C_{3-6}$  cycloalkyl, COR,  $-C_{1-6}$  alkylene- $O-C_{1-6}$  alkyl,  $C_{1-6}$  alkoxy,  $-C_{1-6}$  alkylene-aryl, COOR, aryl, benzyl,  $C_{3-10}$  heterocyclyl, or heteroaryl,

15

or  $NR^7R^8$  are taken together to form a 5-10 membered saturated or unsaturated heterocyclic ring containing, in addition to the nitrogen atom attached to  $R^7$  and  $R^8$ , one or two additional heteroatoms selected from N, O, and S, said heterocyclic ring optionally substituted with CN, halo, or  $C_{1-6}$  alkyl.

20

25

Another embodiment of the invention is the compound described immediately above wherein Y is N, X is C-H, and Z is C-H.

In yet another embodiment, the compound of Formula I is further defined such that W is C-H.



Still another embodiment further defines the compound of Formula I so that R<sup>1</sup> is aryl or heteroaryl, optionally substituted with one, two or three substituents selected from R<sup>a</sup>.

A further embodiment of the invention is illustrated by the compound as described immediately above but R<sup>2</sup> is further defined as C<sub>1-6</sub> alkyl, optionally substituted with one, two or three substituents selected from R<sup>a</sup>.

And yet another embodiment is the compound described above wherein R<sup>a</sup> is further defined as C<sub>1-10</sub> alkyl, NR<sup>7</sup>R<sup>8</sup>, aryl, or heterocyclyl, said alkyl, aryl, and heterocyclyl optionally substituted with one or two substituents selected from CN, halo, aryl, C<sub>1-6</sub> alkoxy, -C<sub>1-6</sub> alkylene-O-C<sub>1-6</sub> alkyl, and C<sub>1-6</sub> alkyl.

Still another embodiment is a compound of Formula I, wherein:

W, X, and Z are C-H;

Y is N;

R<sup>1</sup> is aryl or heteroaryl, said aryl and heteroaryl optionally substituted with R<sup>a</sup>;

R<sup>2</sup> is H or C<sub>1-6</sub> alkyl, said alkyl optionally substituted with one, two or three substituents selected from R<sup>a</sup>; and

R<sup>3</sup> is H, halo, CO<sub>2</sub>R, OR or C<sub>1-6</sub> alkyl.

Another embodiment of the invention is a compound selected from a group consisting of:  
3-(5-thiophen-3-yl-pyridin-3-yl)-indole;

- 1-(2-morpholin-4-yl-ethyl)-3-(5-thiophen-3-yl-pyridin-3-yl)-indole;  
1-(2-piperidin-1-yl-ethyl)-3-(5-thiophen-3-yl-pyridin-3-yl)-indole;  
1-(3-piperidin-1-yl-propyl)-3-(5-thiophen-3-yl-pyridin-3-yl)-indole;  
dimethyl-{3-[3-(5-thiophen-3-yl-pyridin-3-yl)-indol-1-yl]-propyl}-amine;  
5 dimethyl-{2-[3-(5-thiophen-3-yl-pyridin-3-yl)-indol-1-yl]-ethyl}-amine;  
1-(1-methyl-piperidin-3-ylmethyl)-3-(5-thiophen-3-yl-pyridin-3-yl)-indole;  
1-[3-(4-methyl-piperazin-1-yl)-propyl]-3-(5-thiophen-3-yl-pyridin-3-yl)-  
indole;  
benzyl-(2-methoxy-ethyl)-(2-[3-(5-thiophen-3-yl-pyridin-3-yl)-indol-1-yl]-  
10 ethyl)-amine;  
1-(2-azepan-1-yl-ethyl)-3-(5-thiophen-3-yl-pyridin-3-yl)-indole;  
diethyl-{2-[3-(5-thiophen-3-yl-pyridin-3-yl)-indol-1-yl]-ethyl}-amine;  
benzyl-ethyl-(2-[3-(5-thiophen-3-yl-pyridin-3-yl)-indol-1-yl]-ethyl)-amine;  
dimethyl-{2-[3-(5-thiophen-3-yl-pyridin-3-yl)-indol-1-yl]-propyl}-amine;  
15 diisopropyl-{2-[3-(5-thiophen-3-yl-pyridin-3-yl)-indol-1-yl]-ethyl}-amine;  
dimethyl-{2-methyl-3-[3-(5-thiophen-3-yl-pyridin-3-yl)-indol-1-yl]-propyl}-  
amine;  
benzyl-methyl-{2-[3-(5-thiophen-3-yl-pyridin-3-yl)-indol-1-yl]-ethyl}-  
amine;  
20 1-{2-[3-(5-thiophen-3-yl-pyridin-3-yl)-indol-1-yl]-ethyl}-piperidine-4-  
carbonitrile;  
5-methoxy-3-(5-thiophen-3-yl-pyridin-3-yl)-indole;  
5-methoxy-1-(2-morpholin-4-yl-ethyl)-3-(5-thiophen-3-yl-pyridin-3-yl)-  
indole;  
25 5-methoxy-1-(2-piperidin-1-yl-ethyl)-3-(5-thiophen-3-yl-pyridin-3-yl)-  
indole;  
5-methoxy-1-(3-piperidin-1-yl-propyl)-3-(5-thiophen-3-yl-pyridin-3-yl)-  
indole;  
dimethyl-{5-methoxy-3-[3-(5-thiophen-3-yl-pyridin-3-yl)-indol-1-yl]-  
30 propyl}-amine;

- 5-methoxy-1-(1-methyl-piperidin-3-ylmethyl)-3-(5-thiophen-3-yl-pyridin-3-yl)-indole;  
5-methoxy-1-[3-(4-methyl-piperazin-1-yl)-propyl]-3-(5-thiophen-3-yl-pyridin-3-yl)-indole;
- 5 dimethyl-{2-[5-methoxy-3-(5-thiophen-3-yl-pyridin-3-yl)-indol-1-yl]-propyl}-amine;  
dimethyl-{2-methyl-3-[5-methoxy-3-(5-thiophen-3-yl-pyridin-3-yl)-indol-1-yl]-propyl}-amine;  
1-{2-[5-methoxy-3-(5-thiophen-3-yl-pyridin-3-yl)-indol-1-yl]-ethyl}-
- 10 piperidine-4-carbonitrile;  
4-chloro-3-(5-thiophen-3-yl-pyridin-3-yl)-indole;  
4-chloro-1-(2-morpholin-4-yl-ethyl)-3-(5-thiophen-3-yl-pyridin-3-yl)-indole;  
4-chloro-1-(2-piperidin-1-yl-ethyl)-3-(5-thiophen-3-yl-pyridin-3-yl)-indole;  
4-chloro-1-(3-piperidin-1-yl-propyl)-3-(5-thiophen-3-yl-pyridin-3-yl)-indole;
- 15 dimethyl-{4-chloro-3-[3-(5-thiophen-3-yl-pyridin-3-yl)-indol-1-yl]-propyl}-amine;  
4-chloro-1-(1-methyl-piperidin-3-ylmethyl)-3-(5-thiophen-3-yl-pyridin-3-yl)-indole;  
4-chloro-1-[3-(4-methyl-piperazin-1-yl)-propyl]-3-(5-thiophen-3-yl-pyridin-
- 20 3-yl)-indole;  
dimethyl-{2-[4-chloro-3-(5-thiophen-3-yl-pyridin-3-yl)-indol-1-yl]-propyl}-amine;  
dimethyl-{2-methyl-3-[4-chloro-3-(5-thiophen-3-yl-pyridin-3-yl)-indol-1-yl]-propyl}-amine;
- 25 1-{2-[4-chloro-3-(5-thiophen-3-yl-pyridin-3-yl)-indol-1-yl]-ethyl}-piperidine-4-carbonitrile;  
5-chloro-3-(5-thiophen-3-yl-pyridin-3-yl)-indole;  
5-chloro-1-(2-morpholin-4-yl-ethyl)-3-(5-thiophen-3-yl-pyridin-3-yl)-indole;  
5-chloro-1-(2-piperidin-1-yl-ethyl)-3-(5-thiophen-3-yl-pyridin-3-yl)-indole;
- 30 5-chloro-1-(3-piperidin-1-yl-propyl)-3-(5-thiophen-3-yl-pyridin-3-yl)-indole;

- dimethyl-{4-chloro-3-[3-(5-thiophen-3-yl-pyridin-3-yl)-indol-1-yl]-propyl}-amine;
- 5-chloro-1-(1-methyl-piperidin-3-ylmethyl)-3-(5-thiophen-3-yl-pyridin-3-yl)-indole;
- 5 5-chloro-1-[3-(4-methyl-piperazin-1-yl)-propyl]-3-(5-thiophen-3-yl-pyridin-3-yl)-indole;
- dimethyl-{2-[5-chloro-3-(5-thiophen-3-yl-pyridin-3-yl)-indol-1-yl]-propyl}-amine;
- dimethyl-{2-methyl-3-[5-chloro-3-(5-thiophen-3-yl-pyridin-3-yl)-indol-1-yl]-propyl}-amine;
- 10 1-{2-[5-chloro-3-(5-thiophen-3-yl-pyridin-3-yl)-indol-1-yl]-ethyl}-piperidine-4-carbonitrile;
- 7-methoxy-3-(5-thiophen-3-yl-pyridin-3-yl)-indole;
- 7-methoxy-1-(2-morpholin-4-yl-ethyl)-3-(5-thiophen-3-yl-pyridin-3-yl)-indole;
- 15 7-methoxy-1-(2-piperidin-1-yl-ethyl)-3-(5-thiophen-3-yl-pyridin-3-yl)-indole;
- 7-methoxy-1-(3-piperidin-1-yl-propyl)-3-(5-thiophen-3-yl-pyridin-3-yl)-indole;
- 20 dimethyl-{7-methoxy-3-[3-(5-thiophen-3-yl-pyridin-3-yl)-indol-1-yl]-propyl}-amine;
- 7-methoxy-1-(1-methyl-piperidin-3-ylmethyl)-3-(5-thiophen-3-yl-pyridin-3-yl)-indole;
- 7-methoxy-1-[3-(4-methyl-piperazin-1-yl)-propyl]-3-(5-thiophen-3-yl-pyridin-3-yl)-indole;
- 25 dimethyl-{2-[7-methoxy-3-(5-thiophen-3-yl-pyridin-3-yl)-indol-1-yl]-propyl}-amine;
- dimethyl-{2-methyl-3-[7-methoxy-3-(5-thiophen-3-yl-pyridin-3-yl)-indol-1-yl]-propyl}-amine;
- 30 1-{2-[7-methoxy-3-(5-thiophen-3-yl-pyridin-3-yl)-indol-1-yl]-ethyl}-piperidine-4-carbonitrile;

- 6-chloro-3-(5-thiophen-3-yl-pyridin-3-yl)-indole;  
6-chloro-1-(2-morpholin-4-yl-ethyl)-3-(5-thiophen-3-yl-pyridin-3-yl)-indole;  
6-chloro-1-(2-piperidin-1-yl-ethyl)-3-(5-thiophen-3-yl-pyridin-3-yl)-indole;  
6-chloro-1-(3-piperidin-1-yl-propyl)-3-(5-thiophen-3-yl-pyridin-3-yl)-indole;  
5 dimethyl-[6-chloro-3-[3-(5-thiophen-3-yl-pyridin-3-yl)-indol-1-yl]-propyl]-  
amine;  
6-chloro-1-(1-methyl-piperidin-3-ylmethyl)-3-(5-thiophen-3-yl-pyridin-3-  
yl)-indole;  
6-chloro-1-[3-(4-methyl-piperazin-1-yl)-propyl]-3-(5-thiophen-3-yl-pyridin-  
10 3-yl)-indole;  
dimethyl-[2-[6-chloro-3-(5-thiophen-3-yl-pyridin-3-yl)-indol-1-yl]-propyl]-  
amine;  
dimethyl-[2-methyl-3-[6-chloro-3-(5-thiophen-3-yl-pyridin-3-yl)-indol-1-yl]-  
propyl]-amine;  
15 1-[2-[6-chloro-3-(5-thiophen-3-yl-pyridin-3-yl)-indol-1-yl]-ethyl]-piperidine-  
4-carbonitrile;  
3-(5-thiophen-3-yl-pyridin-3-yl)-indole-5-carbonitrile;  
1-(2-morpholin-4-yl-ethyl)-3-(5-thiophen-3-yl-pyridin-3-yl)-indole-5-  
carbonitrile;  
20 1-(2-piperidin-1-yl-ethyl)-3-(5-thiophen-3-yl-pyridin-3-yl)-indole-5-  
carbonitrile;  
1-(3-piperidin-1-yl-propyl)-3-(5-thiophen-3-yl-pyridin-3-yl)-indole-5-  
carbonitrile;  
1-(3-dimethylamino-propyl)-3-(5-thiophen-3-yl-pyridin-3-yl)-indole-5-  
25 carbonitrile;  
1-(1-methyl-piperidin-3-ylmethyl)-3-(5-thiophen-3-yl-pyridin-3-yl)-indole-  
5-carbonitrile;  
1-[3-(4-methyl-piperazin-1-yl)-propyl]-3-(5-thiophen-3-yl-pyridin-3-yl)-  
indole-5-carbonitrile;  
30 1-(2-dimethylamino-propyl)-3-(5-thiophen-3-yl-pyridin-3-yl)-indole-5-  
carbonitrile;

- 1-(1-dimethylamino-2-methyl-propyl)-3-(5-thiophen-3-yl-pyridin-3-yl)-  
indole-5-carbonitrile;  
1-[2-(4-cyano-piperidin-1-yl-ethyl)-3-(5-thiophen-3-yl-pyridin-3-yl)-indole-  
5-carbonitrile;  
5 3-(5-thiophen-3-yl-pyridin-3-yl)-indole-4-carboxylic acid methyl ester;  
1-(2-morpholin-4-yl-ethyl)-3-(5-thiophen-3-yl-pyridin-3-yl)-indole-4-  
carboxylic acid methyl ester;  
1-(2-piperidin-1-yl-ethyl)-3-(5-thiophen-3-yl-pyridin-3-yl)-indole-4-  
carboxylic acid methyl ester;  
10 1-(3-piperidin-1-yl-propyl)-3-(5-thiophen-3-yl-pyridin-3-yl)-indole-4-  
carboxylic acid methyl ester;  
1-(3-dimethylamino-propyl)-3-(5-thiophen-3-yl-pyridin-3-yl)-indole-4-  
carboxylic acid methyl ester;  
1-(1-methyl-piperidin-3-ylmethyl)-3-(5-thiophen-3-yl-pyridin-3-yl)-indole-  
15 4-carboxylic acid methyl ester;  
1-[3-(4-methyl-piperazin-1-yl)-propyl]-3-(5-thiophen-3-yl-pyridin-3-yl)-  
indole-4-carboxylic acid methyl ester ;  
1-(2-dimethylamino-propyl)-3-(5-thiophen-3-yl-pyridin-3-yl)-indole-4-  
carboxylic acid methyl ester;  
20 1-(1-dimethylamino-2-methyl-propyl)-3-(5-thiophen-3-yl-pyridin-3-yl)-  
indole-4-carboxylic acid methyl ester;  
1-[2-(4-cyano-piperidin-1-yl-ethyl)-3-(5-thiophen-3-yl-pyridin-3-yl)-indole-  
4-carboxylic acid methyl ester;  
3-(5-thiophen-3-yl-pyridin-3-yl)-pyrrolo[2,3]pyridine;  
25 1-(2-morpholin-4-yl-ethyl)-3-(5-thiophen-3-yl-pyridin-3-yl)-  
pyrrolo[2,3]pyridine;  
1-(2-piperidin-1-yl-ethyl)-3-(5-thiophen-3-yl-pyridin-3-yl)-  
pyrrolo[2,3]pyridine;  
1-(3-piperidin-1-yl-propyl)-3-(5-thiophen-3-yl-pyridin-3-yl)-  
30 pyrrolo[2,3]pyridine;

- dimethyl-{3-[3-(5-thiophen-3-yl-pyridin-3-yl)-pyrrolo[2,3]pyridin-1-yl]-propyl}-amine;  
1-(1-methyl-piperidin-3-ylmethyl)-3-(5-thiophen-3-yl-pyridin-3-yl)-pyrrolo[2,3]pyridine;
- 5 1-[3-(4-methyl-piperazin-1-yl)-propyl]-3-(5-thiophen-3-yl-pyridin-3-yl)-pyrrolo[2,3]pyridine;  
dimethyl-{2-[3-(5-thiophen-3-yl-pyridin-3-yl)-pyrrolo[2,3]pyridin-1-yl]-propyl}-amine;  
dimethyl-{2-methyl-3-[3-(5-thiophen-3-yl-pyridin-3-yl)-pyrrolo[2,3]pyridin-
- 10 1-yl]-propyl}-amine;  
1-{2-[3-(5-thiophen-3-yl-pyridin-3-yl)-pyrrolo[2,3]pyridin-1-yl]-ethyl}-piperidine-4-carbonitrile;  
3-(5-phenyl-pyridin-3-yl)-indole;  
1-(2-morpholin-4-yl-ethyl)-3-(5-phenyl-pyridin-3-yl)-indole;
- 15 3-(5-phenyl-pyridin-3-yl)-1-(2-piperidin-1-yl-ethyl)-indole;  
3-(5-phenyl-pyridin-3-yl)-1-(3-piperidin-1-yl-propyl)-indole;  
dimethyl-{3-[3-(5-phenyl-pyridin-3-yl)-indol-1-yl]-propyl}-amine;  
1-(1-methyl-piperidin-3-ylmethyl)-3-(5-phenyl-pyridin-3-yl)-indole;  
1-[3-(4-methyl-piperazin-1-yl)-propyl]-3-(5-phenyl-pyridin-3-yl)-indole;
- 20 dimethyl-{2-[3-(5-phenyl-pyridin-3-yl)-indol-1-yl]-propyl}-amine;  
dimethyl-{2-methyl-3-[3-(5-phenyl-pyridin-3-yl)-indol-1-yl]-propyl}-amine;  
1-{2-[3-(5-phenyl-pyridin-3-yl)-indol-1-yl]-ethyl}-piperidine-4-carbonitrile;  
5-methoxy-3-(5-phenyl-pyridin-3-yl)-indole;  
5-methoxy-1-(2-morpholin-4-yl-ethyl)-3-(5-phenyl-pyridin-3-yl)-indole;
- 25 5-methoxy-3-(5-phenyl-pyridin-3-yl)-1-(2-piperidin-1-yl-ethyl)-indole;  
5-methoxy-3-(5-phenyl-pyridin-3-yl)-1-(3-piperidin-1-yl-propyl)-indole;  
dimethyl-{5-methoxy-3-[3-(5-phenyl-pyridin-3-yl)-indol-1-yl]-propyl}-amine;  
1-(1-methyl-piperidin-3-ylmethyl)-5-methoxy-3-(5-phenyl-pyridin-3-yl)-
- 30 indole;

- 1-[3-(4-methyl-piperazin-1-yl)-propyl]-5-methoxy-3-(5-phenyl-pyridin-3-yl)-indole;  
dimethyl-{2-[5-methoxy-3-(5-phenyl-pyridin-3-yl)-indol-1-yl]-propyl}-amine;
- 5 dimethyl-{2-methyl-3-[5-methoxy-3-(5-phenyl-pyridin-3-yl)-indol-1-yl]-propyl}-amine;  
1-{2-[5-methoxy-3-(5-phenyl-pyridin-3-yl)-indol-1-yl]-ethyl}-piperidine-4-carbonitrile;  
4-chloro-3-(5-phenyl-pyridin-3-yl)-indole;
- 10 4-chloro-1-(2-morpholin-4-yl-ethyl)-3-(5-phenyl-pyridin-3-yl)-indole;  
4-chloro-3-(5-phenyl-pyridin-3-yl)-1-(2-piperidin-1-yl-ethyl)-indole;  
4-chloro-3-(5-phenyl-pyridin-3-yl)-1-(3-piperidin-1-yl-propyl)-indole;  
dimethyl-{4-chloro-3-[3-(5-phenyl-pyridin-3-yl)-indol-1-yl]-propyl}-amine;  
1-(1-methyl-piperidin-3-ylmethyl)-4-chloro-3-(5-phenyl-pyridin-3-yl)-
- 15 indole;  
1-[3-(4-methyl-piperazin-1-yl)-propyl]-4-chloro-3-(5-phenyl-pyridin-3-yl)-indole;  
dimethyl-{2-[4-chloro-3-(5-phenyl-pyridin-3-yl)-indol-1-yl]-propyl}-amine;  
dimethyl-{2-methyl-3-[4-chloro-3-(5-phenyl-pyridin-3-yl)-indol-1-yl]-
- 20 propyl}-amine;  
1-{2-[4-chloro-3-(5-phenyl-pyridin-3-yl)-indol-1-yl]-ethyl}-piperidine-4-carbonitrile;  
5-chloro-3-(5-phenyl-pyridin-3-yl)-indole;  
5-chloro-1-(2-morpholin-4-yl-ethyl)-3-(5-phenyl-pyridin-3-yl)-indole;
- 25 5-chloro-3-(5-phenyl-pyridin-3-yl)-1-(2-piperidin-1-yl-ethyl)-indole;  
5-chloro-3-(5-phenyl-pyridin-3-yl)-1-(3-piperidin-1-yl-propyl)-indole;  
dimethyl-{5-chloro-3-[3-(5-phenyl-pyridin-3-yl)-indol-1-yl]-propyl}-amine;  
1-(1-methyl-piperidin-3-ylmethyl)-5-chloro-3-(5-phenyl-pyridin-3-yl)-
- 30 indole;  
1-[3-(4-methyl-piperazin-1-yl)-propyl]-5-chloro-3-(5-phenyl-pyridin-3-yl)-indole;



- dimethyl-{2-[5-chloro-3-(5-phenyl-pyridin-3-yl)-indol-1-yl]-propyl}-amine;  
dimethyl-{2-methyl-3-[5-chloro-3-(5-phenyl-pyridin-3-yl)-indol-1-yl]-  
propyl}-amine;  
1-{2-[5-chloro-3-(5-phenyl-pyridin-3-yl)-indol-1-yl]-ethyl}-piperidine-4-  
5 carbonitrile;  
7-methoxy-3-(5-phenyl-pyridin-3-yl)-indole;  
7-methoxy-1-(2-morpholin-4-yl-ethyl)-3-(5-phenyl-pyridin-3-yl)-indole;  
7-methoxy-3-(5-phenyl-pyridin-3-yl)-1-(2-piperidin-1-yl-ethyl)-indole;  
7-methoxy-3-(5-phenyl-pyridin-3-yl)-1-(3-piperidin-1-yl-propyl)-indole;  
10 dimethyl-{7-methoxy-3-[3-(5-phenyl-pyridin-3-yl)-indol-1-yl]-propyl}-  
amine;  
1-(1-methyl-piperidin-3-ylmethyl)-7-methoxy-3-(5-phenyl-pyridin-3-yl)-  
indole;  
1-[3-(4-methyl-piperazin-1-yl)-propyl]-7-methoxy-3-(5-phenyl-pyridin-3-  
15 yl)-indole;  
dimethyl-{2-[7-methoxy-3-(5-phenyl-pyridin-3-yl)-indol-1-yl]-propyl}-  
amine;  
dimethyl-{2-methyl-3-[7-methoxy-3-(5-phenyl-pyridin-3-yl)-indol-1-yl]-  
propyl}-amine;  
20 1-{2-[7-methoxy-3-(5-phenyl-pyridin-3-yl)-indol-1-yl]-ethyl}-piperidine-4-  
carbonitrile;  
6-chloro-3-(5-phenyl-pyridin-3-yl)-indole;  
6-chloro-1-(2-morpholin-4-yl-ethyl)-3-(5-phenyl-pyridin-3-yl)-indole;  
6-chloro-3-(5-phenyl-pyridin-3-yl)-1-(2-piperidin-1-yl-ethyl)-indole;  
25 6-chloro-3-(5-phenyl-pyridin-3-yl)-1-(3-piperidin-1-yl-propyl)-indole;  
dimethyl-{6-chloro-3-[3-(5-phenyl-pyridin-3-yl)-indol-1-yl]-propyl}-amine;  
1-(1-methyl-piperidin-3-ylmethyl)-6-chloro-3-(5-phenyl-pyridin-3-yl)-  
indole;  
1-[3-(4-methyl-piperazin-1-yl)-propyl]-6-chloro-3-(5-phenyl-pyridin-3-yl)-  
30 indole;  
dimethyl-{2-[6-chloro-3-(5-phenyl-pyridin-3-yl)-indol-1-yl]-propyl}-amine;

- dimethyl-(2-methyl-3-[6-chloro-3-(5-phenyl-pyridin-3-yl)-indol-1-yl]-propyl)-amine;
- 1-(2-[6-chloro-3-(5-phenyl-pyridin-3-yl)-indol-1-yl]-ethyl)-piperidine-4-carbonitrile;
- 5 3-(5-phenyl-pyridin-3-yl)-indole-5-carbonitrile;
- 1-(2-morpholin-4-yl-ethyl)-3-(5-phenyl-pyridin-3-yl)-indole-5-carbonitrile;
- 1-(2-piperidin-1-yl-ethyl)-3-(5-phenyl-pyridin-3-yl)-indole-5-carbonitrile;
- 1-(3-piperidin-1-yl-propyl)-3-(5-phenyl-pyridin-3-yl)-indole-5-carbonitrile;
- 1-(3-dimethylamino-propyl)-3-(5-phenyl-pyridin-3-yl)-indole-5-
- 10 carbonitrile;
- 1-(1-methyl-piperidin-3-ylmethyl)-3-(5-phenyl-pyridin-3-yl)-indole-5-carbonitrile;
- 1-[3-(4-methyl-piperazin-1-yl)-propyl]-3-(5-phenyl-pyridin-3-yl)-indole-5-carbonitrile;
- 15 1-(2-dimethylamino-propyl)-3-(5-phenyl-pyridin-3-yl)-indole-5-carbonitrile;
- 1-(1-dimethylamino-2-methyl-propyl)-3-(5-phenyl-pyridin-3-yl)-indole-5-carbonitrile;
- 1-[2-(4-cyano-piperidin-1-yl-ethyl)-3-(5-phenyl-pyridin-3-yl)-indole-5-
- 20 carbonitrile;
- 3-(5-phenyl-pyridin-3-yl)-indole-4-carboxylic acid methyl ester;
- 1-(2-morpholin-4-yl-ethyl)-3-(5-phenyl-pyridin-3-yl)-indole-4-carboxylic acid methyl ester;
- 1-(2-piperidin-1-yl-ethyl)-3-(5-phenyl-pyridin-3-yl)-indole-4-carboxylic
- 25 acid methyl ester;
- 1-(3-piperidin-1-yl-propyl)-3-(5-phenyl-pyridin-3-yl)-indole-4-carboxylic acid methyl ester;
- 1-(3-dimethylamino-propyl)-3-(5-phenyl-pyridin-3-yl)-indole-4-carboxylic acid methyl ester;
- 30 1-(1-methyl-piperidin-3-ylmethyl)-3-(5-phenyl-pyridin-3-yl)-indole-4-carboxylic acid methyl ester;

- 1-[3-(4-methyl-piperazin-1-yl)-propyl]-3-(5-phenyl-pyridin-3-yl)-indole-4-carboxylic acid methyl ester ;  
1-(2-dimethylamino-propyl)-3-(5-phenyl-pyridin-3-yl)-indole-4-carboxylic acid methyl ester;
- 5 1-(1-dimethylamino-2-methyl-propyl)-3-(5-phenyl-pyridin-3-yl)-indole-4-carboxylic acid methyl ester;  
1-[2-(4-cyano-piperidin-1-yl-ethyl)]-3-(5-phenyl-pyridin-3-yl)-indole-4-carboxylic acid methyl ester;  
3-(5-phenyl-pyridin-3-yl)-pyrrolo[2,3]pyridine;
- 10 1-(2-morpholin-4-yl-ethyl)-3-(5-phenyl-pyridin-3-yl)-pyrrolo[2,3]pyridine;  
1-(2-piperidin-1-yl-ethyl)-3-(5-phenyl-pyridin-3-yl)-pyrrolo[2,3]pyridine;  
1-(3-piperidin-1-yl-propyl)-3-(5-phenyl-pyridin-3-yl)-pyrrolo[2,3]pyridine;  
dimethyl-{3-[3-(5-phenyl-pyridin-3-yl)-pyrrolo[2,3]pyridin-1-yl]-propyl}-amine;
- 15 1-(1-methyl-piperidin-3-ylmethyl)-3-(5-phenyl-pyridin-3-yl)-pyrrolo[2,3]pyridine;  
1-[3-(4-methyl-piperazin-1-yl)-propyl]-3-(5-phenyl-pyridin-3-yl)-pyrrolo[2,3]pyridine;  
dimethyl-{2-[3-(5-phenyl-pyridin-3-yl)-pyrrolo[2,3]pyridin-1-yl]-propyl}-
- 20 amine;  
dimethyl-{2-methyl-3-[3-(5-phenyl-pyridin-3-yl)-pyrrolo[2,3]pyridin-1-yl]-propyl}-amine;  
1-{2-[3-(5-phenyl-pyridin-3-yl)-pyrrolo[2,3]pyridin-1-yl]-ethyl}-piperidine-4-carbonitrile;
- 25 3-[5-(3-methoxy-phenyl)-pyridin-3-yl]-indole;  
3-[5-(3-methoxy-phenyl)-pyridin-3-yl]-1-(2-morpholin-4-yl-ethyl)-indole;  
3-[5-(3-methoxy-phenyl)-pyridin-3-yl]-1-(2-piperidin-1-yl-ethyl)-indole;  
3-[5-(3-methoxy-phenyl)-pyridin-3-yl]-1-(3-piperidin-1-yl-propyl)-indole;  
dimethyl-{3-[3-(5-(3-methoxy-phenyl)-pyridin-3-yl)-indol-1-yl]-propyl}-
- 30 amine;

- 3-[5-(3-methoxy-phenyl)-pyridin-3-yl]-1-(1-methyl-piperidin-3-ylmethyl)-indole;
- 3-[5-(3-methoxy-phenyl)-pyridin-3-yl]-1-[3-(4-methyl-piperazin-1-yl)-propyl]-indole;
- 5 dimethyl-2-[3-(5-(3-methoxy-phenyl)-1-pyridin-3-yl)-indol-1-yl]-propyl-amine;
- dimethyl-2-methyl-3-[3-(5-(3-methoxy-phenyl)-pyridin-3-yl)-indol-1-yl]-propyl-amine;
- 1-(2-[3-(5-(3-methoxy-phenyl)-pyridin-3-yl)-indol-1-yl]-ethyl)-piperidine-4-
- 10 carbonitrile;
- 5-methoxy-3-[5-(3-methoxy-phenyl)-pyridin-3-yl]-indole;
- 5-methoxy-3-[5-(3-methoxy-phenyl)-pyridin-3-yl]-1-(2-morpholin-4-yl-ethyl)-indole;
- 5-methoxy-3-[5-(3-methoxy-phenyl)-pyridin-3-yl]-1-(2-piperidin-1-yl-
- 15 ethyl)-indole;
- 5-methoxy-3-[5-(3-methoxy-phenyl)-pyridin-3-yl]-1-(3-piperidin-1-yl-propyl)-indole;
- dimethyl-3-[5-methoxy-3-(5-(3-methoxy-phenyl)-pyridin-3-yl)-indol-1-yl]-propyl-amine;
- 20 5-methoxy-3-[5-(3-methoxy-phenyl)-pyridin-3-yl]-1-(1-methyl-piperidin-3-ylmethyl)-indole;
- 5-methoxy-3-[5-(3-methoxy-phenyl)-pyridin-3-yl]-1-[3-(4-methyl-piperazin-1-yl)-propyl]-indole;
- dimethyl-2-[5-methoxy-3-(5-(3-methoxy-phenyl)-1-pyridin-3-yl)-indol-1-
- 25 yl]-propyl-amine;
- dimethyl-2-methyl-3-[5-methoxy-3-(5-(3-methoxy-phenyl)-pyridin-3-yl)-indol-1-yl]-propyl-amine;
- 1-(2-[5-methoxy-3-(5-(3-methoxy-phenyl)-pyridin-3-yl)-indol-1-yl]-ethyl)-piperidine-4-carbonitrile;
- 30 4-chloro-3-[5-(3-methoxy-phenyl)-pyridin-3-yl]-indole;

- 4-chloro-3-[5-(3-methoxy-phenyl)-pyridin-3-yl]-1-(2-morpholin-4-yl-ethyl)-indole;
- 4-chloro-3-[5-(3-methoxy-phenyl)-pyridin-3-yl]-1-(2-piperidin-1-yl-ethyl)-indole;
- 5 4-chloro-3-[5-(3-methoxy-phenyl)-pyridin-3-yl]-1-(3-piperidin-1-yl-propyl)-indole;
- dimethyl-{3-[4-chloro-3-(5-(3-methoxy-phenyl)-pyridin-3-yl)-indol-1-yl]-propyl}-amine;
- 4-chloro-3-[5-(3-methoxy-phenyl)-pyridin-3-yl]-1-(1-methyl-piperidin-3-ylmethyl)-indole;
- 10 4-chloro-3-[5-(3-methoxy-phenyl)-pyridin-3-yl]-1-[3-(4-methyl-piperazin-1-yl)-propyl]-indole;
- dimethyl-{2-[4-chloro-3-(5-(3-methoxy-phenyl)-1-pyridin-3-yl)-indol-1-yl]-propyl}-amine;
- 15 dimethyl-{2-methyl-3-[4-chloro-3-(5-(3-methoxy-phenyl)-pyridin-3-yl)-indol-1-yl]-propyl}-amine;
- 1-(2-[4-chloro-3-(5-(3-methoxy-phenyl)-pyridin-3-yl)-indol-1-yl]-ethyl)-piperidine-4-carbonitrile;
- 5-chloro-3-[5-(3-methoxy-phenyl)-pyridin-3-yl]-indole;
- 20 5-chloro-3-[5-(3-methoxy-phenyl)-pyridin-3-yl]-1-(2-morpholin-4-yl-ethyl)-indole;
- 5-chloro-3-[5-(3-methoxy-phenyl)-pyridin-3-yl]-1-(2-piperidin-1-yl-ethyl)-indole;
- 5-chloro-3-[5-(3-methoxy-phenyl)-pyridin-3-yl]-1-(3-piperidin-1-yl-propyl)-indole;
- 25 dimethyl-{3-[5-chloro-3-(5-(3-methoxy-phenyl)-pyridin-3-yl)-indol-1-yl]-propyl}-amine;
- 5-chloro-3-[5-(3-methoxy-phenyl)-pyridin-3-yl]-1-(1-methyl-piperidin-3-ylmethyl)-indole;
- 30 5-chloro-3-[5-(3-methoxy-phenyl)-pyridin-3-yl]-1-[3-(4-methyl-piperazin-1-yl)-propyl]-indole;

- dimethyl-{2-[5-chloro-3-(5-(3-methoxy-phenyl)-1-pyridin-3-yl)-indol-1-yl]-propyl}-amine;
- dimethyl-{2-methyl-3-[5-chloro-3-(5-(3-methoxy-phenyl)-pyridin-3-yl)-indol-1-yl]-propyl}-amine;
- 5 1-{2-[5-chloro-3-(5-(3-methoxy-phenyl)-pyridin-3-yl)-indol-1-yl]-ethyl}-piperidine-4-carbonitrile;
- 7-methoxy-3-[5-(3-methoxy-phenyl)-pyridin-3-yl]-indole;
- 7-methoxy-3-[5-(3-methoxy-phenyl)-pyridin-3-yl]-1-(2-morpholin-4-yl-ethyl)-indole;
- 10 7-methoxy-3-[5-(3-methoxy-phenyl)-pyridin-3-yl]-1-(2-piperidin-1-yl-ethyl)-indole;
- 7-methoxy-3-[5-(3-methoxy-phenyl)-pyridin-3-yl]-1-(3-piperidin-1-yl-propyl)-indole;
- dimethyl-{3-[7-methoxy-3-(5-(3-methoxy-phenyl)-pyridin-3-yl)-indol-1-yl]-propyl}-amine;
- 15 7-methoxy-3-[5-(3-methoxy-phenyl)-pyridin-3-yl]-1-(1-methyl-piperidin-3-ylmethyl)-indole;
- 7-methoxy-3-[5-(3-methoxy-phenyl)-pyridin-3-yl]-1-[3-(4-methyl-piperazin-1-yl)-propyl]-indole;
- 20 dimethyl-{2-[7-methoxy-3-(5-(3-methoxy-phenyl)-1-pyridin-3-yl)-indol-1-yl]-propyl}-amine;
- dimethyl-{2-methyl-3-[7-methoxy-3-(5-(3-methoxy-phenyl)-pyridin-3-yl)-indol-1-yl]-propyl}-amine;
- 1-{2-[7-methoxy-3-(5-(3-methoxy-phenyl)-pyridin-3-yl)-indol-1-yl]-ethyl}-piperidine-4-carbonitrile;
- 25 6-chloro-3-[5-(3-methoxy-phenyl)-pyridin-3-yl]-indole;
- 6-chloro-3-[5-(3-methoxy-phenyl)-pyridin-3-yl]-1-(2-morpholin-4-yl-ethyl)-indole;
- 6-chloro-3-[5-(3-methoxy-phenyl)-pyridin-3-yl]-1-(2-piperidin-1-yl-ethyl)-indole;
- 30 indole;

- 6-chloro-3-[5-(3-methoxy-phenyl)-pyridin-3-yl]-1-(3-piperidin-1-yl-propyl)-indole;  
dimethyl-{3-[6-chloro-3-(5-(3-methoxy-phenyl)-pyridin-3-yl)-indol-1-yl]-propyl}-amine;
- 5 6-chloro-3-[5-(3-methoxy-phenyl)-pyridin-3-yl]-1-(1-methyl-piperidin-3-ylmethyl)-indole;  
6-chloro-3-[5-(3-methoxy-phenyl)-pyridin-3-yl]-1-[3-(4-methyl-piperazin-1-yl)-propyl]-indole;  
dimethyl-{2-[6-chloro-3-(5-(3-methoxy-phenyl)-1-pyridin-3-yl)-indol-1-yl]-propyl}-amine;
- 10 dimethyl-{2-methyl-3-[6-chloro-3-(5-(3-methoxy-phenyl)-pyridin-3-yl)-indol-1-yl]-propyl}-amine;  
1-{2-[6-chloro-3-(5-(3-methoxy-phenyl)-pyridin-3-yl)-indol-1-yl]-ethyl}-piperidine-4-carbonitrile;
- 15 3-[5-(3-methoxy-phenyl)-pyridin-3-yl]-indole-5-carbonitrile;  
3-[5-(3-methoxy-phenyl)-pyridin-3-yl]-1-(2-morpholin-4-yl-ethyl)-indole-5-carbonitrile;  
3-[5-(3-methoxy-phenyl)-pyridin-3-yl]-1-(2-piperidin-1-yl-ethyl)-indole-5-carbonitrile;
- 20 3-[5-(3-methoxy-phenyl)-pyridin-3-yl]-1-(3-piperidin-1-yl-propyl)-indole-5-carbonitrile;  
1-(3-dimethylamino-propyl)-3-[5-(3-methoxy-phenyl)-pyridin-3-yl]-indole-5-carbonitrile;  
3-[5-(3-methoxy-phenyl)-pyridin-3-yl]-1-(1-methyl-piperidin-3-ylmethyl)-
- 25 indole-5-carbonitrile;  
3-[5-(3-methoxy-phenyl)-pyridin-3-yl]-1-[3-(4-methyl-piperazin-1-yl)-propyl]-indole-5-carbonitrile;  
1-(2-dimethylamino-propyl)-3-[5-(3-methoxy-phenyl)-pyridin-3-yl]-indole-5-carbonitrile;
- 30 1-(1-dimethylamino-2-methyl-propyl)-3-[5-(3-methoxy-phenyl)-pyridin-3-yl]-indole-5-carbonitrile;

- 1-[2-(4-cyano-piperidin-1-yl-ethyl)-3-[5-(3-methoxy-phenyl)-pyridin-3-yl]-indole-5-carbonitrile;  
3-[5-(3-methoxy-phenyl)-pyridin-3-yl]-indole-4-carboxylic acid methyl ester;  
5 3-[5-(3-methoxy-phenyl)-pyridin-3-yl]-1-(2-morpholin-4-yl-ethyl)-indole-4-carboxylic acid methyl ester;  
3-[5-(3-methoxy-phenyl)-pyridin-3-yl]-1-(2-piperidin-1-yl-ethyl)-indole-4-carboxylic acid methyl ester;  
3-[5-(3-methoxy-phenyl)-pyridin-3-yl]-1-(3-piperidin-1-yl-propyl)-indole-4-  
10 carboxylic acid methyl ester;  
1-(3-dimethylamino-propyl)-3-[5-(3-methoxy-phenyl)-pyridin-3-yl]-indole-4-carboxylic acid methyl ester;  
3-[5-(3-methoxy-phenyl)-pyridin-3-yl]-1-(1-methyl-piperidin-3-ylmethyl)-indole-4-carboxylic acid methyl ester;  
15 3-[5-(3-methoxy-phenyl)-pyridin-3-yl]-1-[3-(4-methyl-piperazin-1-yl)-propyl]-indole-4-carboxylic acid methyl ester;  
1-(2-dimethylamino-propyl)-3-[5-(3-methoxy-phenyl)-pyridin-3-yl]-indole-4-carboxylic acid methyl ester;  
1-(1-dimethylamino-2-methyl-propyl)-3-[5-(3-methoxy-phenyl)-pyridin-3-  
20 yl]-indole-4-carboxylic acid methyl ester;  
1-[2-(4-cyano-piperidin-1-yl-ethyl)-3-[5-(3-methoxy-phenyl)-pyridin-3-yl]-indole-4-carboxylic acid methyl ester;  
3-[5-(3-methoxy-phenyl)-pyridin-3-yl]-pyrrolo[2,3]pyridine;  
3-[5-(3-methoxy-phenyl)-pyridin-3-yl]-1-(2-morpholin-4-yl-ethyl)-  
25 pyrrolo[2,3]pyridine;  
3-[5-(3-methoxy-phenyl)-pyridin-3-yl]-1-(2-piperidin-1-yl-ethyl)-pyrrolo[2,3]pyridine;  
3-[5-(3-methoxy-phenyl)-pyridin-3-yl]-1-(3-piperidin-1-yl-propyl)-pyrrolo[2,3]pyridine;  
30 dimethyl-{3-[3-(5-(3-methoxy-phenyl)-pyridin-3-yl)-pyrrolo[2,3]pyridin-1-yl]-propyl}-amine;



- 3-[5-(3-methoxy-phenyl)-pyridin-3-yl]-1-(1-methyl-piperidin-3-ylmethyl)-pyrrolo[2,3]pyridine;
- 3-[5-(3-methoxy-phenyl)-pyridin-3-yl]-1-[3-(4-methyl-piperazin-1-yl)-propyl]-pyrrolo[2,3]pyridine;
- 5 dimethyl-{2-[3-(5-(3-methoxy-phenyl)-1-pyridin-3-yl)-pyrrolo[2,3]pyridin-1-yl]-propyl}-amine;
- dimethyl-{2-methyl-3-[3-(5-(3-methoxy-phenyl)-pyridin-3-yl)-pyrrolo[2,3]pyridin-1-yl]-propyl}-amine;
- 1-{2-[3-(5-(3-methoxy-phenyl)-pyridin-3-yl)-pyrrolo[2,3]pyridin-1-yl]-ethyl}-piperidine-4-carbonitrile;
- 10 3-[5-(4-methoxy-phenyl)-pyridin-3-yl]-indole;
- 3-[5-(4-methoxy-phenyl)-pyridin-3-yl]-1-(2-morpholin-4-yl-ethyl)-indole;
- 3-[5-(4-methoxy-phenyl)-pyridin-3-yl]-1-(2-piperidin-1-yl-ethyl)-indole;
- 3-[5-(4-methoxy-phenyl)-pyridin-3-yl]-1-(3-piperidin-1-yl-propyl)-indole;
- 15 dimethyl-{3-[3-(5-(4-methoxy-phenyl)-pyridin-3-yl)-indol-1-yl]-propyl}-amine;
- 3-[5-(4-methoxy-phenyl)-pyridin-3-yl]-1-(1-methyl-piperidin-3-ylmethyl)-indole;
- 3-[5-(4-methoxy-phenyl)-pyridin-3-yl]-1-[3-(4-methyl-piperazin-1-yl)-propyl]-indole;
- 20 dimethyl-{2-[3-(5-(4-methoxy-phenyl)-1-pyridin-3-yl)-indol-1-yl]-propyl}-amine;
- dimethyl-{2-methyl-3-[3-(5-(4-methoxy-phenyl)-pyridin-3-yl)-indol-1-yl]-propyl}-amine;
- 25 1-{2-[3-(5-(4-methoxy-phenyl)-pyridin-3-yl)-indol-1-yl]-ethyl}-piperidine-4-carbonitrile;
- 5-methoxy-3-[5-(4-methoxy-phenyl)-pyridin-3-yl]-1-(2-morpholin-4-yl-ethyl)-indole;
- 5-methoxy-3-[5-(4-methoxy-phenyl)-pyridin-3-yl]-1-(2-piperidin-1-yl-ethyl)-indole;
- 30

- 5-methoxy-3-[5-(4-methoxy-phenyl)-pyridin-3-yl]-1-(3-piperidin-1-yl-propyl)-indole;  
dimethyl-{3-[5-methoxy-3-(5-(4-methoxy-phenyl)-pyridin-3-yl)-indol-1-yl]-propyl}-amine;
- 5 5-methoxy-3-[5-(4-methoxy-phenyl)-pyridin-3-yl]-1-(1-methyl-piperidin-3-ylmethyl)-indole;  
5-methoxy-3-[5-(4-methoxy-phenyl)-pyridin-3-yl]-1-[3-(4-methyl-piperazin-1-yl)-propyl]-indole;  
dimethyl-{2-[5-methoxy-3-(5-(4-methoxy-phenyl)-1-pyridin-3-yl)-indol-1-yl]-propyl}-amine;
- 10 dimethyl-{2-methyl-3-[5-methoxy-3-(5-(4-methoxy-phenyl)-pyridin-3-yl)-indol-1-yl]-propyl}-amine;  
1-{2-[5-methoxy-3-(5-(4-methoxy-phenyl)-pyridin-3-yl)-indol-1-yl]-ethyl}-piperidine-4-carbonitrile;
- 15 4-chloro-3-[5-(4-methoxy-phenyl)-pyridin-3-yl]-indole;  
4-chloro-3-[5-(4-methoxy-phenyl)-pyridin-3-yl]-1-(2-morpholin-4-yl-ethyl)-indole;  
4-chloro-3-[5-(4-methoxy-phenyl)-pyridin-3-yl]-1-(2-piperidin-1-yl-ethyl)-indole;
- 20 4-chloro-3-[5-(4-methoxy-phenyl)-pyridin-3-yl]-1-(3-piperidin-1-yl-propyl)-indole;  
dimethyl-{3-[4-chloro-3-(5-(4-methoxy-phenyl)-pyridin-3-yl)-indol-1-yl]-propyl}-amine;  
4-chloro-3-[5-(4-methoxy-phenyl)-pyridin-3-yl]-1-(1-methyl-piperidin-3-ylmethyl)-indole;
- 25 4-chloro-3-[5-(4-methoxy-phenyl)-pyridin-3-yl]-1-[3-(4-methyl-piperazin-1-yl)-propyl]-indole;  
dimethyl-{2-[4-chloro-3-(5-(4-methoxy-phenyl)-1-pyridin-3-yl)-indol-1-yl]-propyl}-amine;
- 30 dimethyl-{2-methyl-3-[4-chloro-3-(5-(4-methoxy-phenyl)-pyridin-3-yl)-indol-1-yl]-propyl}-amine;

- 1-{2-[4-chloro-3-(5-(4-methoxy-phenyl)-pyridin-3-yl)-indol-1-yl]-ethyl}-  
piperidine-4-carbonitrile;  
5-chloro-3-[5-(4-methoxy-phenyl)-pyridin-3-yl]-indole;  
5-chloro-3-[5-(4-methoxy-phenyl)-pyridin-3-yl]-1-(2-morpholin-4-yl-ethyl)-  
5 indole;  
5-chloro-3-[5-(4-methoxy-phenyl)-pyridin-3-yl]-1-(2-piperidin-1-yl-ethyl)-  
indole;  
5-chloro-3-[5-(4-methoxy-phenyl)-pyridin-3-yl]-1-(3-piperidin-1-yl-propyl)-  
indole;  
10 dimethyl-{3-[5-chloro-3-(5-(4-methoxy-phenyl)-pyridin-3-yl)-indol-1-yl]-  
propyl}-amine;  
5-chloro-3-[5-(4-methoxy-phenyl)-pyridin-3-yl]-1-(1-methyl-piperidin-3-  
ylmethyl)-indole;  
5-chloro-3-[5-(4-methoxy-phenyl)-pyridin-3-yl]-1-[3-(4-methyl-piperazin-1-  
15 yl)-propyl]-indole;  
dimethyl-{2-[5-chloro-3-(5-(3-methoxy-phenyl)-1-pyridin-3-yl)-indol-1-yl]-  
propyl}-amine;  
dimethyl-{2-methyl-3-[5-chloro-3-(5-(4-methoxy-phenyl)-pyridin-3-yl)-  
indol-1-yl]-propyl}-amine;  
20 1-{2-[5-chloro-3-(5-(4-methoxy-phenyl)-pyridin-3-yl)-indol-1-yl]-ethyl}-  
piperidine-4-carbonitrile;  
7-methoxy-3-[5-(4-methoxy-phenyl)-pyridin-3-yl]-indole;  
7-methoxy-3-[5-(4-methoxy-phenyl)-pyridin-3-yl]-1-(2-morpholin-4-yl-  
ethyl)-indole;  
25 7-methoxy-3-[5-(4-methoxy-phenyl)-pyridin-3-yl]-1-(2-piperidin-1-yl-  
ethyl)-indole;  
7-methoxy-3-[5-(4-methoxy-phenyl)-pyridin-3-yl]-1-(3-piperidin-1-yl-  
propyl)-indole;  
dimethyl-{3-[7-methoxy-3-(5-(4-methoxy-phenyl)-pyridin-3-yl)-indol-1-yl]-  
30 propyl}-amine;

- 7-methoxy-3-[5-(4-methoxy-phenyl)-pyridin-3-yl]-1-(1-methyl-piperidin-3-ylmethyl)-indole;
- 7-methoxy-3-[5-(4-methoxy-phenyl)-pyridin-3-yl]-1-[3-(4-methyl-piperazin-1-yl)-propyl]-indole;
- 5 dimethyl-{2-[7-methoxy-3-(5-(4-methoxy-phenyl)-1-pyridin-3-yl)-indol-1-yl]-propyl}-amine;
- dimethyl-{2-methyl-3-[7-methoxy-3-(5-(4-methoxy-phenyl)-pyridin-3-yl)-indol-1-yl]-propyl}-amine;
- 1-{2-[7-methoxy-3-(5-(4-methoxy-phenyl)-pyridin-3-yl)-indol-1-yl]-ethyl}-
- 10 piperidine-4-carbonitrile;
- 6-chloro-3-[5-(4-methoxy-phenyl)-pyridin-3-yl]-indole;
- 6-chloro-3-[5-(4-methoxy-phenyl)-pyridin-3-yl]-1-(2-morpholin-4-yl-ethyl)-indole;
- 6-chloro-3-[5-(4-methoxy-phenyl)-pyridin-3-yl]-1-(2-piperidin-1-yl-ethyl)-
- 15 indole;
- 6-chloro-3-[5-(4-methoxy-phenyl)-pyridin-3-yl]-1-(3-piperidin-1-yl-propyl)-indole;
- dimethyl-{3-[6-chloro-3-(5-(4-methoxy-phenyl)-pyridin-3-yl)-indol-1-yl]-propyl}-amine;
- 20 6-chloro-3-[5-(4-methoxy-phenyl)-pyridin-3-yl]-1-(1-methyl-piperidin-3-ylmethyl)-indole;
- 6-chloro-3-[5-(4-methoxy-phenyl)-pyridin-3-yl]-1-[3-(4-methyl-piperazin-1-yl)-propyl]-indole;
- dimethyl-{2-[6-chloro-3-(5-(4-methoxy-phenyl)-1-pyridin-3-yl)-indol-1-yl]-
- 25 propyl}-amine;
- dimethyl-{2-methyl-3-[6-chloro-3-(5-(3-methoxy-phenyl)-pyridin-3-yl)-indol-1-yl]-propyl}-amine;
- 1-{2-[6-chloro-3-(5-(3-methoxy-phenyl)-pyridin-3-yl)-indol-1-yl]-ethyl}-
- piperidine-4-carbonitrile;
- 30 3-[5-(4-methoxy-phenyl)-pyridin-3-yl]-indole-5-carbonitrile;

- 3-[5-(3-methoxy-phenyl)-pyridin-3-yl]-1-(2-morpholin-4-yl-ethyl)-indole-5-carbonitrile;
- 3-[5-(4-methoxy-phenyl)-pyridin-3-yl]-1-(2-piperidin-1-yl-ethyl)-indole-5-carbonitrile;
- 5 3-[5-(4-methoxy-phenyl)-pyridin-3-yl]-1-(3-piperidin-1-yl-propyl)-indole-5-carbonitrile;
- 1-(3-dimethylamino-propyl)-3-[5-(4-methoxy-phenyl)-pyridin-3-yl]-indole-5-carbonitrile;
- 3-[5-(4-methoxy-phenyl)-pyridin-3-yl]-1-(1-methyl-piperidin-3-ylmethyl)-
- 10 indole-5-carbonitrile;
- 3-[5-(4-methoxy-phenyl)-pyridin-3-yl]-1-[3-(4-methyl-piperazin-1-yl)-propyl]-indole-5-carbonitrile;
- 1-(2-dimethylamino-propyl)-3-[5-(4-methoxy-phenyl)-pyridin-3-yl]-indole-5-carbonitrile;
- 15 1-(1-dimethylamino-2-methyl-propyl)-3-[5-(4-methoxy-phenyl)-pyridin-3-yl]-indole-5-carbonitrile;
- 1-[2-(4-cyano-piperidin-1-yl-ethyl)-3-[5-(4-methoxy-phenyl)-pyridin-3-yl]-indole-5-carbonitrile;
- 3-[5-(4-methoxy-phenyl)-pyridin-3-yl]-indole-4-carboxylic acid methyl
- 20 ester;
- 3-[5-(4-methoxy-phenyl)-pyridin-3-yl]-1-(2-morpholin-4-yl-ethyl)-indole-4-carboxylic acid methyl ester;
- 3-[5-(4-methoxy-phenyl)-pyridin-3-yl]-1-(2-piperidin-1-yl-ethyl)-indole-4-carboxylic acid methyl ester;
- 25 3-[5-(4-methoxy-phenyl)-pyridin-3-yl]-1-(3-piperidin-1-yl-propyl)-indole-4-carboxylic acid methyl ester;
- 1-(3-dimethylamino-propyl)-3-[5-(4-methoxy-phenyl)-pyridin-3-yl]-indole-4-carboxylic acid methyl ester;
- 3-[5-(4-methoxy-phenyl)-pyridin-3-yl]-1-(1-methyl-piperidin-3-ylmethyl)-
- 30 indole-4-carboxylic acid methyl ester;

- 3-[5-(4-methoxy-phenyl)-pyridin-3-yl]-1-[3-(4-methyl-piperazin-1-yl)-propyl]-indole-4-carboxylic acid methyl ester;
- 1-(2-dimethylamino-propyl)-3-[5-(4-methoxy-phenyl)-pyridin-3-yl]-indole-4-carboxylic acid methyl ester;
- 5 1-(1-dimethylamino-2-methyl-propyl)-3-[5-(4-methoxy-phenyl)-pyridin-3-yl]-indole-4-carboxylic acid methyl ester;
- 1-[2-(4-cyano-piperidin-1-yl-ethyl)-3-[5-(4-methoxy-phenyl)-pyridin-3-yl]-indole-4-carboxylic acid methyl ester;
- 3-[5-(4-methoxy-phenyl)-pyridin-3-yl]-pyrrolo[2,3]pyridine;
- 10 3-[5-(4-methoxy-phenyl)-pyridin-3-yl]-1-(2-morpholin-4-yl-ethyl)-pyrrolo[2,3]pyridine;
- 3-[5-(4-methoxy-phenyl)-pyridin-3-yl]-1-(2-piperidin-1-yl-ethyl)-pyrrolo[2,3]pyridine;
- 3-[5-(4-methoxy-phenyl)-pyridin-3-yl]-1-(3-piperidin-1-yl-propyl)-pyrrolo[2,3]pyridine;
- 15 dimethyl-{3-[3-(5-(4-methoxy-phenyl)-pyridin-3-yl)-pyrrolo[2,3]pyridin-1-yl]-propyl}-amine;
- 3-[5-(4-methoxy-phenyl)-pyridin-3-yl]-1-(1-methyl-piperidin-3-ylmethyl)-pyrrolo[2,3]pyridine;
- 20 3-[5-(4-methoxy-phenyl)-pyridin-3-yl]-1-[3-(4-methyl-piperazin-1-yl)-propyl]-pyrrolo[2,3]pyridine;
- dimethyl-{2-[3-(5-(4-methoxy-phenyl)-l-pyridin-3-yl)-pyrrolo[2,3]pyridin-1-yl]-propyl}-amine;
- dimethyl-{2-methyl-3-[3-(5-(4-methoxy-phenyl)-pyridin-3-yl)-pyrrolo[2,3]pyridin-1-yl]-propyl}-amine;
- 25 1-{2-[3-(5-(4-methoxy-phenyl)-pyridin-3-yl)-pyrrolo[2,3]pyridin-1-yl]-ethyl}-piperidine-4-carbonitrile;
- 3-[5-(3-chloro-phenyl)-pyridin-3-yl]-indole;
- 3-[5-(3-chloro-phenyl)-pyridin-3-yl]-1-(2-morpholin-4-yl-ethyl)-indole;
- 30 3-[5-(3-chloro-phenyl)-pyridin-3-yl]-1-(2-piperidin-1-yl-ethyl)-indole;
- 3-[5-(3-chloro-phenyl)-pyridin-3-yl]-1-(3-piperidin-1-yl-propyl)-indole;

- dimethyl-{3-[3-(5-(3-chloro-phenyl)-pyridin-3-yl)-indol-1-yl]-propyl}-amine;
- 3-[5-(3-chloro-phenyl)-pyridin-3-yl]-1-(1-methyl-piperidin-3-ylmethyl)-indole;
- 5 3-[5-(3-chloro-phenyl)-pyridin-3-yl]-1-[3-(4-methyl-piperazin-1-yl)-propyl]-indole;
- dimethyl-{2-[3-(5-(3-chloro-phenyl)-1-pyridin-3-yl)-indol-1-yl]-propyl}-amine;
- dimethyl-{2-methyl-3-[3-(5-(3-chloro-phenyl)-pyridin-3-yl)-indol-1-yl]-propyl}-amine;
- 10 1-{2-[3-(5-(3-chloro-phenyl)-pyridin-3-yl)-indol-1-yl]-ethyl}-piperidine-4-carbonitrile;
- 3-[5-(3-chloro-phenyl)-pyridin-3-yl]-5-methoxy-indole;
- 3-[5-(3-chloro-phenyl)-pyridin-3-yl]-5-methoxy-1-(2-morpholin-4-yl-ethyl)-indole;
- 15 3-[5-(3-chloro-phenyl)-pyridin-3-yl]-5-methoxy-1-(2-piperidin-1-yl-ethyl)-indole;
- 3-[5-(3-chloro-phenyl)-pyridin-3-yl]-5-methoxy-1-(3-piperidin-1-yl-propyl)-indole;
- 20 dimethyl-{3-[3-(5-(3-chloro-phenyl)-pyridin-3-yl)-5-methoxy-indol-1-yl]-propyl}-amine;
- 3-[5-(3-chloro-phenyl)-pyridin-3-yl]-1-(1-methyl-piperidin-3-ylmethyl)-5-methoxy-indole;
- 3-[5-(3-chloro-phenyl)-pyridin-3-yl]-1-[3-(4-methyl-piperazin-1-yl)-propyl]-5-methoxy-indole;
- 25 5-methoxy-indole;
- dimethyl-{2-[3-(5-(3-chloro-phenyl)-1-pyridin-3-yl)-5-methoxy-indol-1-yl]-propyl}-amine;
- dimethyl-{2-methyl-3-[3-(5-(3-chloro-phenyl)-pyridin-3-yl)-5-methoxy-indol-1-yl]-propyl}-amine;
- 30 1-{2-[3-(5-(3-chloro-phenyl)-pyridin-3-yl)-5-methoxy-indol-1-yl]-ethyl}-piperidine-4-carbonitrile;

- 4-chloro-3-[5-(3-chloro-phenyl)-pyridin-3-yl]-indole;  
4-chloro-3-[5-(3-chloro-phenyl)-pyridin-3-yl]-1-(2-morpholin-4-yl-ethyl)-  
indole;  
4-chloro-3-[5-(3-chloro-phenyl)-pyridin-3-yl]-1-(2-piperidin-1-yl-ethyl)-  
5 indole;  
4-chloro-3-[5-(3-chloro-phenyl)-pyridin-3-yl]-1-(3-piperidin-1-yl-propyl)-  
indole;  
dimethyl-{3-[4-chloro-3-(5-(3-chloro-phenyl)-pyridin-3-yl)-indol-1-yl]-  
propyl}-amine;  
10 4-chloro-3-[5-(3-chloro-phenyl)-pyridin-3-yl]-1-(1-methyl-piperidin-3-  
ylmethyl)-indole;  
4-chloro-3-[5-(3-chloro-phenyl)-pyridin-3-yl]-1-[3-(4-methyl-piperazin-1-  
yl)-propyl]-indole;  
dimethyl-{2-[4-chloro-3-(5-(3-chloro-phenyl)-1-pyridin-3-yl)-indol-1-yl]-  
15 propyl}-amine;  
dimethyl-{2-methyl-3-[4-chloro-3-(5-(3-chloro-phenyl)-pyridin-3-yl)-indol-  
1-yl]-propyl}-amine;  
1-(2-[4-chloro-3-(5-(3-chloro-phenyl)-pyridin-3-yl)-indol-1-yl]-ethyl)-  
piperidine-4-carbonitrile;  
20 5-chloro-3-[5-(3-chloro-phenyl)-pyridin-3-yl]-indole;  
5-chloro-3-[5-(3-chloro-phenyl)-pyridin-3-yl]-1-(2-morpholin-4-yl-ethyl)-  
indole;  
5-chloro-3-[5-(3-chloro-phenyl)-pyridin-3-yl]-1-(2-piperidin-1-yl-ethyl)-  
indole;  
25 5-chloro-3-[5-(3-chloro-phenyl)-pyridin-3-yl]-1-(3-piperidin-1-yl-propyl)-  
indole;  
dimethyl-{3-[5-chloro-3-(5-(3-chloro-phenyl)-pyridin-3-yl)-indol-1-yl]-  
propyl}-amine;  
5-chloro-3-[5-(3-chloro-phenyl)-pyridin-3-yl]-1-(1-methyl-piperidin-3-  
30 ylmethyl)-indole;



- 5-chloro-3-[5-(3-chloro-phenyl)-pyridin-3-yl]-1-[3-(4-methyl-piperazin-1-yl)-propyl]-indole;  
dimethyl-{2-[5-chloro-3-(5-(3-chloro-phenyl)-1-pyridin-3-yl)-indol-1-yl]-propyl}-amine;
- 5 dimethyl-{2-methyl-3-[5-chloro-3-(5-(3-chloro-phenyl)-pyridin-3-yl)-indol-1-yl]-propyl}-amine;  
1-{2-[5-chloro-3-(5-(3-chloro-phenyl)-pyridin-3-yl)-indol-1-yl]-ethyl}-piperidine-4-carbonitrile;  
3-[5-(3-chloro-phenyl)-pyridin-3-yl]-7-methoxy-indole;
- 10 3-[5-(3-chloro-phenyl)-pyridin-3-yl]-7-methoxy-1-(2-morpholin-4-yl-ethyl)-indole;  
3-[5-(3-chloro-phenyl)-pyridin-3-yl]-7-methoxy-1-(2-piperidin-1-yl-ethyl)-indole;  
3-[5-(3-chloro-phenyl)-pyridin-3-yl]-7-methoxy-1-(3-piperidin-1-yl-propyl)-
- 15 indole;  
dimethyl-{3-[3-(5-(3-chloro-phenyl)-pyridin-3-yl)-7-methoxy-indol-1-yl]-propyl}-amine;  
3-[5-(3-chloro-phenyl)-pyridin-3-yl]-1-(1-methyl-piperidin-3-ylmethyl)-7-methoxy-indole;
- 20 3-[5-(3-chloro-phenyl)-pyridin-3-yl]-1-[3-(4-methyl-piperazin-1-yl)-propyl]-7-methoxy-indole;  
dimethyl-{2-[3-(5-(3-chloro-phenyl)-1-pyridin-3-yl)-7-methoxy-indol-1-yl]-propyl}-amine;  
dimethyl-{2-methyl-3-[3-(5-(3-chloro-phenyl)-pyridin-3-yl)-7-methoxy-
- 25 indol-1-yl]-propyl}-amine;  
1-{2-[3-(5-(3-chloro-phenyl)-pyridin-3-yl)-7-methoxy-indol-1-yl]-ethyl}-piperidine-4-carbonitrile;  
6-chloro-3-[5-(3-chloro-phenyl)-pyridin-3-yl]-indole;  
6-chloro-3-[5-(3-chloro-phenyl)-pyridin-3-yl]-1-(2-morpholin-4-yl-ethyl)-
- 30 indole;

- 6-chloro-3-[5-(3-chloro-phenyl)-pyridin-3-yl]-1-(2-piperidin-1-yl-ethyl)-indole;
- 6-chloro-3-[5-(3-chloro-phenyl)-pyridin-3-yl]-1-(3-piperidin-1-yl-propyl)-indole;
- 5 dimethyl-{3-[6-chloro-3-(5-(3-chloro-phenyl)-pyridin-3-yl)-indol-1-yl]-propyl}-amine;
- 6-chloro-3-[5-(3-chloro-phenyl)-pyridin-3-yl]-1-(1-methyl-piperidin-3-ylmethyl)-indole;
- 6-chloro-3-[5-(3-chloro-phenyl)-pyridin-3-yl]-1-[3-(4-methyl-piperazin-1-yl)-propyl]-indole;
- 10 dimethyl-{2-[6-chloro-3-(5-(3-chloro-phenyl)-1-pyridin-3-yl)-indol-1-yl]-propyl}-amine;
- dimethyl-{2-methyl-3-[6-chloro-3-(5-(3-chloro-phenyl)-pyridin-3-yl)-indol-1-yl]-propyl}-amine;
- 15 1-{2-[6-chloro-3-(5-(3-chloro-phenyl)-pyridin-3-yl)-indol-1-yl]-ethyl}-piperidine-4-carbonitrile;
- 3-[5-(3-chloro-phenyl)-pyridin-3-yl]-indole-5-carbonitrile;
- 3-[5-(3-chloro-phenyl)-pyridin-3-yl]-1-(2-morpholin-4-yl-ethyl)-indole-5-carbonitrile;
- 20 3-[5-(3-chloro-phenyl)-pyridin-3-yl]-1-(2-piperidin-1-yl-ethyl)-indole-5-carbonitrile;
- 3-[5-(3-chloro-phenyl)-pyridin-3-yl]-1-(3-piperidin-1-yl-propyl)-indole-5-carbonitrile;
- 1-(3-dimethylamino-propyl)-3-[5-(3-chloro-phenyl)-pyridin-3-yl]-indole-5-
- 25 carbonitrile;
- 3-[5-(3-chloro-phenyl)-pyridin-3-yl]-1-(1-methyl-piperidin-3-ylmethyl)-indole-5-carbonitrile;
- 3-[5-(3-chloro-phenyl)-pyridin-3-yl]-1-[3-(4-methyl-piperazin-1-yl)-propyl]-indole-5-carbonitrile;
- 30 1-(2-dimethylamino-propyl)-3-[5-(3-chloro-phenyl)-pyridin-3-yl]-indole-5-carbonitrile;

- 1-(1-dimethylamino-2-methyl-propyl)-3-[5-(3-chloro-phenyl)-pyridin-3-yl]-indole-5-carbonitrile;
- 1-[2-(4-cyano-piperidin-1-yl-ethyl)-3-[5-(3-chloro-phenyl)-pyridin-3-yl]-indole-5-carbonitrile;
- 5 3-[5-(3-chloro-phenyl)-pyridin-3-yl]-indole-4-carboxylic acid methyl ester;
- 3-[5-(3-chloro-phenyl)-pyridin-3-yl]-1-(2-morpholin-4-yl-ethyl)-indole-4-carboxylic acid methyl ester;
- 3-[5-(3-chloro-phenyl)-pyridin-3-yl]-1-(2-piperidin-1-yl-ethyl)-indole-4-carboxylic acid methyl ester;
- 10 3-[5-(3-chloro-phenyl)-pyridin-3-yl]-1-(3-piperidin-1-yl-propyl)-indole-4-carboxylic acid methyl ester;
- 1-(3-dimethylamino-propyl)-3-[5-(3-chloro-phenyl)-pyridin-3-yl]-indole-4-carboxylic acid methyl ester;
- 3-[5-(3-chloro-phenyl)-pyridin-3-yl]-1-(1-methyl-piperidin-3-ylmethyl)-indole-4-carboxylic acid methyl ester;
- 15 3-[5-(3-chloro-phenyl)-pyridin-3-yl]-1-[3-(4-methyl-piperazin-1-yl)-propyl]-indole-4-carboxylic acid methyl ester;
- 1-(2-dimethylamino-propyl)-3-[5-(3-chloro-phenyl)-pyridin-3-yl]-indole-4-carboxylic acid methyl ester;
- 20 1-(1-dimethylamino-2-methyl-propyl)-3-[5-(3-chloro-phenyl)-pyridin-3-yl]-indole-4-carboxylic acid methyl ester;
- 1-[2-(4-cyano-piperidin-1-yl-ethyl)-3-[5-(3-chloro-phenyl)-pyridin-3-yl]-indole-4-carboxylic acid methyl ester;
- 3-[5-(3-chloro-phenyl)-pyridin-3-yl]-pyrrolo[2,3]pyridine;
- 25 3-[5-(3-chloro-phenyl)-pyridin-3-yl]-1-(2-morpholin-4-yl-ethyl)-pyrrolo[2,3]pyridine;
- 3-[5-(3-chloro-phenyl)-pyridin-3-yl]-1-(2-piperidin-1-yl-ethyl)-pyrrolo[2,3]pyridine;
- 3-[5-(3-chloro-phenyl)-pyridin-3-yl]-1-(3-piperidin-1-yl-propyl)-pyrrolo[2,3]pyridine;
- 30 pyridine;

- dimethyl-{3-[3-(5-(3-chloro-phenyl)-pyridin-3-yl)-pyrrolo[2,3]pyridin-1-yl]-propyl}-amine;  
3-[5-(3-chloro-phenyl)-pyridin-3-yl]-1-(1-methyl-piperidin-3-ylmethyl)-pyrrolo[2,3]pyridine;  
5 3-[5-(3-chloro-phenyl)-pyridin-3-yl]-1-[3-(4-methyl-piperazin-1-yl)-propyl]-pyrrolo[2,3]pyridine;  
dimethyl-{2-[3-(5-(3-chloro-phenyl)-1-pyridin-3-yl)-pyrrolo[2,3]pyridin-1-yl]-propyl}-amine;  
dimethyl-{2-methyl-3-[3-(5-(3-chloro-phenyl)-pyridin-3-yl)-pyrrolo[2,3]pyridin-1-yl]-propyl}-amine;  
10 1-{2-[3-(5-(3-chloro-phenyl)-pyridin-3-yl)-pyrrolo[2,3]pyridin-1-yl]-ethyl}-piperidine-4-carbonitrile;  
3-[5-(4-chloro-phenyl)-pyridin-3-yl]-indole;  
3-[5-(4-chloro-phenyl)-pyridin-3-yl]-1-(2-morpholin-4-yl-ethyl)-indole;  
15 3-[5-(4-chloro-phenyl)-pyridin-3-yl]-1-(2-piperidin-1-yl-ethyl)-indole;  
3-[5-(4-chloro-phenyl)-pyridin-3-yl]-1-(3-piperidin-1-yl-propyl)-indole;  
dimethyl-{3-[3-(5-(4-chloro-phenyl)-pyridin-3-yl)-indol-1-yl]-propyl}-amine;  
3-[5-(4-chloro-phenyl)-pyridin-3-yl]-1-(1-methyl-piperidin-3-ylmethyl)-indole;  
20 3-[5-(4-chloro-phenyl)-pyridin-3-yl]-1-[3-(4-methyl-piperazin-1-yl)-propyl]-indole;  
dimethyl-{2-[3-(5-(4-chloro-phenyl)-1-pyridin-3-yl)-indol-1-yl]-propyl}-amine;  
dimethyl-{2-methyl-3-[3-(5-(4-chloro-phenyl)-pyridin-3-yl)-indol-1-yl]-propyl}-amine;  
25 1-{2-[3-(5-(4-chloro-phenyl)-pyridin-3-yl)-indol-1-yl]-ethyl}-piperidine-4-carbonitrile;  
3-[5-(4-chloro-phenyl)-pyridin-3-yl]-5-methoxy-indole;  
30 3-[5-(4-chloro-phenyl)-pyridin-3-yl]-5-methoxy-1-(2-morpholin-4-yl-ethyl)-indole;

- 3-[5-(4-chloro-phenyl)-pyridin-3-yl]-5-methoxy-1-(2-piperidin-1-yl-ethyl)-indole;
- 3-[5-(4-chloro-phenyl)-pyridin-3-yl]-5-methoxy-1-(3-piperidin-1-yl-propyl)-indole;
- 5 dimethyl-{3-[3-(5-(4-chloro-phenyl)-pyridin-3-yl)-5-methoxy-indol-1-yl]-propyl}-amine;
- 3-[5-(4-chloro-phenyl)-pyridin-3-yl]-1-(1-methyl-piperidin-3-ylmethyl)-5-methoxy-indole;
- 3-[5-(4-chloro-phenyl)-pyridin-3-yl]-1-[3-(4-methyl-piperazin-1-yl)-propyl]-5-methoxy-indole;
- 10 dimethyl-{2-[3-(5-(4-chloro-phenyl)-1-pyridin-3-yl)-5-methoxy-indol-1-yl]-propyl}-amine;
- dimethyl-{2-methyl-3-[3-(5-(4-chloro-phenyl)-pyridin-3-yl)-5-methoxy-indol-1-yl]-propyl}-amine;
- 15 1-{2-[3-(5-(4-chloro-phenyl)-pyridin-3-yl)-5-methoxy-indol-1-yl]-ethyl}-piperidine-4-carbonitrile;
- 4-chloro-3-[5-(4-chloro-phenyl)-pyridin-3-yl]-indole;
- 4-chloro-3-[5-(4-chloro-phenyl)-pyridin-3-yl]-1-(2-morpholin-4-yl-ethyl)-indole;
- 20 4-chloro-3-[5-(4-chloro-phenyl)-pyridin-3-yl]-1-(2-piperidin-1-yl-ethyl)-indole;
- 4-chloro-3-[5-(4-chloro-phenyl)-pyridin-3-yl]-1-(3-piperidin-1-yl-propyl)-indole;
- dimethyl-{3-[4-chloro-3-(5-(4-chloro-phenyl)-pyridin-3-yl)-indol-1-yl]-propyl}-amine;
- 25 4-chloro-3-[5-(4-chloro-phenyl)-pyridin-3-yl]-1-(1-methyl-piperidin-3-ylmethyl)-indole;
- 4-chloro-3-[5-(4-chloro-phenyl)-pyridin-3-yl]-1-[3-(4-methyl-piperazin-1-yl)-propyl]-indole;
- 30 dimethyl-{2-[4-chloro-3-(5-(4-chloro-phenyl)-1-pyridin-3-yl)-indol-1-yl]-propyl}-amine;

- dimethyl-{2-methyl-3-[4-chloro-3-(5-(4-chloro-phenyl)-pyridin-3-yl)-indol-1-yl]-propyl}-amine;  
1-{2-[4-chloro-3-(5-(4-chloro-phenyl)-pyridin-3-yl)-indol-1-yl]-ethyl}-piperidine-4-carbonitrile;
- 5 5-chloro-3-[5-(4-chloro-phenyl)-pyridin-3-yl]-indole;  
5-chloro-3-[5-(4-chloro-phenyl)-pyridin-3-yl]-1-(2-morpholin-4-yl-ethyl)-indole;  
5-chloro-3-[5-(4-chloro-phenyl)-pyridin-3-yl]-1-(2-piperidin-1-yl-ethyl)-indole;
- 10 5-chloro-3-[5-(4-chloro-phenyl)-pyridin-3-yl]-1-(3-piperidin-1-yl-propyl)-indole;  
dimethyl-{3-[5-chloro-3-(5-(4-chloro-phenyl)-pyridin-3-yl)-indol-1-yl]-propyl}-amine;  
5-chloro-3-[5-(4-chloro-phenyl)-pyridin-3-yl]-1-(1-methyl-piperidin-3-ylmethyl)-indole;
- 15 5-chloro-3-[5-(4-chloro-phenyl)-pyridin-3-yl]-1-[3-(4-methyl-piperazin-1-yl)-propyl]-indole;  
dimethyl-{2-[5-chloro-3-(5-(4-chloro-phenyl)-1-pyridin-3-yl)-indol-1-yl]-propyl}-amine;
- 20 dimethyl-{2-methyl-3-[5-chloro-3-(5-(4-chloro-phenyl)-pyridin-3-yl)-indol-1-yl]-propyl}-amine;  
1-{2-[5-chloro-3-(5-(4-chloro-phenyl)-pyridin-3-yl)-indol-1-yl]-ethyl}-piperidine-4-carbonitrile;  
3-[5-(4-chloro-phenyl)-pyridin-3-yl]-7-methoxy-indole;
- 25 3-[5-(4-chloro-phenyl)-pyridin-3-yl]-7-methoxy-1-(2-morpholin-4-yl-ethyl)-indole;  
3-[5-(4-chloro-phenyl)-pyridin-3-yl]-7-methoxy-1-(2-piperidin-1-yl-ethyl)-indole;  
3-[5-(4-chloro-phenyl)-pyridin-3-yl]-7-methoxy-1-(3-piperidin-1-yl-propyl)-
- 30 indole;


- dimethyl-{3-[3-(5-(4-chloro-phenyl)-pyridin-3-yl)-7-methoxy-indol-1-yl]-propyl}-amine;
- 3-[5-(4-chloro-phenyl)-pyridin-3-yl]-1-(1-methyl-piperidin-3-ylmethyl)-7-methoxy-indole;
- 5 3-[5-(4-chloro-phenyl)-pyridin-3-yl]-1-[3-(4-methyl-piperazin-1-yl)-propyl]-7-methoxy-indole;
- dimethyl-{2-[3-(5-(3-chloro-phenyl)-1-pyridin-3-yl)-7-methoxy-indol-1-yl]-propyl}-amine;
- dimethyl-{2-methyl-3-[3-(5-(4-chloro-phenyl)-pyridin-3-yl)-7-methoxy-indol-1-yl]-propyl}-amine;
- 10 1-[2-[3-(5-(4-chloro-phenyl)-pyridin-3-yl)-7-methoxy-indol-1-yl]-ethyl]-piperidine-4-carbonitrile;
- 6-chloro-3-[5-(4-chloro-phenyl)-pyridin-3-yl]-indole;
- 6-chloro-3-[5-(4-chloro-phenyl)-pyridin-3-yl]-1-(2-morpholin-4-yl-ethyl)-indole;
- 15 6-chloro-3-[5-(4-chloro-phenyl)-pyridin-3-yl]-1-(2-piperidin-1-yl-ethyl)-indole;
- 6-chloro-3-[5-(4-chloro-phenyl)-pyridin-3-yl]-1-(3-piperidin-1-yl-propyl)-indole;
- 20 dimethyl-{3-[6-chloro-3-(5-(4-chloro-phenyl)-pyridin-3-yl)-indol-1-yl]-propyl}-amine;
- 6-chloro-3-[5-(4-chloro-phenyl)-pyridin-3-yl]-1-(1-methyl-piperidin-3-ylmethyl)-indole;
- 6-chloro-3-[5-(4-chloro-phenyl)-pyridin-3-yl]-1-[3-(4-methyl-piperazin-1-yl)-propyl]-indole;
- 25 dimethyl-{2-[6-chloro-3-(5-(4-chloro-phenyl)-1-pyridin-3-yl)-indol-1-yl]-propyl}-amine;
- dimethyl-{2-methyl-3-[6-chloro-3-(5-(4-chloro-phenyl)-pyridin-3-yl)-indol-1-yl]-propyl}-amine;
- 30 1-[2-[6-chloro-3-(5-(4-chloro-phenyl)-pyridin-3-yl)-indol-1-yl]-ethyl]-piperidine-4-carbonitrile;

- 3-[5-(4-chloro-phenyl)-pyridin-3-yl]-indole-5-carbonitrile;  
3-[5-(4-chloro-phenyl)-pyridin-3-yl]-1-(2-morpholin-4-yl-ethyl)-indole-5-carbonitrile;  
3-[5-(4-chloro-phenyl)-pyridin-3-yl]-1-(2-piperidin-1-yl-ethyl)-indole-5-carbonitrile;  
5 3-[5-(4-chloro-phenyl)-pyridin-3-yl]-1-(3-piperidin-1-yl-propyl)-indole-5-carbonitrile;  
1-(3-dimethylamino-propyl)-3-[5-(4-chloro-phenyl)-pyridin-3-yl]-indole-5-carbonitrile;  
10 3-[5-(4-chloro-phenyl)-pyridin-3-yl]-1-(1-methyl-piperidin-3-ylmethyl)-indole-5-carbonitrile;  
3-[5-(4-chloro-phenyl)-pyridin-3-yl]-1-[3-(4-methyl-piperazin-1-yl)-propyl]-indole-5-carbonitrile;  
1-(2-dimethylamino-propyl)-3-[5-(4-chloro-phenyl)-pyridin-3-yl]-indole-5-carbonitrile;  
15 1-(1-dimethylamino-2-methyl-propyl)-3-[5-(4-chloro-phenyl)-pyridin-3-yl]-indole-5-carbonitrile;  
1-[2-(4-cyano-piperidin-1-yl-ethyl)-3-[5-(4-chloro-phenyl)-pyridin-3-yl]-indole-5-carbonitrile;  
20 3-[5-(4-chloro-phenyl)-pyridin-3-yl]-indole-4-carboxylic acid methyl ester;  
3-[5-(4-chloro-phenyl)-pyridin-3-yl]-1-(2-morpholin-4-yl-ethyl)-indole-4-carboxylic acid methyl ester;  
3-[5-(4-chloro-phenyl)-pyridin-3-yl]-1-(2-piperidin-1-yl-ethyl)-indole-4-carboxylic acid methyl ester;  
25 3-[5-(4-chloro-phenyl)-pyridin-3-yl]-1-(3-piperidin-1-yl-propyl)-indole-4-carboxylic acid methyl ester;  
1-(3-dimethylamino-propyl)-3-[5-(4-chloro-phenyl)-pyridin-3-yl]-indole-4-carboxylic acid methyl ester;  
3-[5-(4-chloro-phenyl)-pyridin-3-yl]-1-(1-methyl-piperidin-3-ylmethyl)-indole-4-carboxylic acid methyl ester;  
30 indole-4-carboxylic acid methyl ester;




- 3-[5-(4-chloro-phenyl)-pyridin-3-yl]-1-[3-(4-methyl-piperazin-1-yl)-propyl]-indole-4-carboxylic acid methyl ester;
- 1-(2-dimethylamino-propyl)-3-[5-(4-chloro-phenyl)-pyridin-3-yl]-indole-4-carboxylic acid methyl ester;
- 5 1-(1-dimethylamino-2-methyl-propyl)-3-[5-(4-chloro-phenyl)-pyridin-3-yl]-indole-4-carboxylic acid methyl ester;
- 1-[2-(4-cyano-piperidin-1-yl-ethyl)-3-[5-(4-chloro-phenyl)-pyridin-3-yl]-indole-4-carboxylic acid methyl ester;
- 3-[5-(4-chloro-phenyl)-pyridin-3-yl]-pyrrolo[2,3]pyridine;
- 10 3-[5-(4-chloro-phenyl)-pyridin-3-yl]-1-(2-morpholin-4-yl-ethyl)-pyrrolo[2,3]pyridine;
- 3-[5-(4-chloro-phenyl)-pyridin-3-yl]-1-(2-piperidin-1-yl-ethyl)-pyrrolo[2,3]pyridine;
- 3-[5-(4-chloro-phenyl)-pyridin-3-yl]-1-(3-piperidin-1-yl-propyl)-pyrrolo[2,3]pyridine; dimethyl-{3-[3-(5-(4-chloro-phenyl)-pyridin-3-yl)-pyrrolo[2,3]pyridin-1-yl]-propyl}-amine;
- 15 3-[5-(4-chloro-phenyl)-pyridin-3-yl]-1-(1-methyl-piperidin-3-ylmethyl)-pyrrolo[2,3]pyridine;
- 3-[5-(4-chloro-phenyl)-pyridin-3-yl]-1-[3-(4-methyl-piperazin-1-yl)-propyl]-pyrrolo[2,3]pyridine ;
- 20 dimethyl-{2-[3-(5-(4-chloro-phenyl)-1-pyridin-3-yl)-pyrrolo[2,3]pyridin-1-yl]-propyl}-amine;
- dimethyl-{2-methyl-3-[3-(5-(4-chloro-phenyl)-pyridin-3-yl)-pyrrolo[2,3]pyridin-1-yl]-propyl}-amine; and
- 25 1-[2-[3-(5-(4-chloro-phenyl)-pyridin-3-yl)-pyrrolo[2,3]pyridin-1-yl]-ethyl]-piperidine-4-carbonitrile.

A more preferred embodiment is a compound selected from a group consisting of:




1-[3-(4-methyl-piperazin-1-yl)-propyl]-3-(5-thiophen-3-yl-pyridin-3-yl)-1*H*-indole;

5




5-chloro-1-[3-(4-methyl-piperazin-1-yl)-propyl]-3-(5-thiophen-3-yl-pyridin-3-yl)-1*H*-indole;

10




1-[3-(4-methyl-piperazin-1-yl)-propyl]-3-(5-thiophen-3-yl-pyridin-3-yl)-1-*H*-indole-5-carbonitrile;

15




5-methoxy-1-[3-(4-methyl-piperazin-1-yl)-propyl]-3-(5-thiophen-3-yl-pyridin-3-yl)-1*H*-indole;

5



1-(3-piperidin-1-yl-propyl)-3-(5-thiophen-3-yl-pyridin-3-yl)-1*H*-indole; and



10

1-(2-morpholin-4-yl-ethyl)-3-(5-thiophen-3-yl-pyridin-3-yl)-1*H*-indole.

Also included is a method of treating or preventing a tyrosine kinase dependent disease or condition in a mammal which comprises administering to a mammalian patient in need of such treatment a therapeutically effective amount of a compound of formula I or a pharmaceutically acceptable salt or hydrate thereof.

Also included is a method of treating or preventing cancer in a mammalian patient in need of such treatment which is comprised of administering to said patient a therapeutically effective amount of a compound of formula I or a pharmaceutically acceptable salt or hydrate thereof.

Also included in the present invention is a method of treating or preventing diseases in which neoangiogenesis is implicated, which is comprised of administering to a mammalian patient in need of such treatment a compound of formula I or a pharmaceutically acceptable salt or hydrate thereof in a therapeutically effective amount.

More particularly, a method of treating or preventing ocular disease in which neoangiogenesis occurs is included herein, which is comprised of administering to a mammalian patient in need of such treatment a compound of formula I or a pharmaceutically acceptable salt or hydrate thereof in a therapeutically effective amount.

More particularly, a method of treating or preventing retinal vascularization is included herein, which is comprised of administering to a mammalian patient in need of such treatment a compound of formula I or a pharmaceutically acceptable salt or hydrate thereof in a therapeutically effective amount. Diabetic retinopathy is an example of a disease in which neoangiogenesis or retinal vascularization is part of the overall disease etiology. Also included is a method of treating or preventing age-related macular degeneration. The methods of treatment are a more preferred embodiment of the present invention.

These and other aspects of the invention will be apparent from the teachings contained herein.

The compounds of the present invention may have asymmetric centers and occur as racemates, racemic mixtures, and as individual diastereomers, with all possible isomers, including optical isomers, being included in the present invention. When any variable (e.g. aryl, heterocycle,  $R^1$ ,  $R^2$  etc.) occurs more than one time in any constituent, its definition on each occurrence is independent of every other occurrence. Also, combinations of substituents and/or variables are permissible only if such combinations result in stable compounds. For example, " $NR^{c_2}$ " may be any of the following if  $R^c$  is defined as H,  $CH_3$ , or OH:  $N(OH)(CH_3)$ ,  $NH_2$ ,  $N(CH_3)_2$ ,  $NH(CH_3)$ , etc.

As used herein, "alkyl" is intended to include both branched and straight-chain saturated, monovalent aliphatic hydrocarbon groups having the specified number of carbon atoms. For example,  $C_{1-10}$ , as in  $(C_{1-10})$ alkyl is defined to identify the group as having 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 carbons in a linear or branched arrangement, such that  $(C_{1-10})$ alkyl specifically includes methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, nonyl and decyl. "Alkoxy" represents an alkyl group of indicated number of carbon atoms attached through an oxygen bridge. "Halogen" or "halo" as used herein means fluoro, chloro, bromo and iodo. Cycloalkyl refers to a cyclic or bicyclic saturated chain of three to ten carbons. Examples of cycloalkyls are cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, tetrahydro-naphthalene, etc.

The term "alkylenyl" or "alkylene" refers to a divalent alkane (hydrocarbon) derived radical containing from 1 to 10 carbon atoms unless otherwise defined. It may be straight, branched or cyclic. Examples of alkylenes are  $-CH_2-$ ,  $-CH_2CH_2-$ ,  $-CH(CH_3)CH_2-$ , etc. Similarly, " $-C_{1-6}$  alkylene-O- $C_{1-6}$  alkyl" includes the following:  $-CH_2CH_2-$  O- $CH_2CH_3$ ,  $-CH(CH_3)CH_2-$  O- $CH_2CH_3$ , etc.

As used herein, "aryl" is intended to mean any stable monocyclic or bicyclic carbon ring of up to 7 members in each ring, wherein at least one ring is aromatic and attachment to the substituted group is via the aromatic ring. Examples of such aryl elements include  
5 phenyl, naphthyl, tetrahydronaphthyl, indanyl, biphenyl, phenanthryl, anthryl or acenaphthyl. An aryl group may be substituted with one to three substituents selected from R<sup>a</sup>.

The term heteroaryl, as used herein, represents, a 5- to 7-membered aromatic heterocycle containing from 1 to 4 heteroatoms  
10 selected from the group consisting of O, N and S, and includes any bicyclic group in which any of the above-defined heteroaryl rings is fused to a benzene ring. Heteroaryl groups within the scope of this definition include but are not limited to: acridinyl, carbazolyl, cinnolinyl, quinoxalinyl, pyrrazolyl, indolyl, benzotriazolyl, furanyl, thienyl,  
15 benzothienyl, benzofuranyl, quinolinyl, isoquinolinyl, pyrazinyl, pyridazinyl, pyridinyl, pyrimidinyl, and pyrrolyl. A heteroaryl group may be substituted with one to three substituents selected from R<sup>a</sup>.

As appreciated by those skilled in the art, "halo" or "halogen" as used herein is intended to include chloro, fluoro, bromo  
20 and iodo. The term "heterocycle" or "heterocyclyl" as used herein is intended to mean a 5- to 10-membered aromatic or nonaromatic heterocycle containing from 1 to 4 heteroatoms selected from the group consisting of O, N and S, and includes bicyclic groups. The term "heterocyclyl", therefore, is intended to encompass the definition of  
25 "heteroaryl" described above. Examples of heterocyclyl include, but are not limited to, the following: benzoimidazolyl, benzofuranyl, benzofurazanyl, benzopyrazolyl, benzotriazolyl, benzothiophenyl, benzoxazolyl, carbazolyl, carbolinyl, cinnolinyl, furanyl, imidazolyl, indolinyl, indolyl, indolazinyl, indazolyl, isobenzofuranyl, isoindolyl,  
30 isoquinolyl, isothiazolyl, isoxazolyl, naphthpyridinyl, oxadiazolyl, oxazolyl, oxetanyl, pyranyl, pyrazinyl, pyrazolyl, pyridazinyl,

pyridopyridinyl, pyridazinyl, pyridyl, pyrimidyl, pyrrolyl, quinazolinyl, quinolyl, quinoxalinyl, tetrahydropyranyl, tetrazolyl, tetrazolopyridyl, thiadiazolyl, thiazolyl, thienyl, triazolyl, azetidiny, 1,4-dioxanyl, hexahydroazepinyl, piperazinyl, piperidinyl, pyrrolidinyl, morpholinyl, 5 thiomorpholinyl, dihydrobenzoimidazolyl, dihydrobenzofuranyl, dihydrobenzothiophenyl, dihydrobenzoxazolyl, dihydrofuranly, dihydroimidazolyl, dihydroindolyl, dihydroisooxazolyl, dihydroisothiazolyl, dihydrooxadiazolyl, dihydrooxazolyl, dihydropyrazinyl, dihydropyrazolyl, dihydropyridinyl, 10 dihydropyrimidinyl, dihydropyrrolyl, dihydroquinolinyl, dihydrotetrazolyl, dihydrothiadiazolyl, dihydrothiazolyl, dihydrothienyl, dihydrotriazolyl, dihydroazetidiny, methylenedioxybenzoyl, tetrahydrofuranly, and tetrahydrothienyl, and N-oxides thereof. The heterocyclyl group may be substituted with one to three substituents 15 selected from R<sup>a</sup>.

It is understood that substituents and substitution patterns on the compounds of the instant invention can be selected by one of ordinary skill in the art to provide compounds that are chemically stable and that can be readily synthesized by techniques known in the art, as 20 well as those methods set forth below, from readily available starting materials. If used, the phrase "optionally substituted with one or more substituents" means that the group to which the phrase refers is either unsubstituted (i.e., only hydrogen atoms present at any substitutable position) or substituted with one or more substituents, where there can 25 be as many substituents from the selected list as are possible and still form a stable compound. Preferentially, the group is unsubstituted or substituted with one to three substituents from the list.

Preferentially, only one of X, Y and Z is N, and the remainder are C-H. Most preferentially Y is N and X and Z are C-H.

Preferentially,  $R^1$  is heterocyclyl. More preferentially  $R^1$  is heteroaryl. And most preferentially  $R^1$  is thiophene.

Preferentially, W is C-H. Preferentially,  $R^2$  is alkyl substituted with one or two groups selected from  $R^a$ . The more preferred definition of  $R^a$  is  $NR^7R^8$ , where  $R^7$  and  $R^8$  are alkyl, alkylene-O-alkyl, or  $NR^7R^8$  is taken together to form a heterocyclyl, optionally substituted with CN, halo or alkyl. Preferred heterocyclyls in this context are piperidine, piperazine, and azepin. Preferentially  $R^3$  is H, CN,  $CO_2R$ , OR, halo or alkyl.

10 The pharmaceutically acceptable salts of the compounds of this invention include the conventional non-toxic salts of the compounds of this invention as formed, e.g., from non-toxic inorganic or organic acids. For example, such conventional non-toxic salts include those derived from inorganic acids such as hydrochloric, hydrobromic, 15 sulfuric, sulfamic, phosphoric, nitric and the like; and the salts prepared from organic acids such as acetic, propionic, succinic, glycolic, stearic, lactic, malic, tartaric, citric, ascorbic, pantoic, maleic, hydroxymaleic, phenylacetic, glutamic, benzoic, salicylic, sulfanilic, 2-acetoxy-benzoic, fumaric, toluenesulfonic, methanesulfonic, ethane 20 disulfonic, oxalic, isethionic, trifluoroacetic and the like.

The pharmaceutically acceptable salts of the compounds of this invention can be synthesized from the compounds of this invention which contain a basic moiety by conventional chemical methods. Generally, the salts are prepared either by ion exchange 25 chromatography or by reacting the free base with stoichiometric amounts or with an excess of the desired salt-forming inorganic or organic acid in a suitable solvent or various combinations of solvents.

As used herein, the term "composition" is intended to encompass a product comprising the specified ingredients in the




specified amounts, as well as any products which result, either directly or indirectly, from combination of the specified ingredients in the specified amounts.


The compounds of this invention may be prepared by  
5 employing reactions as shown in the schemes below, in addition to other standard manipulations as are known in the literature or exemplified in the experimental procedures. These schemes, therefore, are not limited by the compounds listed nor by any particular substituents employed for illustrative purposes. Substituent numbering as shown in the Schemes  
10 do not necessarily correlate to that used in the claims.

As shown in Scheme 1, the desired compounds can be prepared via the palladium catalyzed coupling of a boronic indole with a bromopyridine substrate. Analogs may also be prepared via the alternative route illustrated in Scheme 2.


Scheme 1



## Scheme 1 (continued)



Scheme 2



5

- The invention described herein includes a pharmaceutical  
 10 composition which is comprised of a compound of formula I or a  
 pharmaceutically acceptable salt, hydrate or prodrug thereof in  
 combination with a carrier. As used herein the terms "pharmaceutic-  
 ally acceptable salts" and "hydrates" refer to those salts and hydrated  
 forms of the compound which would be apparent to the pharmaceutical  
 15 chemist, i.e., those which favorably affect the physical or pharmaco-  
 kinetic properties of the compound, such as solubility, palatability,  
 absorption, distribution, metabolism and excretion. Other factors,

more practical in nature, which are also important in the selection, are the cost of the raw materials, ease of crystallization, yield, stability, solubility, hygroscopicity and flowability of the resulting bulk drug.

When a compound of formula I is present as a salt or  
5 hydrate which is non-pharmaceutically acceptable, this can be converted to a salt or hydrate form which is pharmaceutically acceptable in accordance with the present invention.

When the compound is negatively charged, it is balanced by a counterion, e.g., an alkali metal cation such as sodium or potassium.  
10 Other suitable counterions include calcium, magnesium, zinc, ammonium, or alkylammonium cations such as tetramethylammonium, tetrabutylammonium, choline, triethylhydroammonium, meglumine, triethanolhydroammonium, etc. An appropriate number of counterions is associated with the molecule to  
15 maintain overall charge neutrality. Likewise when the compound is positively charged, e.g., protonated, an appropriate number of negatively charged counterions is present to maintain overall charge neutrality.

Pharmaceutically acceptable salts also include acid addition salts. Thus, the compound can be used in the form of salts  
20 derived from inorganic or organic acids or bases. Examples include acetate, adipate, alginate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, citrate, camphorate, camphorsulfonate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, fumarate, glucoheptanoate, glycerophosphate, hemisulfate,  
25 heptanoate, hexanoate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethanesulfonate, lactate, maleate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, oxalate, pamoate, pectinate, persulfate, 3-phenylpropionate, picrate, pivalate, propionate, succinate, tartrate, thiocyanate, tosylate and undecanoate. Base salts include  
30 ammonium salts, alkali metal salts such as sodium and potassium salts, alkaline earth metal salts such as calcium and magnesium salts,

salts with organic bases such as dicyclohexylamine salts, N-methyl-D-glucamine, and salts with amino acids such as arginine, lysine, and so forth. Also, the basic nitrogen-containing groups may be quaternized with such agents as lower alkyl halides, such as methyl, ethyl, propyl, 5 and butyl chloride, bromides and iodides; dialkyl sulfates like dimethyl, diethyl, dibutyl; and diamyl sulfates, long chain halides such as decyl, lauryl, myristyl and stearyl chlorides, bromides and iodides, aralkyl halides like benzyl and phenethyl bromides and others. Other pharmaceutically acceptable salts include the sulfate salt ethanolate and 10 sulfate salts.

The compounds of the present invention, may have asymmetric centers and occur as racemates, racemic mixtures and as individual diastereomers, or enantiomers with all isomeric forms being included in the present invention. When any variable (e.g., aryl, 15 heteroaryl,  $R^1$ , etc.) occurs more than one time in any constituent or in Formula I, its definition on each occurrence is independent of its definition at every other occurrence, unless otherwise stated.

The compounds of the invention can be formulated in a pharmaceutical composition by combining the compound with a 20 pharmaceutically acceptable carrier. Examples of such compositions and carriers are set forth below.

The compounds may be employed in powder or crystalline form, in solution or in suspension. They may be administered orally, parenterally (intravenously or intramuscularly), topically, 25 transdermally or by inhalation.

Thus, the carrier employed may be, for example, either a solid or liquid. Examples of solid carriers include lactose, terra alba, sucrose, talc, gelatin, agar, pectin, acacia, magnesium stearate, stearic acid and the like. Examples of liquid carriers include syrup, peanut oil, 30 olive oil, water and the like. Similarly, the carrier for oral use may

include time delay material well known in the art, such as glyceryl monostearate or glyceryl distearate alone or with a wax.

Topical applications may be formulated in carriers such as hydrophobic or hydrophilic bases to form ointments, creams, lotions, in  
5 aqueous, oleaginous or alcoholic liquids to form paints or in dry diluents to form powders. Such topical formulations can be used to treat ocular diseases as well as inflammatory diseases such as rheumatoid arthritis, psoriasis, contact dermatitis, delayed hypersensitivity reactions and the like.

10 Examples of oral solid dosage forms include tablets, capsules, troches, lozenges and the like. The size of the dosage form will vary widely, but preferably will be from about 25 mg to about 500mg. Examples of oral liquid dosage forms include solutions, suspensions, syrups, emulsions, soft gelatin capsules and the like. Examples of  
15 injectable dosage forms include sterile injectable liquids, e.g., solutions, emulsions and suspensions. Examples of injectable solids would include powders which are reconstituted, dissolved or suspended in a liquid prior to injection.

In injectable compositions, the carrier is typically  
20 comprised of sterile water, saline or another injectable liquid, e.g., peanut oil for intramuscular injections. Also, various buffering agents, preservatives and the like can be included.

For the methods of treatment disclosed herein, dosages can be varied depending upon the overall condition of the patient, the nature  
25 of the illness being treated and other factors. An example of a suitable oral dosage range is from about 0.1 to about 80 mg/kg per day, in single or divided doses. An example of a suitable parenteral dosage range is from about 0.1 to about 80 mg/kg per day, in single or divided dosages, administered by intravenous or intramuscular injection. An example of  
30 a topical dosage range is from about 0.1 mg to about 150 mg, applied externally from about one to four times a day. An example of an


inhalation dosage range is from about 0.01 mg/kg to about 1 mg/kg per day.

The compounds may be administered in conventional dosages as a single agent or in combination with other therapeutically active compounds.

### EXAMPLES

Examples provided are intended to assist in a further understanding of the invention. Particular materials employed, species and conditions are intended to be further illustrative of the invention and not limiting of the reasonable scope thereof.

#### EXAMPLE 1



A deoxygenated solution of 3,5-dibromopyridine (4.00 g, 16.9 mmol, 1 equiv), 3-thiopheneboronic acid (2.38 g, 18.6 mmol, 1.10 equiv),  $\text{Pd(PPh}_3)_4$  (781 mg, 0.676 mmol, 0.0433 equiv), and 2.0 M  $\text{Na}_2\text{CO}_3$  (16.9 mL, 33.8 mmol, 2.00 equiv) in dioxane (40 ml) was heated under argon




at reflux for 20 h. The reaction mixture was allowed to cool, then partitioned between water (200 mL) and ethyl acetate (2 x 300 mL). The combined organic layers were dried over sodium sulfate and concentrated. The residue was purified by flash column

5 chromatography (5% ethyl acetate in dichloromethane) to afford 3-bromo-5-thiophen-3-yl-pyridine as a white solid.


$^1\text{H}$  NMR (300 MHz,  $\text{CDCl}_3$ )  $\delta$  8.78 (d, 1H,  $J = 1.8$  Hz), 8.59 (d, 1H,  $J = 1.8$  Hz), 8.02 (t, 1H,  $J = 1.8$  Hz), 7.56 (dd, 1H,  $J = 2.8, 1.2$  Hz), 7.47 (dd, 1H,  $J = 4.8, 2.8$  Hz), 7.37 (dd, 1H,  $J = 4.8, 2.8$  Hz); TLC (5% EtOAc in  $\text{CH}_2\text{Cl}_2$ ),  $R_f =$

10 0.58.



A deoxygenated solution of 3-bromo-5-thiophen-3-yl-pyridine  
 15 (250 mg, 1.04 mmol, 1 equiv), 1-tosyl-3-indoleboronic acid (430 mg, 1.36 mmol, 1.31 equiv, prepared according to Zheng, Q; Yang, Y; Martin, A. R. *Heterocycles* **1994**, *37*, 1761),  $\text{Pd}(\text{PPh}_3)_4$  (60 mg, 0.052 mmol, 0.050 equiv), and 2.0 M  $\text{Na}_2\text{CO}_3$  (1.0 mL, 2.0 mmol, 1.9 equiv) in dioxane (10 mL) was heated under argon at reflux for 20 h. The reaction mixture was  
 20 allowed to cool, then partitioned between water (100 mL) and ethyl acetate (2 x 100 mL). The combined organic layers were dried over sodium sulfate and concentrated. The residue was purified by flash column chromatography (40% ethyl acetate in hexane) to afford 3-(5-thiophen-3-yl-pyridin-3-yl)-1-(toluene-4-sulfonyl)-indole as a white foam.

$^1\text{H}$  NMR (300 MHz,  $\text{CDCl}_3$ )  $\delta$  8.86 (d, 1H,  $J = 2.0$  Hz), 8.77 (d, 1H,  $J = 2.2$  Hz), 8.09 (br d, 1H,  $J = 8.1$  Hz), 8.06 (t, 1H,  $J = 2.2$  Hz), 7.84 (d, 2H,  $J = 8.5$  Hz), 7.80 (s, 1H), 7.76 (br d, 1H,  $J = 7.8$  Hz), 7.59 (dd, 1H,  $J = 2.7, 1.2$  Hz), 7.48 (dd, 1H,  $J = 5.1, 2.9$  Hz), 7.44 (dd, 1H,  $J = 5.1, 1.2$  Hz), 7.41 (br t,  $J = 7.3$  Hz), 7.32 (br t, 1H,  $J = 7.6$  Hz), 7.26 (d, 2H,  $J = 8.0$  Hz), 2.36 (s, 3H); TLC (40% EtOAc in hexane),  $R_f = 0.26$ .




10

A solution of 3-(5-thiophen-3-yl-pyridin-3-yl)-1-(toluene-4-sulfonyl)-indole (350 g, 0.812 mmol, 1 equiv) and KOH (228 mg, 4.06 mmol, 5.00 equiv) in a 2:1 mixture of ethanol and water (40 ml) was heated at reflux for 6 h. The reaction mixture was allowed to cool, then concentrated to dryness. The residual solid was suspended in water (200 mL) and extracted with ethyl acetate (2 x 100 mL). The combined organic layers were dried over  $\text{Na}_2\text{SO}_4$  and concentrated. The solid residue was suspended in hot ethyl acetate (30 mL) and filtered to afford the titled compound as a white solid.

$^1\text{H}$  NMR (300 MHz,  $\text{CDCl}_3$ )  $\delta$  8.85 (d, 1H,  $J = 2.0$  Hz), 8.79 (d, 1H,  $J = 2.0$  Hz), 8.53 (br s, 1H), 8.16 (t, 1H,  $J = 2.0$  Hz), 7.94 (br d, 1H,  $J = 7.8$  Hz), 7.60 (dd, 1H,  $J = 2.7, 1.4$  Hz), 7.50-7.47 (m, 3H), 7.31 (td, 1H,  $J = 7.6, 1.2$  Hz), 7.25 (td, 1H,  $J = 7.8, 1.2$  Hz); TLC (40% EtOAc in hexane),  $R_f = 0.19$ ; HRMS (electrospray FT/ICR) calcd for  $\text{C}_{17}\text{H}_{13}\text{N}_2\text{S}$   $[\text{M}+\text{H}]^+$  277.0794, found 277.0804.

25

EXAMPLE 2


5

95% Sodium hydride (217 mg, 8.60 mmol, 9.50 equiv), 4-(2-chloroethyl)morpholine hydrochloride (202 mg, 1.086 mmol, 1.20 equiv), and sodium iodide (136 mg, 0.905, 1.00 equiv) were sequentially added to a solution of 3-(5-thiophen-3-yl-pyridin-3-yl)-indole (250 mg, 0.905 mmol, 10 1 equiv) in DMF (60 mL) at 23°C. The resulting mixture was heated at 100°C for 60 h. The reaction mixture was allowed to cool, then concentrated. The brown-colored residue was partitioned between water (500 ml) and ethyl acetate (3 x 150 mL). The combined organic extracts were dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated. The residual oil was dissolved in 15 ethyl ether (100 ml), and the resulting solution was subjected to a gentle stream of HCl gas. The precipitate was filtered and washed with ethyl ether (50 ml) to afford compound 2 as a yellow solid.

<sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 9.14 (t, 1H, *J* = 2.0 Hz), 9.05 (d, 1H, *J* = 2.0 Hz), 9.01 (d, 1H, *J* = 2.0 Hz), 8.28 (dd, 1H, *J* = 2.9, 1.6 Hz), 8.26 (s, 1H), 8.04 (br d, 1H, *J* = 7.6 Hz), 7.78 (dd, 1H, *J* = 5.2, 1.6 Hz), 7.74 (br d, 1H, *J* = 8.1 Hz), 7.72 (dd, 1H, *J* = 5.2, 2.9 Hz), 7.43 (br t, 1H, *J* = 8.1 Hz), 7.36 (br t, 1H, *J* = 7.8 Hz), 4.87 (t, 2H, *J* = 6.7 Hz), 4.05 (br m, 2H), 3.91 (br m, 2H), 3.75 (t, 2H, *J* = 6.7 Hz), 3.58 (br m, 2H), 3.29 (br m, 2H); HRMS (electrospray FT/ICR) calcd for C<sub>23</sub>H<sub>24</sub>N<sub>3</sub>OS [M+H]<sup>+</sup> 390.1634, found 390.1646; Anal. Calcd for C<sub>23</sub>H<sub>23</sub>N<sub>3</sub>OS + 2.10 HCl + 1.30 H<sub>2</sub>O:

C, 56.42; H, 5.70; N, 8.58.

10 Found C, 56.48; H, 5.86; N, 8.22.

EXAMPLE 3

15

95% Sodium hydride (217 mg, 8.60 mmol, 9.50 equiv), 1-(2-chloroethyl)piperidine hydrochloride (200 mg, 1.086 mmol, 1.20 equiv), and sodium iodide (136 mg, 0.905, 1.00 equiv) were sequentially added to

a solution of 3-(5-thiophen-3-yl-pyridin-3-yl)-indole (250 mg, 0.905 mmol, 1 equiv) in DMF (60 mL) at 23°C. The resulting mixture was heated at 100°C for 60 h. The reaction mixture was allowed to cool, then concentrated. The brown-colored residue was partitioned between water (500 ml) and ethyl acetate (3 x 150 mL). The combined organic extracts were dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated. The residual oil was dissolved in ethyl ether (100 ml), and the resulting solution was subjected to a gentle stream of HCl gas. The precipitate was filtered and washed with ethyl ether (50 ml) to afford compound 3 as a yellow solid.


<sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 9.13 (t, 1H, *J* = 2.0 Hz), 9.05 (d, 1H, *J* = 2.0 Hz), 9.01 (d, 1H, *J* = 2.0 Hz), 8.28 (dd, 1H, *J* = 2.9, 1.6 Hz), 8.26 (s, 1H), 8.04 (br d, 1H, *J* = 7.6 Hz), 7.78 (dd, 1H, *J* = 5.2, 1.6 Hz), 7.74 (br d, 1H, *J* = 8.1 Hz), 7.72 (dd, 1H, *J* = 5.2, 2.9 Hz), 7.43 (br t, 1H, *J* = 8.1 Hz), 7.36 (br t, 1H, *J* = 7.8 Hz), 4.84 (t, 2H, *J* = 6.7 Hz), 3.67 (t, 2H, *J* = 6.7 Hz), 4.05 (br d, 2H, *J* = 7.3 Hz), 3.08 (br td, 2H, *J* = 6.3, 1.8 Hz), 2.01-1.82 (br m, 5H), 1.54 (m, 1H); HRMS (electrospray FT/ICR) calc'd for C<sub>24</sub>H<sub>26</sub>N<sub>3</sub>S [M+H]<sup>+</sup> 388.1841, found 388.1849;

Anal. Calcd for C<sub>24</sub>H<sub>25</sub>N<sub>3</sub>S + 2.50 HCl + 0.10 ethyl ether:

C, 60.28; H, 5.91; N, 8.64.

Found C, 59.95; H, 6.22; N, 8.63.


#### EXAMPLE 4



compound 4

3-(5-thiophen-3-yl-pyridin-3-yl)-indole (Compound 1) was prepared by the following alternative reaction sequence for the syntheses of compounds 4-17.


5



A deoxygenated solution of 3-bromo-5-thiophen-3-yl-pyridine (2.50 g, 10.4 mmol, 1 equiv), 1-(*t*-butyloxycarbonyl)-3-indoleboronic acid (4.073 g, 15.6 mmol, 1.50 equiv),  $\text{Pd(PPh}_3)_4$  (601 mg, 0.520 mmol, 0.0500 equiv), and 2.0 M  $\text{Na}_2\text{CO}_3$  (10.4 mL, 20.8 mmol, 2.00 equiv) in dioxane (120 mL) was heated under argon at reflux for 20 h. The reaction mixture was allowed to cool, then partitioned between water (500 mL) and ethyl acetate (3 x 150 mL). The combined organic layers were washed sequentially with water (500 mL) and brine (500 mL), then dried over sodium sulfate and concentrated. The residue was purified by flash column chromatography (40% ethyl acetate in hexane) to afford 3-(5-thiophen-3-yl-pyridin-3-yl)-1-(*t*-butyloxycarbonyl)-indole as a colorless oil. The oil was dissolved in ethyl acetate (100 mL), and the resulting solution was cooled to 0°C, then saturated with HCl gas. The solution was allowed to warm to 23°C and stirred for 30 minutes. The precipitate was filtered and washed with ethyl ether (50 mL). The solid was then

partitioned between ethyl acetate (150 mL) and aqueous saturated  $\text{NaHCO}_3$  solution (150 mL). The organic layer was dried over  $\text{Na}_2\text{SO}_4$  and concentrated to give compound 1 (3-(5-thiophen-3-yl-pyridin-3-yl)-indole) as a white solid.

- 5  $^1\text{H}$  NMR (300 MHz,  $\text{CDCl}_3$ )  $\delta$  8.86 (d, 1H,  $J = 2.0$  Hz), 8.77 (d, 1H,  $J = 2.2$  Hz), 8.09 (br d, 1H,  $J = 8.1$  Hz), 8.06 (t, 1H,  $J = 2.2$  Hz), 7.84 (d, 2H,  $J = 8.5$  Hz), 7.80 (s, 1H), 7.76 (br d, 1H,  $J = 7.8$  Hz), 7.59 (dd, 1H,  $J = 2.7, 1.2$  Hz), 7.48 (dd, 1H,  $J = 5.1, 2.9$  Hz), 7.44 (dd, 1H,  $J = 5.1, 1.2$  Hz), 7.41 (br t,  $J = 7.3$  Hz), 7.32 (br t, 1H,  $J = 7.6$  Hz), 7.26 (d, 2H,  $J = 8.0$  Hz), 2.36 (s, 3H); TLC  
10 (40% EtOAc in hexane),  $R_f = 0.26$ .




- 15 95% Sodium hydride (217 mg, 8.60 mmol, 9.50 equiv), 1-(2-chloropropyl)piperidine hydrochloride (200 mg, 1.086 mmol, 1.20 equiv), and sodium iodide (136 mg, 0.905, 1.00 equiv) were sequentially added to a solution of 3-(5-thiophen-3-yl-pyridin-3-yl)-indole (250 mg, 0.905 mmol, 1 equiv) in DMF (50 mL) at 23°C. The resulting mixture was heated at 100°C for 60 h. The reaction mixture was allowed to cool, then concen-

trated. The brown-colored residue was partitioned between water (500 ml) and ethyl acetate (3 x 150 mL). The combined organic extracts were washed with brine (500 mL) then dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated. The residual oil was dissolved in ethyl ether (100 ml), and the resulting solution was subjected to a gentle stream of HCl gas. The precipitate was filtered and washed with ethyl ether (50 ml) to afford compound 4 as a yellow solid.

<sup>1</sup>H NMR (300 MHz, CD<sub>3</sub>OD) δ 9.13 (t, 1H, *J* = 2.0 Hz), 9.05 (d, 1H, *J* = 2.0 Hz), 8.98 (d, 1H, *J* = 2.0 Hz), 8.29 (dd, 1H, *J* = 2.9, 1.5 Hz), 8.23 (s, 1H), 8.03 (br d, 1H, *J* = 7.3 Hz), 7.78 (dd, 1H, *J* = 5.1, 1.5 Hz), 7.72 (dd, 1H, *J* = 5.1, 2.9 Hz), 7.66 (br d, 1H, *J* = 8.1 Hz), 7.39 (br td, 1H, *J* = 7.6, 1.2 Hz), 7.32 (br td, 1H, *J* = 8.1, 1.5 Hz), 4.46 (t, 2H, *J* = 6.8 Hz), 3.52 (br d, 2H, *J* = 12.5 Hz), 3.17 (m, 2H), 2.92 (br td, 2H, *J* = 12.9, 2.8 Hz), 2.43 (m, 2H), 1.98-1.70 (br m, 5H), 1.50 (m, 1H); HRMS (electrospray FT/ICR) calcd for C<sub>25</sub>H<sub>28</sub>N<sub>3</sub>S [M+H]<sup>+</sup> 402.1998, found 402.2013;  
Anal. Calcd for C<sub>25</sub>H<sub>27</sub>N<sub>3</sub>S + 2.50 HCl + 0.40 H<sub>2</sub>O:  
C, 60.06; H, 6.11; N, 8.41.  
Found C, 60.10; H, 6.19; N, 8.07.

#### EXAMPLE 5-17

















A general experimental procedure for the preparation of compounds 5-17 is given below. The product mass spectral data are summarized in Table 1 below.















95% Sodium hydride (21.7 mg, 0.860 mmol, 9.50 equiv), the appropriate alkyl chloride (0.109 mmol, 1.20 equiv), and sodium iodide (13.6 mg, 0.0905, 1.00 equiv) were sequentially added to a solution of 3-(5-thiophen-3-yl-pyridin-3-yl)-indole (25.0 mg, 0.0905 mmol, 1 equiv) in DMF (1 mL) at 23°C. The resulting mixture was heated at 100°C for 20 h. The reaction mixture was allowed to cool, then concentrated. The brown-colored residue was partitioned between water (3 ml) and ethyl acetate (3 x 3 mL). The combined organic extracts were dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated to afford the desired product as yellow oil. Compounds 7, 8, and 15 were purified by flash column chromatography (10-20% MeOH in CH<sub>2</sub>Cl<sub>2</sub>).

**Table 1**

Cmpd	Structure	RCl	Calcd Mass [M+H] <sup>+</sup>	Found Mass (FAB <sup>+</sup> )
5			C <sub>22</sub> H <sub>24</sub> N <sub>3</sub> S= 362.17	362.17
6			C <sub>21</sub> H <sub>22</sub> N <sub>3</sub> S= 348.15	348.15

7			$C_{24}H_{26}N_3S=$ 388.18	388.18
8			$C_{25}H_{29}N_3S=$ 417.21	417.20
9			$C_{29}H_{30}N_3OS=$ 468.21	468.21
10			$C_{25}H_{28}N_3S=$ 402.20	402.20
11			$C_{23}H_{26}N_3S=$ 376.18	376.18

12			$C_{28}H_{28}N_3S=$ 438.20	438.20
13			$C_{22}H_{24}N_3S=$ 362.17	362.17
14			$C_{25}H_{30}N_3S=$ 404.22	404.21
15			$C_{23}H_{26}N_3S=$ 376.18	376.18
16			$C_{27}H_{26}N_3S=$ 424.18	424.19

17			$C_{25}H_{25}N_3S=$ 413.18	413.18
----	---	--	-------------------------------	--------

\*After purification by flash column chromatography (10-20% MeOH in  $CH_2Cl_2$ )

The activity of the disclosed compounds as kinase inhibitors  
 5 was demonstrated in accordance with the following protocols.

#### VEGF RECEPTOR KINASE ASSAY

VEGF receptor kinase activity is measured by incorporation  
 of radio-labeled phosphate into polyglutamic acid, tyrosine, 4:1 (pEY)  
 10 substrate. The phosphorylated pEY product is trapped onto a filter  
 membrane and the incorporation of radio-labeled phosphate quantified by  
 scintillation counting.

#### MATERIALS

##### 15 VEGF receptor kinase

The intracellular tyrosine kinase domains of human KDR  
 (Terman, B.I. et al. Oncogene (1991) vol. 6, pp. 1677-1683.) and Flt-1  
 (Shibuya, M. et al. Oncogene (1990) vol. 5, pp. 519-524) were cloned as  
 glutathione S-transferase (GST) gene fusion proteins. This was  
 20 accomplished by cloning the cytoplasmic domain of the KDR kinase as  
 an in frame fusion at the carboxy terminus of the GST gene. Soluble  
 recombinant GST-kinase domain fusion proteins were expressed in  
 Spodoptera frugiperda (Sf21) insect cells (Invitrogen) using a  
 baculovirus expression vector (pAcG2T, Pharmingen).

Lysis buffer

50 mM Tris pH 7.4, 0.5 M NaCl, 5 mM DTT, 1 mM EDTA,  
0.5% triton X-100, 10% glycerol, 10 mg/ml of each leupeptin, pepstatin  
5 and aprotinin and 1mM phenylmethanesulfonyl fluoride (all Sigma).

Wash buffer

50 mM Tris pH 7.4, 0.5 M NaCl, 5 mM DTT, 1 mM EDTA,  
0.05% triton X-100, 10% glycerol, 10 mg/ml of each leupeptin, pepstatin  
10 and aprotinin and 1mM phenylmethanesulfonyl fluoride.

Dialysis buffer

50 mM Tris pH 7.4, 0.5 M NaCl, 5 mM DTT, 1 mM EDTA,  
0.05% triton X-100, 50% glycerol, 10 mg/ml of each leupeptin, pepstatin  
15 and aprotinin and 1mM phenylmethanesulfonyl fluoride

10 X reaction buffer

200 mM Tris, pH 7.4, 1.0 M NaCl, 50 mM MnCl<sub>2</sub>, 10 mM  
DTT and 5 mg/ml bovine serum albumin (Sigma).

20

Enzyme dilution buffer

50 mM Tris, pH 7.4, 0.1 M NaCl, 1 mM DTT, 10% glycerol,  
100 mg/ml BSA.

25 10 X Substrate

750 µg/ml poly (glutamic acid, tyrosine; 4:1) (Sigma).

Stop solution

30 30% trichloroacetic acid, 0.2 M sodium pyrophosphate (both  
Fisher).

Wash solution

15% trichloroacetic acid, 0.2 M sodium pyrophosphate.

Filter plates

5 Millipore #MAFC NOB, GF/C glass fiber 96 well plate.

METHODA. Protein purification

1. Sf21 cells were infected with recombinant virus at a  
10 multiplicity of infection of 5 virus particles/ cell and grown at 27°C for 48  
hours.

2. All steps were performed at 4°C. Infected cells were  
harvested by centrifugation at 1000 X g and lysed at 4°C for 30 minutes  
with 1/10 volume of lysis buffer followed by centrifugation at 100,000Xg  
15 for 1 hour. The supernatant was then passed over a glutathione  
Sepharose column (Pharmacia) equilibrated in lysis buffer and washed  
with 5 volumes of the same buffer followed by 5 volumes of wash buffer.  
Recombinant GST-KDR protein was eluted with wash buffer/10 mM  
reduced glutathione (Sigma) and dialyzed against dialysis buffer.

20

B. VEGF receptor kinase assay

1. Add 5 µl of inhibitor or control to the assay in 50% DMSO.  
2. Add 35 µl of reaction mix containing 5 µl of 10 X reaction  
buffer, 5 µl 25 mM ATP/10 µCi [<sup>33</sup>P]ATP (Amersham), and 5 µl 10 X  
25 substrate.

3. Start the reaction by the addition of 10 µl of KDR (25 nM)  
in enzyme dilution buffer.

4. Mix and incubate at room temperature for 15 minutes.

5. Stop by the addition of 50 µl stop solution.

30 6. Incubate for 15 minutes at 4°C.

7. Transfer a 90 µl aliquot to filter plate.
8. Aspirate and wash 3 times with wash solution.
9. Add 30 µl of scintillation cocktail, seal plate and count in a Wallac Microbeta scintillation counter.

5

#### Human Umbilical Vein Endothelial Cell Mitogenesis Assay

- Expression of VEGF receptors that mediate mitogenic responses to the growth factor is largely restricted to vascular endothelial cells. Human umbilical vein endothelial cells (HUVECs) in
- 10 culture proliferate in response to VEGF treatment and can be used as an assay system to quantify the effects of KDR kinase inhibitors on VEGF stimulation. In the assay described, quiescent HUVEC monolayers are treated with vehicle or test compound 2 hours prior to addition of VEGF or basic fibroblast growth factor (bFGF). The mitogenic response to
- 15 VEGF or bFGF is determined by measuring the incorporation of [<sup>3</sup>H]thymidine into cellular DNA.

#### Materials

##### 20 HUVECs

HUVECs frozen as primary culture isolates are obtained from Clonetics Corp. Cells are maintained in Endothelial Growth Medium (EGM; Clonetics) and are used for mitogenic assays at passages 3-7.

25

##### Culture Plates

NUNCNCLON 96-well polystyrene tissue culture plates (NUNC #167008).

Assay Medium

Dulbecco's modification of Eagle's medium containing 1 g/ml glucose (low-glucose DMEM; Mediatech) plus 10% (v/v) fetal bovine serum (Clonetics).

5

Test Compounds

Working stocks of test compounds are diluted serially in 100% dimethylsulfoxide (DMSO) to 400-fold greater than their desired final concentrations. Final dilutions to 1X concentration are made directly into Assay Medium immediately prior to addition to cells.

10

10X Growth factors

Solutions of human VEGF<sub>165</sub> (500 ng/ml; R&D Systems) and bFGF (10 ng/ml; R&D Systems) are prepared in Assay Medium.

15

10X [<sup>3</sup>H]Thymidine

[Methyl-<sup>3</sup>H]Thymidine (20 Ci/mmol; Dupont-NEN) is diluted to 80 uCi/ml in low-glucose DMEM.

20 Cell Wash Medium

Hank's balanced salt solution (Mediatech) containing 1 mg/ml bovine serum albumin (Boehringer-Mannheim).

Cell Lysis Solution25 1 N NaOH, 2% (w/v) Na<sub>2</sub>CO<sub>3</sub>.Method

1. HUVEC monolayers maintained in EGM are harvested by trypsinization and plated at a density of 4000 cells per 100 ul Assay Medium per well in 96-well plates. Cells are growth-arrested for 24 hours at 37°C in a humidified atmosphere containing 5% CO<sub>2</sub>.

30



2. Growth-arrest medium is replaced by 100 ul Assay Medium containing either vehicle (0.25% [v/v] DMSO) or the desired final concentration of test compound. All determinations are performed in triplicate. Cells are then incubated at 37°C/5% CO<sub>2</sub> for 2 hours to  
5 allow test compounds to enter cells.

3. After the 2-hour pretreatment period, cells are stimulated by addition of 10 ul/well of either Assay Medium, 10X VEGF solution or 10X bFGF solution. Cells are then incubated at 37°C/5% CO<sub>2</sub>.


4. After 24 hours in the presence of growth factors, 10X  
10 [<sup>3</sup>H]Thymidine (10 ul/well) is added.

5. Three days after addition of [<sup>3</sup>H]thymidine, medium is removed by aspiration, and cells are washed twice with Cell Wash Medium (400 ul/well followed by 200 ul/well). The washed, adherent cells are then solubilized by addition of Cell Lysis Solution (100 ul/well)  
15 and warming to 37°C for 30 minutes. Cell lysates are transferred to 7-ml glass scintillation vials containing 150 ul of water. Scintillation cocktail (5 ml/vial) is added, and cell-associated radioactivity is determined by liquid scintillation spectroscopy.

Based upon the foregoing assays the compounds of formula  
20 I are inhibitors of VEGF and thus are useful for the inhibition of neoangiogenesis, such as in the treatment of ocular disease, e.g., diabetic retinopathy and in the treatment of cancers, e.g., solid tumors. The instant compounds inhibit VEGF-stimulated mitogenesis of human vascular endothelial cells in culture with IC<sub>50</sub> values between 0.01 - 5.0  
25 µM. These compounds also show selectivity over related tyrosine kinases (e.g. FGFR1 and the Src family).

WHAT IS CLAIMED IS:

1. A compound in accordance with formula I:



or a pharmaceutically acceptable salt or hydrate thereof,

10 wherein

W, X, Y and Z are independently CH or N;

15  $R^1$  is H,  $C_{1-10}$  alkyl,  $C_{3-6}$  cycloalkyl, aryl, halo,  $CF_3$ , heterocyclyl, said alkyl, aryl, and heterocyclyl optionally substituted with one to three substituents selected from  $R^a$ ;

20  $R^2$  is H,  $C_{1-6}$  alkyl, aryl, heteroaryl,  $C_{3-6}$  cycloalkyl, said alkyl, aryl, heteroaryl or cycloalkyl optionally substituted with one to three substituents selected from  $R^a$ ;

25  $R^3$  is H, halo, CN,  $-C_{1-6}$  alkylene- $CO_2R$ ,  $C_{1-6}$  alkoxy,  $-C_{1-6}$  alkylene- $O-C_{1-6}$  alkyl,  $C_{1-6}$  alkyl, aryl, heteroaryl,  $C_{3-6}$  cycloalkyl or  $CO_2R$ , said alkyl, aryl, heteroaryl and cycloalkyl optionally substituted with one to three substituents selected from  $R^a$ ;

$R^a$  is  $C_{1-10}$  alkyl, halogen,  $CF_3$ ,  $NO_2$ , OR,  $NR^7R^8$ , aryl, heterocyclyl, said alkyl, aryl, and heterocyclyl optionally

substituted with one or two substituents selected from NO<sub>2</sub>, CN, halo, aryl, C<sub>1-6</sub> alkoxy, -C<sub>1-6</sub> alkylene-O-C<sub>1-6</sub> alkyl, C<sub>1-6</sub> alkyl, and CF<sub>3</sub>;

5 R is H, or C<sub>1-6</sub> alkyl; and

R<sup>7</sup> and R<sup>8</sup> are independently H, C<sub>1-10</sub> alkyl, C<sub>3-6</sub> cycloalkyl, COR, -C<sub>1-6</sub> alkylene-O-C<sub>1-6</sub> alkyl, C<sub>1-6</sub> alkoxy, -C<sub>1-6</sub> alkylene-aryl, COOR, aryl, benzyl, or heterocyclyl,

10

or NR<sup>7</sup>R<sup>8</sup> are taken together to form a 5-10 membered saturated or unsaturated heterocyclic ring containing, in addition to the nitrogen atom attached to R<sup>7</sup> and R<sup>8</sup>, one or two additional heteroatoms selected from N, O, and S, said heterocyclic ring optionally substituted with CN, halo, or C<sub>1-6</sub> alkyl.

15

2. The compound of Claim 1, wherein

20 W is C-H or N;

X, Y and Z are CH or N, provided only one of X, Y and Z is N;

R<sup>1</sup> is H, C<sub>1-10</sub> alkyl, C<sub>3-6</sub> cycloalkyl, aryl, halo, CF<sub>3</sub>, or heterocyclyl, said alkyl, cycloalkyl aryl, and heterocyclyl are optionally substituted with one to three substituents selected from R<sup>a</sup>;

25

- $R^2$  is H,  $C_{1-6}$  alkyl, aryl, heteroaryl, or C3-6 cycloalkyl, said alkyl, aryl, heteroaryl and cycloalkyl are optionally substituted with one to three substituents selected from  $R^a$ ;
- 5  $R^3$  is H, halo, CN,  $-C_{1-6}$  alkylene- $CO_2R$ ,  $C_{1-6}$  alkoxy,  $-C_{1-6}$  alkylene-O- $C_{1-6}$  alkyl,  $C_{1-6}$  alkyl, aryl, heteroaryl,  $C_{3-6}$  cycloalkyl or  $CO_2R$ , said alkyl, aryl, heteroaryl and cycloalkyl optionally substituted with one to three substituents selected from  $R^a$ ;
- 10  $R^a$  is  $C_{1-10}$  alkyl, halogen,  $CF_3$ ,  $NO_2$ , OR,  $NR^7R^8$ , aryl, or heterocyclyl, said alkyl, aryl, and heterocyclyl optionally substituted with one or two substituents selected from  $NO_2$ , CN, halo, aryl,  $C_{1-6}$  alkoxy,  $-C_{1-6}$  alkylene-O- $C_{1-6}$  alkyl,  $C_{1-6}$  alkyl, and  $CF_3$ ;
- 15  $R$  is H or  $C_{1-6}$  alkyl; and
- $R^7$  and  $R^8$  are independently H,  $C_{1-10}$  alkyl, C3-6 cycloalkyl, COR,  $-C_{1-6}$  alkylene-O- $C_{1-6}$  alkyl,  $C_{1-6}$  alkoxy,  $-C_{1-6}$  alkylene-aryl, COOR, aryl, benzyl,  $C_{3-10}$  heterocyclyl, or heteroaryl,
- 20 or  $NR^7R^8$  are taken together to form a 5-10 membered saturated or unsaturated heterocyclic ring containing, in addition to the nitrogen atom attached to  $R^7$  and  $R^8$ , one or two additional heteroatoms selected from N, O, and S, said heterocyclic ring optionally substituted with CN, halo, or  $C_{1-6}$  alkyl.
- 25

3. A compound according to claim 2 wherein Y is N, X is C-H, and Z is C-H.

4. A compound according to claim 3 wherein W is C-H.

5

5. A compound according to claim 4 wherein  $R^1$  is aryl, or heteroaryl, optionally substituted with one, two or three substituents selected from  $R^a$ .

10

6. A compound according to claim 5 wherein  $R^2$  is  $C_{1-6}$  alkyl, optionally substituted with one, two or three substituents selected from  $R^a$ .

15

7. A compound according to claim 6 wherein  $R^a$  is  $C_{1-10}$  alkyl,  $NR^7R^8$ , aryl, or heterocyclyl, said alkyl, aryl, and heterocyclyl optionally substituted with one or two substituents selected from CN, halo, aryl,  $C_{1-6}$  alkoxy,  $-C_{1-6}$  alkylene-O- $C_{1-6}$  alkyl, and  $C_{1-6}$  alkyl.

20

8. A compound according to claim 2, wherein:

W, X, and Z are C-H;

Y is N;

25

$R^1$  is aryl or heteroaryl, said aryl and heteroaryl optionally substituted with  $R^a$ ;

$R^2$  is

H or  $C_{1-6}$  alkyl, said alkyl optionally substituted with one, two or three substituents selected from  $R^a$ ; and

R<sup>3</sup> is H, CO<sub>2</sub>R, OR, halo or C<sub>1-6</sub> alkyl.

9. A compound in accordance with claim 1 which is:

- 5
- 3-(5-thiophen-3-yl-pyridin-3-yl)-indole;  
1-(2-morpholin-4-yl-ethyl)-3-(5-thiophen-3-yl-pyridin-3-yl)-indole;  
1-(2-piperidin-1-yl-ethyl)-3-(5-thiophen-3-yl-pyridin-3-yl)-indole;  
1-(3-piperidin-1-yl-propyl)-3-(5-thiophen-3-yl-pyridin-3-yl)-indole;  
10 dimethyl-{3-[3-(5-thiophen-3-yl-pyridin-3-yl)-indol-1-yl]-propyl}-amine;  
dimethyl-{2-[3-(5-thiophen-3-yl-pyridin-3-yl)-indol-1-yl]-ethyl}-amine;  
1-(1-methyl-piperidin-3-ylmethyl)-3-(5-thiophen-3-yl-pyridin-3-yl)-indole;  
1-[3-(4-methyl-piperazin-1-yl)-propyl]-3-(5-thiophen-3-yl-pyridin-3-yl)-  
indole;  
15 benzyl-(2-methoxy-ethyl)-{2-[3-(5-thiophen-3-yl-pyridin-3-yl)-indol-1-yl]-  
ethyl}-amine;  
1-(2-azepan-1-yl-ethyl)-3-(5-thiophen-3-yl-pyridin-3-yl)-indole;  
diethyl-{2-[3-(5-thiophen-3-yl-pyridin-3-yl)-indol-1-yl]-ethyl}-amine;  
benzyl-ethyl-{2-[3-(5-thiophen-3-yl-pyridin-3-yl)-indol-1-yl]-ethyl}-amine;  
20 dimethyl-{2-[3-(5-thiophen-3-yl-pyridin-3-yl)-indol-1-yl]-propyl}-amine;  
diisopropyl-{2-[3-(5-thiophen-3-yl-pyridin-3-yl)-indol-1-yl]-ethyl}-amine;  
dimethyl-{2-methyl-3-[3-(5-thiophen-3-yl-pyridin-3-yl)-indol-1-yl]-propyl}-  
amine;  
benzyl-methyl-{2-[3-(5-thiophen-3-yl-pyridin-3-yl)-indol-1-yl]-ethyl}-  
25 amine;  
1-{2-[3-(5-thiophen-3-yl-pyridin-3-yl)-indol-1-yl]-ethyl}-piperidine-4-  
carbonitrile;  
5-methoxy-3-(5-thiophen-3-yl-pyridin-3-yl)-indole;  
5-methoxy-1-(2-morpholin-4-yl-ethyl)-3-(5-thiophen-3-yl-pyridin-3-yl)-  
30 indole;

- 5-methoxy-1-(2-piperidin-1-yl-ethyl)-3-(5-thiophen-3-yl-pyridin-3-yl)-indole;
- 5-methoxy-1-(3-piperidin-1-yl-propyl)-3-(5-thiophen-3-yl-pyridin-3-yl)-indole;
- 5 dimethyl-[5-methoxy-3-[3-(5-thiophen-3-yl-pyridin-3-yl)-indol-1-yl]-propyl]-amine;
- 5-methoxy-1-(1-methyl-piperidin-3-ylmethyl)-3-(5-thiophen-3-yl-pyridin-3-yl)-indole;
- 5-methoxy-1-[3-(4-methyl-piperazin-1-yl)-propyl]-3-(5-thiophen-3-yl-pyridin-3-yl)-indole;
- 10 dimethyl-[2-[5-methoxy-3-(5-thiophen-3-yl-pyridin-3-yl)-indol-1-yl]-propyl]-amine;
- dimethyl-[2-methyl-3-[5-methoxy-3-(5-thiophen-3-yl-pyridin-3-yl)-indol-1-yl]-propyl]-amine;
- 15 1-[2-[5-methoxy-3-(5-thiophen-3-yl-pyridin-3-yl)-indol-1-yl]-ethyl]-piperidine-4-carbonitrile;
- 4-chloro-3-(5-thiophen-3-yl-pyridin-3-yl)-indole;
- 4-chloro-1-(2-morpholin-4-yl-ethyl)-3-(5-thiophen-3-yl-pyridin-3-yl)-indole;
- 4-chloro-1-(2-piperidin-1-yl-ethyl)-3-(5-thiophen-3-yl-pyridin-3-yl)-indole;
- 20 4-chloro-1-(3-piperidin-1-yl-propyl)-3-(5-thiophen-3-yl-pyridin-3-yl)-indole;
- dimethyl-[4-chloro-3-[3-(5-thiophen-3-yl-pyridin-3-yl)-indol-1-yl]-propyl]-amine;
- 4-chloro-1-(1-methyl-piperidin-3-ylmethyl)-3-(5-thiophen-3-yl-pyridin-3-yl)-indole;
- 25 4-chloro-1-[3-(4-methyl-piperazin-1-yl)-propyl]-3-(5-thiophen-3-yl-pyridin-3-yl)-indole;
- dimethyl-[2-[4-chloro-3-(5-thiophen-3-yl-pyridin-3-yl)-indol-1-yl]-propyl]-amine;
- dimethyl-[2-methyl-3-[4-chloro-3-(5-thiophen-3-yl-pyridin-3-yl)-indol-1-yl]-propyl]-amine;
- 30

- 1-{2-[4-chloro-3-(5-thiophen-3-yl-pyridin-3-yl)-indol-1-yl]-ethyl}-piperidine-4-carbonitrile;  
5-chloro-3-(5-thiophen-3-yl-pyridin-3-yl)-indole;  
5-chloro-1-(2-morpholin-4-yl-ethyl)-3-(5-thiophen-3-yl-pyridin-3-yl)-indole;  
5 5-chloro-1-(2-piperidin-1-yl-ethyl)-3-(5-thiophen-3-yl-pyridin-3-yl)-indole;  
5-chloro-1-(3-piperidin-1-yl-propyl)-3-(5-thiophen-3-yl-pyridin-3-yl)-indole;  
dimethyl-{4-chloro-3-[3-(5-thiophen-3-yl-pyridin-3-yl)-indol-1-yl]-propyl}-amine;  
5-chloro-1-(1-methyl-piperidin-3-ylmethyl)-3-(5-thiophen-3-yl-pyridin-3-yl)-indole;  
10 5-chloro-1-[3-(4-methyl-piperazin-1-yl)-propyl]-3-(5-thiophen-3-yl-pyridin-3-yl)-indole;  
dimethyl-{2-[5-chloro-3-(5-thiophen-3-yl-pyridin-3-yl)-indol-1-yl]-propyl}-amine;  
15 dimethyl-{2-methyl-3-[5-chloro-3-(5-thiophen-3-yl-pyridin-3-yl)-indol-1-yl]-propyl}-amine;  
1-{2-[5-chloro-3-(5-thiophen-3-yl-pyridin-3-yl)-indol-1-yl]-ethyl}-piperidine-4-carbonitrile;  
7-methoxy-3-(5-thiophen-3-yl-pyridin-3-yl)-indole;  
20 7-methoxy-1-(2-morpholin-4-yl-ethyl)-3-(5-thiophen-3-yl-pyridin-3-yl)-indole;  
7-methoxy-1-(2-piperidin-1-yl-ethyl)-3-(5-thiophen-3-yl-pyridin-3-yl)-indole;  
7-methoxy-1-(3-piperidin-1-yl-propyl)-3-(5-thiophen-3-yl-pyridin-3-yl)-indole;  
25 dimethyl-{7-methoxy-3-[3-(5-thiophen-3-yl-pyridin-3-yl)-indol-1-yl]-propyl}-amine;  
7-methoxy-1-(1-methyl-piperidin-3-ylmethyl)-3-(5-thiophen-3-yl-pyridin-3-yl)-indole;  
30 7-methoxy-1-[3-(4-methyl-piperazin-1-yl)-propyl]-3-(5-thiophen-3-yl-pyridin-3-yl)-indole;



- dimethyl-{2-[7-methoxy-3-(5-thiophen-3-yl-pyridin-3-yl)-indol-1-yl]-propyl}-amine;
- dimethyl-{2-methyl-3-[7-methoxy-3-(5-thiophen-3-yl-pyridin-3-yl)-indol-1-yl]-propyl}-amine;
- 5 1-{2-[7-methoxy-3-(5-thiophen-3-yl-pyridin-3-yl)-indol-1-yl]-ethyl}-piperidine-4-carbonitrile;
- 6-chloro-3-(5-thiophen-3-yl-pyridin-3-yl)-indole;
- 6-chloro-1-(2-morpholin-4-yl-ethyl)-3-(5-thiophen-3-yl-pyridin-3-yl)-indole;
- 6-chloro-1-(2-piperidin-1-yl-ethyl)-3-(5-thiophen-3-yl-pyridin-3-yl)-indole;
- 10 6-chloro-1-(3-piperidin-1-yl-propyl)-3-(5-thiophen-3-yl-pyridin-3-yl)-indole;
- dimethyl-{6-chloro-3-[3-(5-thiophen-3-yl-pyridin-3-yl)-indol-1-yl]-propyl}-amine;
- 6-chloro-1-(1-methyl-piperidin-3-ylmethyl)-3-(5-thiophen-3-yl-pyridin-3-yl)-indole;
- 15 6-chloro-1-[3-(4-methyl-piperazin-1-yl)-propyl]-3-(5-thiophen-3-yl-pyridin-3-yl)-indole;
- dimethyl-{2-[6-chloro-3-(5-thiophen-3-yl-pyridin-3-yl)-indol-1-yl]-propyl}-amine;
- dimethyl-{2-methyl-3-[6-chloro-3-(5-thiophen-3-yl-pyridin-3-yl)-indol-1-yl]-propyl}-amine;
- 20 1-{2-[6-chloro-3-(5-thiophen-3-yl-pyridin-3-yl)-indol-1-yl]-ethyl}-piperidine-4-carbonitrile;
- 3-(5-thiophen-3-yl-pyridin-3-yl)-indole-5-carbonitrile;
- 1-(2-morpholin-4-yl-ethyl)-3-(5-thiophen-3-yl-pyridin-3-yl)-indole-5-
- 25 carbonitrile;
- 1-(2-piperidin-1-yl-ethyl)-3-(5-thiophen-3-yl-pyridin-3-yl)-indole-5-carbonitrile;
- 1-(3-piperidin-1-yl-propyl)-3-(5-thiophen-3-yl-pyridin-3-yl)-indole-5-carbonitrile;
- 30 1-(3-dimethylamino-propyl)-3-(5-thiophen-3-yl-pyridin-3-yl)-indole-5-carbonitrile;

- 1-(1-methyl-piperidin-3-ylmethyl)-3-(5-thiophen-3-yl-pyridin-3-yl)-indole-5-carbonitrile;
- 1-[3-(4-methyl-piperazin-1-yl)-propyl]-3-(5-thiophen-3-yl-pyridin-3-yl)-indole-5-carbonitrile;
- 5 1-(2-dimethylamino-propyl)-3-(5-thiophen-3-yl-pyridin-3-yl)-indole-5-carbonitrile;
- 1-(1-dimethylamino-2-methyl-propyl)-3-(5-thiophen-3-yl-pyridin-3-yl)-indole-5-carbonitrile;
- 1-[2-(4-cyano-piperidin-1-yl-ethyl)]-3-(5-thiophen-3-yl-pyridin-3-yl)-indole-10 5-carbonitrile;
- 3-(5-thiophen-3-yl-pyridin-3-yl)-indole-4-carboxylic acid methyl ester;
- 1-(2-morpholin-4-yl-ethyl)-3-(5-thiophen-3-yl-pyridin-3-yl)-indole-4-carboxylic acid methyl ester;
- 1-(2-piperidin-1-yl-ethyl)-3-(5-thiophen-3-yl-pyridin-3-yl)-indole-4-15 carboxylic acid methyl ester;
- 1-(3-piperidin-1-yl-propyl)-3-(5-thiophen-3-yl-pyridin-3-yl)-indole-4-carboxylic acid methyl ester;
- 1-(3-dimethylamino-propyl)-3-(5-thiophen-3-yl-pyridin-3-yl)-indole-4-carboxylic acid methyl ester;
- 20 1-(1-methyl-piperidin-3-ylmethyl)-3-(5-thiophen-3-yl-pyridin-3-yl)-indole-4-carboxylic acid methyl ester;
- 1-[3-(4-methyl-piperazin-1-yl)-propyl]-3-(5-thiophen-3-yl-pyridin-3-yl)-indole-4-carboxylic acid methyl ester ;
- 1-(2-dimethylamino-propyl)-3-(5-thiophen-3-yl-pyridin-3-yl)-indole-4-25 carboxylic acid methyl ester;
- 1-(1-dimethylamino-2-methyl-propyl)-3-(5-thiophen-3-yl-pyridin-3-yl)-indole-4-carboxylic acid methyl ester;
- 1-[2-(4-cyano-piperidin-1-yl-ethyl)]-3-(5-thiophen-3-yl-pyridin-3-yl)-indole-4-carboxylic acid methyl ester;
- 30 3-(5-thiophen-3-yl-pyridin-3-yl)-pyrrolo[2,3]pyridine;

- 1-(2-morpholin-4-yl-ethyl)-3-(5-thiophen-3-yl-pyridin-3-yl)-  
pyrrolo[2,3]pyridine;  
1-(2-piperidin-1-yl-ethyl)-3-(5-thiophen-3-yl-pyridin-3-yl)-  
pyrrolo[2,3]pyridine;  
5 1-(3-piperidin-1-yl-propyl)-3-(5-thiophen-3-yl-pyridin-3-yl)-  
pyrrolo[2,3]pyridine;  
dimethyl-{3-[3-(5-thiophen-3-yl-pyridin-3-yl)-pyrrolo[2,3]pyridin-1-yl]-  
propyl}-amine;  
1-(1-methyl-piperidin-3-ylmethyl)-3-(5-thiophen-3-yl-pyridin-3-yl)-  
10 pyrrolo[2,3]pyridine;  
1-[3-(4-methyl-piperazin-1-yl)-propyl]-3-(5-thiophen-3-yl-pyridin-3-yl)-  
pyrrolo[2,3]pyridine;  
dimethyl-{2-[3-(5-thiophen-3-yl-pyridin-3-yl)-pyrrolo[2,3]pyridin-1-yl]-  
propyl}-amine;  
15 dimethyl-{2-methyl-3-[3-(5-thiophen-3-yl-pyridin-3-yl)-pyrrolo[2,3]pyridin-  
1-yl]-propyl}-amine;  
1-(2-[3-(5-thiophen-3-yl-pyridin-3-yl)-pyrrolo[2,3]pyridin-1-yl]-ethyl)-  
piperidine-4-carbonitrile;  
3-(5-phenyl-pyridin-3-yl)-indole;  
20 1-(2-morpholin-4-yl-ethyl)-3-(5-phenyl-pyridin-3-yl)-indole;  
3-(5-phenyl-pyridin-3-yl)-1-(2-piperidin-1-yl-ethyl)-indole;  
3-(5-phenyl-pyridin-3-yl)-1-(3-piperidin-1-yl-propyl)-indole;  
dimethyl-{3-[3-(5-phenyl-pyridin-3-yl)-indol-1-yl]-propyl}-amine;  
1-(1-methyl-piperidin-3-ylmethyl)-3-(5-phenyl-pyridin-3-yl)-indole;  
25 1-[3-(4-methyl-piperazin-1-yl)-propyl]-3-(5-phenyl-pyridin-3-yl)-indole;  
dimethyl-{2-[3-(5-phenyl-pyridin-3-yl)-indol-1-yl]-propyl}-amine;  
dimethyl-{2-methyl-3-[3-(5-phenyl-pyridin-3-yl)-indol-1-yl]-propyl}-amine;  
1-(2-[3-(5-phenyl-pyridin-3-yl)-indol-1-yl]-ethyl)-piperidine-4-carbonitrile;  
5-methoxy-3-(5-phenyl-pyridin-3-yl)-indole;  
30 5-methoxy-1-(2-morpholin-4-yl-ethyl)-3-(5-phenyl-pyridin-3-yl)-indole;  
5-methoxy-3-(5-phenyl-pyridin-3-yl)-1-(2-piperidin-1-yl-ethyl)-indole;

- 5-methoxy-3-(5-phenyl-pyridin-3-yl)-1-(3-piperidin-1-yl-propyl)-indole;  
dimethyl-{5-methoxy-3-[3-(5-phenyl-pyridin-3-yl)-indol-1-yl]-propyl}-  
amine;  
1-(1-methyl-piperidin-3-ylmethyl)-5-methoxy-3-(5-phenyl-pyridin-3-yl)-  
5 indole;  
1-[3-(4-methyl-piperazin-1-yl)-propyl]-5-methoxy-3-(5-phenyl-pyridin-3-  
yl)-indole;  
dimethyl-{2-[5-methoxy-3-(5-phenyl-pyridin-3-yl)-indol-1-yl]-propyl}-  
amine;  
10 dimethyl-{2-methyl-3-[5-methoxy-3-(5-phenyl-pyridin-3-yl)-indol-1-yl]-  
propyl}-amine;  
1-{2-[5-methoxy-3-(5-phenyl-pyridin-3-yl)-indol-1-yl]-ethyl}-piperidine-4-  
carbonitrile;  
4-chloro-3-(5-phenyl-pyridin-3-yl)-indole;  
15 4-chloro-1-(2-morpholin-4-yl-ethyl)-3-(5-phenyl-pyridin-3-yl)-indole;  
4-chloro-3-(5-phenyl-pyridin-3-yl)-1-(2-piperidin-1-yl-ethyl)-indole;  
4-chloro-3-(5-phenyl-pyridin-3-yl)-1-(3-piperidin-1-yl-propyl)-indole;  
dimethyl-{4-chloro-3-[3-(5-phenyl-pyridin-3-yl)-indol-1-yl]-propyl}-amine;  
1-(1-methyl-piperidin-3-ylmethyl)-4-chloro-3-(5-phenyl-pyridin-3-yl)-  
20 indole;  
1-[3-(4-methyl-piperazin-1-yl)-propyl]-4-chloro-3-(5-phenyl-pyridin-3-yl)-  
indole;  
dimethyl-{2-[4-chloro-3-(5-phenyl-pyridin-3-yl)-indol-1-yl]-propyl}-amine;  
dimethyl-{2-methyl-3-[4-chloro-3-(5-phenyl-pyridin-3-yl)-indol-1-yl]-  
25 propyl}-amine;  
1-{2-[4-chloro-3-(5-phenyl-pyridin-3-yl)-indol-1-yl]-ethyl}-piperidine-4-  
carbonitrile;  
5-chloro-3-(5-phenyl-pyridin-3-yl)-indole;  
5-chloro-1-(2-morpholin-4-yl-ethyl)-3-(5-phenyl-pyridin-3-yl)-indole;  
30 5-chloro-3-(5-phenyl-pyridin-3-yl)-1-(2-piperidin-1-yl-ethyl)-indole;  
5-chloro-3-(5-phenyl-pyridin-3-yl)-1-(3-piperidin-1-yl-propyl)-indole;

- dimethyl-{5-chloro-3-[3-(5-phenyl-pyridin-3-yl)-indol-1-yl]-propyl}-amine;  
1-(1-methyl-piperidin-3-ylmethyl)-5-chloro-3-(5-phenyl-pyridin-3-yl)-  
indole;  
1-[3-(4-methyl-piperazin-1-yl)-propyl]-5-chloro-3-(5-phenyl-pyridin-3-yl)-  
5 indole;  
dimethyl-{2-[5-chloro-3-(5-phenyl-pyridin-3-yl)-indol-1-yl]-propyl}-amine;  
dimethyl-{2-methyl-3-[5-chloro-3-(5-phenyl-pyridin-3-yl)-indol-1-yl]-  
propyl}-amine;  
1-{2-[5-chloro-3-(5-phenyl-pyridin-3-yl)-indol-1-yl]-ethyl}-piperidine-4-  
10 carbonitrile;  
7-methoxy-3-(5-phenyl-pyridin-3-yl)-indole;  
7-methoxy-1-(2-morpholin-4-yl-ethyl)-3-(5-phenyl-pyridin-3-yl)-indole;  
7-methoxy-3-(5-phenyl-pyridin-3-yl)-1-(2-piperidin-1-yl-ethyl)-indole;  
7-methoxy-3-(5-phenyl-pyridin-3-yl)-1-(3-piperidin-1-yl-propyl)-indole;  
15 dimethyl-{7-methoxy-3-[3-(5-phenyl-pyridin-3-yl)-indol-1-yl]-propyl}-  
amine;  
1-(1-methyl-piperidin-3-ylmethyl)-7-methoxy-3-(5-phenyl-pyridin-3-yl)-  
indole;  
1-[3-(4-methyl-piperazin-1-yl)-propyl]-7-methoxy-3-(5-phenyl-pyridin-3-  
20 yl)-indole;  
dimethyl-{2-[7-methoxy-3-(5-phenyl-pyridin-3-yl)-indol-1-yl]-propyl}-  
amine;  
dimethyl-{2-methyl-3-[7-methoxy-3-(5-phenyl-pyridin-3-yl)-indol-1-yl]-  
propyl}-amine;  
25 1-{2-[7-methoxy-3-(5-phenyl-pyridin-3-yl)-indol-1-yl]-ethyl}-piperidine-4-  
carbonitrile;  
6-chloro-3-(5-phenyl-pyridin-3-yl)-indole;  
6-chloro-1-(2-morpholin-4-yl-ethyl)-3-(5-phenyl-pyridin-3-yl)-indole;  
6-chloro-3-(5-phenyl-pyridin-3-yl)-1-(2-piperidin-1-yl-ethyl)-indole;  
30 6-chloro-3-(5-phenyl-pyridin-3-yl)-1-(3-piperidin-1-yl-propyl)-indole;  
dimethyl-{6-chloro-3-[3-(5-phenyl-pyridin-3-yl)-indol-1-yl]-propyl}-amine;

- 1-(1-methyl-piperidin-3-ylmethyl)-6-chloro-3-(5-phenyl-pyridin-3-yl)-indole;
- 1-[3-(4-methyl-piperazin-1-yl)-propyl]-6-chloro-3-(5-phenyl-pyridin-3-yl)-indole;
- 5 dimethyl-{2-[6-chloro-3-(5-phenyl-pyridin-3-yl)-indol-1-yl]-propyl}-amine;  
dimethyl-{2-methyl-3-[6-chloro-3-(5-phenyl-pyridin-3-yl)-indol-1-yl]-propyl}-amine;
- 1-{2-[6-chloro-3-(5-phenyl-pyridin-3-yl)-indol-1-yl]-ethyl}-piperidine-4-carbonitrile;
- 10 3-(5-phenyl-pyridin-3-yl)-indole-5-carbonitrile;  
1-(2-morpholin-4-yl-ethyl)-3-(5-phenyl-pyridin-3-yl)-indole-5-carbonitrile;  
1-(2-piperidin-1-yl-ethyl)-3-(5-phenyl-pyridin-3-yl)-indole-5-carbonitrile;  
1-(3-piperidin-1-yl-propyl)-3-(5-phenyl-pyridin-3-yl)-indole-5-carbonitrile;  
1-(3-dimethylamino-propyl)-3-(5-phenyl-pyridin-3-yl)-indole-5-
- 15 carbonitrile;  
1-(1-methyl-piperidin-3-ylmethyl)-3-(5-phenyl-pyridin-3-yl)-indole-5-carbonitrile;  
1-[3-(4-methyl-piperazin-1-yl)-propyl]-3-(5-phenyl-pyridin-3-yl)-indole-5-carbonitrile;
- 20 1-(2-dimethylamino-propyl)-3-(5-phenyl-pyridin-3-yl)-indole-5-carbonitrile;  
1-(1-dimethylamino-2-methyl-propyl)-3-(5-phenyl-pyridin-3-yl)-indole-5-carbonitrile;  
1-[2-(4-cyano-piperidin-1-yl-ethyl)-3-(5-phenyl-pyridin-3-yl)-indole-5-
- 25 carbonitrile;  
3-(5-phenyl-pyridin-3-yl)-indole-4-carboxylic acid methyl ester;  
1-(2-morpholin-4-yl-ethyl)-3-(5-phenyl-pyridin-3-yl)-indole-4-carboxylic acid methyl ester;  
1-(2-piperidin-1-yl-ethyl)-3-(5-phenyl-pyridin-3-yl)-indole-4-carboxylic
- 30 acid methyl ester;

- 1-(3-piperidin-1-yl-propyl)-3-(5-phenyl-pyridin-3-yl)-indole-4-carboxylic acid methyl ester;
- 1-(3-dimethylamino-propyl)-3-(5-phenyl-pyridin-3-yl)-indole-4-carboxylic acid methyl ester;
- 5 1-(1-methyl-piperidin-3-ylmethyl)-3-(5-phenyl-pyridin-3-yl)-indole-4-carboxylic acid methyl ester;
- 1-[3-(4-methyl-piperazin-1-yl)-propyl]-3-(5-phenyl-pyridin-3-yl)-indole-4-carboxylic acid methyl ester ;
- 1-(2-dimethylamino-propyl)-3-(5-phenyl-pyridin-3-yl)-indole-4-carboxylic acid methyl ester;
- 10 1-(1-dimethylamino-2-methyl-propyl)-3-(5-phenyl-pyridin-3-yl)-indole-4-carboxylic acid methyl ester;
- 1-[2-(4-cyano-piperidin-1-yl-ethyl)-3-(5-phenyl-pyridin-3-yl)-indole-4-carboxylic acid methyl ester;
- 15 3-(5-phenyl-pyridin-3-yl)-pyrrolo[2,3]pyridine;
- 1-(2-morpholin-4-yl-ethyl)-3-(5-phenyl-pyridin-3-yl)-pyrrolo[2,3]pyridine;
- 1-(2-piperidin-1-yl-ethyl)-3-(5-phenyl-pyridin-3-yl)-pyrrolo[2,3]pyridine;
- 1-(3-piperidin-1-yl-propyl)-3-(5-phenyl-pyridin-3-yl)-pyrrolo[2,3]pyridine;
- dimethyl-{3-[3-(5-phenyl-pyridin-3-yl)-pyrrolo[2,3]pyridin-1-yl]-propyl}-
- 20 amine;
- 1-(1-methyl-piperidin-3-ylmethyl)-3-(5-phenyl-pyridin-3-yl)-pyrrolo[2,3]pyridine;
- 1-[3-(4-methyl-piperazin-1-yl)-propyl]-3-(5-phenyl-pyridin-3-yl)-pyrrolo[2,3]pyridine;
- 25 dimethyl-{2-[3-(5-phenyl-pyridin-3-yl)-pyrrolo[2,3]pyridin-1-yl]-propyl}-amine;
- dimethyl-{2-methyl-3-[3-(5-phenyl-pyridin-3-yl)-pyrrolo[2,3]pyridin-1-yl]-propyl}-amine;
- 1-{2-[3-(5-phenyl-pyridin-3-yl)-pyrrolo[2,3]pyridin-1-yl]-ethyl}-piperidine-
- 30 4-carbonitrile;
- 3-[5-(3-methoxy-phenyl)-pyridin-3-yl]-indole;

- 3-[5-(3-methoxy-phenyl)-pyridin-3-yl]-1-(2-morpholin-4-yl-ethyl)-indole;  
3-[5-(3-methoxy-phenyl)-pyridin-3-yl]-1-(2-piperidin-1-yl-ethyl)-indole;  
3-[5-(3-methoxy-phenyl)-pyridin-3-yl]-1-(3-piperidin-1-yl-propyl)-indole;  
dimethyl-{3-[3-(5-(3-methoxy-phenyl)-pyridin-3-yl)-indol-1-yl]-propyl}-  
5 amine;  
3-[5-(3-methoxy-phenyl)-pyridin-3-yl]-1-(1-methyl-piperidin-3-ylmethyl)-  
indole;  
3-[5-(3-methoxy-phenyl)-pyridin-3-yl]-1-[3-(4-methyl-piperazin-1-yl)-  
propyl]-indole;  
10 dimethyl-(2-[3-(5-(3-methoxy-phenyl)-1-pyridin-3-yl)-indol-1-yl]-propyl)-  
amine;  
dimethyl-(2-methyl-3-[3-(5-(3-methoxy-phenyl)-pyridin-3-yl)-indol-1-yl]-  
propyl)-amine;  
1-{2-[3-(5-(3-methoxy-phenyl)-pyridin-3-yl)-indol-1-yl]-ethyl}-piperidine-4-  
15 carbonitrile;  
5-methoxy-3-[5-(3-methoxy-phenyl)-pyridin-3-yl]-indole;  
5-methoxy-3-[5-(3-methoxy-phenyl)-pyridin-3-yl]-1-(2-morpholin-4-yl-  
ethyl)-indole;  
5-methoxy-3-[5-(3-methoxy-phenyl)-pyridin-3-yl]-1-(2-piperidin-1-yl-  
20 ethyl)-indole;  
5-methoxy-3-[5-(3-methoxy-phenyl)-pyridin-3-yl]-1-(3-piperidin-1-yl-  
propyl)-indole;  
dimethyl-{3-[5-methoxy-3-(5-(3-methoxy-phenyl)-pyridin-3-yl)-indol-1-yl]-  
propyl}-amine;  
25 5-methoxy-3-[5-(3-methoxy-phenyl)-pyridin-3-yl]-1-(1-methyl-piperidin-3-  
ylmethyl)-indole;  
5-methoxy-3-[5-(3-methoxy-phenyl)-pyridin-3-yl]-1-[3-(4-methyl-  
piperazin-1-yl)-propyl]-indole;  
dimethyl-(2-[5-methoxy-3-(5-(3-methoxy-phenyl)-1-pyridin-3-yl)-indol-1-  
30 yl]-propyl)-amine;



- dimethyl-{2-methyl-3-[5-methoxy-3-(5-(3-methoxy-phenyl)-pyridin-3-yl)-indol-1-yl]-propyl}-amine;  
1-{2-[5-methoxy-3-(5-(3-methoxy-phenyl)-pyridin-3-yl)-indol-1-yl]-ethyl}-piperidine-4-carbonitrile;
- 5 4-chloro-3-[5-(3-methoxy-phenyl)-pyridin-3-yl]-indole;  
4-chloro-3-[5-(3-methoxy-phenyl)-pyridin-3-yl]-1-(2-morpholin-4-yl-ethyl)-indole;  
4-chloro-3-[5-(3-methoxy-phenyl)-pyridin-3-yl]-1-(2-piperidin-1-yl-ethyl)-indole;
- 10 4-chloro-3-[5-(3-methoxy-phenyl)-pyridin-3-yl]-1-(3-piperidin-1-yl-propyl)-indole;  
dimethyl-{3-[4-chloro-3-(5-(3-methoxy-phenyl)-pyridin-3-yl)-indol-1-yl]-propyl}-amine;  
4-chloro-3-[5-(3-methoxy-phenyl)-pyridin-3-yl]-1-(1-methyl-piperidin-3-ylmethyl)-indole;
- 15 4-chloro-3-[5-(3-methoxy-phenyl)-pyridin-3-yl]-1-[3-(4-methyl-piperazin-1-yl)-propyl]-indole;  
dimethyl-{2-[4-chloro-3-(5-(3-methoxy-phenyl)-1-pyridin-3-yl)-indol-1-yl]-propyl}-amine;
- 20 dimethyl-{2-methyl-3-[4-chloro-3-(5-(3-methoxy-phenyl)-pyridin-3-yl)-indol-1-yl]-propyl}-amine;  
1-{2-[4-chloro-3-(5-(3-methoxy-phenyl)-pyridin-3-yl)-indol-1-yl]-ethyl}-piperidine-4-carbonitrile;  
5-chloro-3-[5-(3-methoxy-phenyl)-pyridin-3-yl]-indole;
- 25 5-chloro-3-[5-(3-methoxy-phenyl)-pyridin-3-yl]-1-(2-morpholin-4-yl-ethyl)-indole;  
5-chloro-3-[5-(3-methoxy-phenyl)-pyridin-3-yl]-1-(2-piperidin-1-yl-ethyl)-indole;  
5-chloro-3-[5-(3-methoxy-phenyl)-pyridin-3-yl]-1-(3-piperidin-1-yl-propyl)-indole;
- 30 indole;

- dimethyl-{3-[5-chloro-3-(5-(3-methoxy-phenyl)-pyridin-3-yl)-indol-1-yl]-propyl}-amine;  
5-chloro-3-[5-(3-methoxy-phenyl)-pyridin-3-yl]-1-(1-methyl-piperidin-3-ylmethyl)-indole;  
5 5-chloro-3-[5-(3-methoxy-phenyl)-pyridin-3-yl]-1-[3-(4-methyl-piperazin-1-yl)-propyl]-indole;  
dimethyl-{2-[5-chloro-3-(5-(3-methoxy-phenyl)-1-pyridin-3-yl)-indol-1-yl]-propyl}-amine;  
dimethyl-{2-methyl-3-[5-chloro-3-(5-(3-methoxy-phenyl)-pyridin-3-yl)-indol-1-yl]-propyl}-amine;  
10 1-{2-[5-chloro-3-(5-(3-methoxy-phenyl)-pyridin-3-yl)-indol-1-yl]-ethyl}-piperidine-4-carbonitrile;  
7-methoxy-3-[5-(3-methoxy-phenyl)-pyridin-3-yl]-indole;  
7-methoxy-3-[5-(3-methoxy-phenyl)-pyridin-3-yl]-1-(2-morpholin-4-yl-ethyl)-indole;  
15 7-methoxy-3-[5-(3-methoxy-phenyl)-pyridin-3-yl]-1-(2-piperidin-1-yl-ethyl)-indole;  
7-methoxy-3-[5-(3-methoxy-phenyl)-pyridin-3-yl]-1-(3-piperidin-1-yl-propyl)-indole;  
20 dimethyl-{3-[7-methoxy-3-(5-(3-methoxy-phenyl)-pyridin-3-yl)-indol-1-yl]-propyl}-amine;  
7-methoxy-3-[5-(3-methoxy-phenyl)-pyridin-3-yl]-1-(1-methyl-piperidin-3-ylmethyl)-indole;  
7-methoxy-3-[5-(3-methoxy-phenyl)-pyridin-3-yl]-1-[3-(4-methyl-piperazin-1-yl)-propyl]-indole;  
25 dimethyl-{2-[7-methoxy-3-(5-(3-methoxy-phenyl)-1-pyridin-3-yl)-indol-1-yl]-propyl}-amine;  
dimethyl-{2-methyl-3-[7-methoxy-3-(5-(3-methoxy-phenyl)-pyridin-3-yl)-indol-1-yl]-propyl}-amine;  
30 1-{2-[7-methoxy-3-(5-(3-methoxy-phenyl)-pyridin-3-yl)-indol-1-yl]-ethyl}-piperidine-4-carbonitrile;

- 6-chloro-3-[5-(3-methoxy-phenyl)-pyridin-3-yl]-indole;  
6-chloro-3-[5-(3-methoxy-phenyl)-pyridin-3-yl]-1-(2-morpholin-4-yl-ethyl)-  
indole;  
6-chloro-3-[5-(3-methoxy-phenyl)-pyridin-3-yl]-1-(2-piperidin-1-yl-ethyl)-  
5 indole;  
6-chloro-3-[5-(3-methoxy-phenyl)-pyridin-3-yl]-1-(3-piperidin-1-yl-propyl)-  
indole;  
dimethyl-{3-[6-chloro-3-(5-(3-methoxy-phenyl)-pyridin-3-yl)-indol-1-yl]-  
propyl}-amine;  
10 6-chloro-3-[5-(3-methoxy-phenyl)-pyridin-3-yl]-1-(1-methyl-piperidin-3-  
ylmethyl)-indole;  
6-chloro-3-[5-(3-methoxy-phenyl)-pyridin-3-yl]-1-[3-(4-methyl-piperazin-1-  
yl)-propyl]-indole;  
dimethyl-{2-[6-chloro-3-(5-(3-methoxy-phenyl)-1-pyridin-3-yl)-indol-1-yl]-  
15 propyl}-amine;  
dimethyl-{2-methyl-3-[6-chloro-3-(5-(3-methoxy-phenyl)-pyridin-3-yl)-  
indol-1-yl]-propyl}-amine;  
1-{2-[6-chloro-3-(5-(3-methoxy-phenyl)-pyridin-3-yl)-indol-1-yl]-ethyl}-  
piperidine-4-carbonitrile;  
20 3-[5-(3-methoxy-phenyl)-pyridin-3-yl]-indole-5-carbonitrile;  
3-[5-(3-methoxy-phenyl)-pyridin-3-yl]-1-(2-morpholin-4-yl-ethyl)-indole-5-  
carbonitrile;  
3-[5-(3-methoxy-phenyl)-pyridin-3-yl]-1-(2-piperidin-1-yl-ethyl)-indole-5-  
carbonitrile;  
25 3-[5-(3-methoxy-phenyl)-pyridin-3-yl]-1-(3-piperidin-1-yl-propyl)-indole-5-  
carbonitrile;  
1-(3-dimethylamino-propyl)-3-[5-(3-methoxy-phenyl)-pyridin-3-yl]-indole-  
5-carbonitrile;  
3-[5-(3-methoxy-phenyl)-pyridin-3-yl]-1-(1-methyl-piperidin-3-ylmethyl)-  
30 indole-5-carbonitrile;

- 3-[5-(3-methoxy-phenyl)-pyridin-3-yl]-1-[3-(4-methyl-piperazin-1-yl)-propyl]-indole-5-carbonitrile;  
1-(2-dimethylamino-propyl)-3-[5-(3-methoxy-phenyl)-pyridin-3-yl]-indole-5-carbonitrile;
- 5 1-(1-dimethylamino-2-methyl-propyl)-3-[5-(3-methoxy-phenyl)-pyridin-3-yl]-indole-5-carbonitrile;  
1-[2-(4-cyano-piperidin-1-yl-ethyl)]-3-[5-(3-methoxy-phenyl)-pyridin-3-yl]-indole-5-carbonitrile;  
3-[5-(3-methoxy-phenyl)-pyridin-3-yl]-indole-4-carboxylic acid methyl  
10 ester;  
3-[5-(3-methoxy-phenyl)-pyridin-3-yl]-1-(2-morpholin-4-yl-ethyl)-indole-4-carboxylic acid methyl ester;  
3-[5-(3-methoxy-phenyl)-pyridin-3-yl]-1-(2-piperidin-1-yl-ethyl)-indole-4-carboxylic acid methyl ester;
- 15 3-[5-(3-methoxy-phenyl)-pyridin-3-yl]-1-(3-piperidin-1-yl-propyl)-indole-4-carboxylic acid methyl ester;  
1-(3-dimethylamino-propyl)-3-[5-(3-methoxy-phenyl)-pyridin-3-yl]-indole-4-carboxylic acid methyl ester;  
3-[5-(3-methoxy-phenyl)-pyridin-3-yl]-1-(1-methyl-piperidin-3-ylmethyl)-  
20 indole-4-carboxylic acid methyl ester;  
3-[5-(3-methoxy-phenyl)-pyridin-3-yl]-1-[3-(4-methyl-piperazin-1-yl)-propyl]-indole-4-carboxylic acid methyl ester;  
1-(2-dimethylamino-propyl)-3-[5-(3-methoxy-phenyl)-pyridin-3-yl]-indole-4-carboxylic acid methyl ester;
- 25 1-(1-dimethylamino-2-methyl-propyl)-3-[5-(3-methoxy-phenyl)-pyridin-3-yl]-indole-4-carboxylic acid methyl ester;  
1-[2-(4-cyano-piperidin-1-yl-ethyl)]-3-[5-(3-methoxy-phenyl)-pyridin-3-yl]-indole-4-carboxylic acid methyl ester;  
3-[5-(3-methoxy-phenyl)-pyridin-3-yl]-pyrrolo[2,3]pyridine;
- 30 3-[5-(3-methoxy-phenyl)-pyridin-3-yl]-1-(2-morpholin-4-yl-ethyl)-pyrrolo[2,3]pyridine;

- 3-[5-(3-methoxy-phenyl)-pyridin-3-yl]-1-(2-piperidin-1-yl-ethyl)-  
pyrrolo[2,3]pyridine;  
3-[5-(3-methoxy-phenyl)-pyridin-3-yl]-1-(3-piperidin-1-yl-propyl)-  
pyrrolo[2,3]pyridine;  
5 dimethyl-{3-[3-(5-(3-methoxy-phenyl)-pyridin-3-yl)-pyrrolo[2,3]pyridin-1-  
yl]-propyl}-amine;  
3-[5-(3-methoxy-phenyl)-pyridin-3-yl]-1-(1-methyl-piperidin-3-ylmethyl)-  
pyrrolo[2,3]pyridine;  
3-[5-(3-methoxy-phenyl)-pyridin-3-yl]-1-[3-(4-methyl-piperazin-1-yl)-  
10 propyl]-pyrrolo[2,3]pyridine;  
dimethyl-{2-[3-(5-(3-methoxy-phenyl)-l-pyridin-3-yl)-pyrrolo[2,3]pyridin-1-  
yl]-propyl}-amine;  
dimethyl-{2-methyl-3-[3-(5-(3-methoxy-phenyl)-pyridin-3-yl)-  
pyrrolo[2,3]pyridin-1-yl]-propyl}-amine;  
15 1-(2-[3-(5-(3-methoxy-phenyl)-pyridin-3-yl)-pyrrolo[2,3]pyridin-1-yl]-ethyl)-  
piperidine-4-carbonitrile;  
3-[5-(4-methoxy-phenyl)-pyridin-3-yl]-indole;  
3-[5-(4-methoxy-phenyl)-pyridin-3-yl]-1-(2-morpholin-4-yl-ethyl)-indole;  
3-[5-(4-methoxy-phenyl)-pyridin-3-yl]-1-(2-piperidin-1-yl-ethyl)-indole;  
20 3-[5-(4-methoxy-phenyl)-pyridin-3-yl]-1-(3-piperidin-1-yl-propyl)-indole;  
dimethyl-{3-[3-(5-(4-methoxy-phenyl)-pyridin-3-yl)-indol-1-yl]-propyl}-  
amine;  
3-[5-(4-methoxy-phenyl)-pyridin-3-yl]-1-(1-methyl-piperidin-3-ylmethyl)-  
indole;  
25 3-[5-(4-methoxy-phenyl)-pyridin-3-yl]-1-[3-(4-methyl-piperazin-1-yl)-  
propyl]-indole;  
dimethyl-{2-[3-(5-(4-methoxy-phenyl)-l-pyridin-3-yl)-indol-1-yl]-propyl}-  
amine;  
dimethyl-{2-methyl-3-[3-(5-(4-methoxy-phenyl)-pyridin-3-yl)-indol-1-yl]-  
30 propyl}-amine;

- 1-(2-[3-(5-(4-methoxy-phenyl)-pyridin-3-yl)-indol-1-yl]-ethyl)-piperidine-4-carbonitrile;  
5-methoxy-3-[5-(4-methoxy-phenyl)-pyridin-3-yl]-1-(2-morpholin-4-yl-ethyl)-indole;  
5 5-methoxy-3-[5-(4-methoxy-phenyl)-pyridin-3-yl]-1-(2-piperidin-1-yl-ethyl)-indole;  
5-methoxy-3-[5-(4-methoxy-phenyl)-pyridin-3-yl]-1-(3-piperidin-1-yl-propyl)-indole;  
dimethyl-{3-[5-methoxy-3-(5-(4-methoxy-phenyl)-pyridin-3-yl)-indol-1-yl]-propyl}-amine;  
10 5-methoxy-3-[5-(4-methoxy-phenyl)-pyridin-3-yl]-1-(1-methyl-piperidin-3-ylmethyl)-indole;  
5-methoxy-3-[5-(4-methoxy-phenyl)-pyridin-3-yl]-1-[3-(4-methyl-piperazin-1-yl)-propyl]-indole;  
15 dimethyl-{2-[5-methoxy-3-(5-(4-methoxy-phenyl)-1-pyridin-3-yl)-indol-1-yl]-propyl}-amine;  
dimethyl-{2-methyl-3-[5-methoxy-3-(5-(4-methoxy-phenyl)-pyridin-3-yl)-indol-1-yl]-propyl}-amine;  
1-(2-[5-methoxy-3-(5-(4-methoxy-phenyl)-pyridin-3-yl)-indol-1-yl]-ethyl)-  
20 piperidine-4-carbonitrile;  
4-chloro-3-[5-(4-methoxy-phenyl)-pyridin-3-yl]-indole;  
4-chloro-3-[5-(4-methoxy-phenyl)-pyridin-3-yl]-1-(2-morpholin-4-yl-ethyl)-indole;  
4-chloro-3-[5-(4-methoxy-phenyl)-pyridin-3-yl]-1-(2-piperidin-1-yl-ethyl)-  
25 indole;  
4-chloro-3-[5-(4-methoxy-phenyl)-pyridin-3-yl]-1-(3-piperidin-1-yl-propyl)-indole;  
dimethyl-{3-[4-chloro-3-(5-(4-methoxy-phenyl)-pyridin-3-yl)-indol-1-yl]-propyl}-amine;  
30 4-chloro-3-[5-(4-methoxy-phenyl)-pyridin-3-yl]-1-(1-methyl-piperidin-3-ylmethyl)-indole;

- 4-chloro-3-[5-(4-methoxy-phenyl)-pyridin-3-yl]-1-[3-(4-methyl-piperazin-1-yl)-propyl]-indole;  
dimethyl-{2-[4-chloro-3-(5-(4-methoxy-phenyl)-1-pyridin-3-yl)-indol-1-yl]-propyl}-amine;
- 5 dimethyl-{2-methyl-3-[4-chloro-3-(5-(4-methoxy-phenyl)-pyridin-3-yl)-indol-1-yl]-propyl}-amine;  
1-{2-[4-chloro-3-(5-(4-methoxy-phenyl)-pyridin-3-yl)-indol-1-yl]-ethyl}-piperidine-4-carbonitrile;  
5-chloro-3-[5-(4-methoxy-phenyl)-pyridin-3-yl]-indole;
- 10 5-chloro-3-[5-(4-methoxy-phenyl)-pyridin-3-yl]-1-(2-morpholin-4-yl-ethyl)-indole;  
5-chloro-3-[5-(4-methoxy-phenyl)-pyridin-3-yl]-1-(2-piperidin-1-yl-ethyl)-indole;  
5-chloro-3-[5-(4-methoxy-phenyl)-pyridin-3-yl]-1-(3-piperidin-1-yl-propyl)-indole;
- 15 dimethyl-{3-[5-chloro-3-(5-(4-methoxy-phenyl)-pyridin-3-yl)-indol-1-yl]-propyl}-amine;  
5-chloro-3-[5-(4-methoxy-phenyl)-pyridin-3-yl]-1-(1-methyl-piperidin-3-ylmethyl)-indole;
- 20 5-chloro-3-[5-(4-methoxy-phenyl)-pyridin-3-yl]-1-[3-(4-methyl-piperazin-1-yl)-propyl]-indole;  
dimethyl-{2-[5-chloro-3-(5-(3-methoxy-phenyl)-1-pyridin-3-yl)-indol-1-yl]-propyl}-amine;  
dimethyl-{2-methyl-3-[5-chloro-3-(5-(4-methoxy-phenyl)-pyridin-3-yl)-indol-1-yl]-propyl}-amine;
- 25 1-{2-[5-chloro-3-(5-(4-methoxy-phenyl)-pyridin-3-yl)-indol-1-yl]-ethyl}-piperidine-4-carbonitrile;  
7-methoxy-3-[5-(4-methoxy-phenyl)-pyridin-3-yl]-indole;  
7-methoxy-3-[5-(4-methoxy-phenyl)-pyridin-3-yl]-1-(2-morpholin-4-yl-ethyl)-indole;
- 30

- 7-methoxy-3-[5-(4-methoxy-phenyl)-pyridin-3-yl]-1-(2-piperidin-1-yl-ethyl)-indole;  
7-methoxy-3-[5-(4-methoxy-phenyl)-pyridin-3-yl]-1-(3-piperidin-1-yl-propyl)-indole;  
5 dimethyl-{3-[7-methoxy-3-(5-(4-methoxy-phenyl)-pyridin-3-yl)-indol-1-yl]-propyl}-amine;  
7-methoxy-3-[5-(4-methoxy-phenyl)-pyridin-3-yl]-1-(1-methyl-piperidin-3-ylmethyl)-indole;  
7-methoxy-3-[5-(4-methoxy-phenyl)-pyridin-3-yl]-1-[3-(4-methyl-  
10 piperazin-1-yl)-propyl]-indole;  
dimethyl-{2-[7-methoxy-3-(5-(4-methoxy-phenyl)-1-pyridin-3-yl)-indol-1-yl]-propyl}-amine;  
dimethyl-{2-methyl-3-[7-methoxy-3-(5-(4-methoxy-phenyl)-pyridin-3-yl)-indol-1-yl]-propyl}-amine;  
15 1-{2-[7-methoxy-3-(5-(4-methoxy-phenyl)-pyridin-3-yl)-indol-1-yl]-ethyl}-piperidine-4-carbonitrile;  
6-chloro-3-[5-(4-methoxy-phenyl)-pyridin-3-yl]-indole;  
6-chloro-3-[5-(4-methoxy-phenyl)-pyridin-3-yl]-1-(2-morpholin-4-yl-ethyl)-indole;  
20 6-chloro-3-[5-(4-methoxy-phenyl)-pyridin-3-yl]-1-(2-piperidin-1-yl-ethyl)-indole;  
6-chloro-3-[5-(4-methoxy-phenyl)-pyridin-3-yl]-1-(3-piperidin-1-yl-propyl)-indole;  
dimethyl-{3-[6-chloro-3-(5-(4-methoxy-phenyl)-pyridin-3-yl)-indol-1-yl]-  
25 propyl}-amine;  
6-chloro-3-[5-(4-methoxy-phenyl)-pyridin-3-yl]-1-(1-methyl-piperidin-3-ylmethyl)-indole;  
6-chloro-3-[5-(4-methoxy-phenyl)-pyridin-3-yl]-1-[3-(4-methyl-piperazin-1-yl)-propyl]-indole;  
30 dimethyl-{2-[6-chloro-3-(5-(4-methoxy-phenyl)-1-pyridin-3-yl)-indol-1-yl]-propyl}-amine;



- dimethyl-(2-methyl-3-[6-chloro-3-(5-(3-methoxy-phenyl)-pyridin-3-yl)-indol-1-yl]-propyl)-amine;
- 1-(2-[6-chloro-3-(5-(3-methoxy-phenyl)-pyridin-3-yl)-indol-1-yl]-ethyl)-piperidine-4-carbonitrile;
- 5 3-[5-(4-methoxy-phenyl)-pyridin-3-yl]-indole-5-carbonitrile;
- 3-[5-(3-methoxy-phenyl)-pyridin-3-yl]-1-(2-morpholin-4-yl-ethyl)-indole-5-carbonitrile;
- 3-[5-(4-methoxy-phenyl)-pyridin-3-yl]-1-(2-piperidin-1-yl-ethyl)-indole-5-carbonitrile;
- 10 3-[5-(4-methoxy-phenyl)-pyridin-3-yl]-1-(3-piperidin-1-yl-propyl)-indole-5-carbonitrile;
- 1-(3-dimethylamino-propyl)-3-[5-(4-methoxy-phenyl)-pyridin-3-yl]-indole-5-carbonitrile;
- 3-[5-(4-methoxy-phenyl)-pyridin-3-yl]-1-(1-methyl-piperidin-3-ylmethyl)-indole-5-carbonitrile;
- 15 3-[5-(4-methoxy-phenyl)-pyridin-3-yl]-1-[3-(4-methyl-piperazin-1-yl)-propyl]-indole-5-carbonitrile;
- 1-(2-dimethylamino-propyl)-3-[5-(4-methoxy-phenyl)-pyridin-3-yl]-indole-5-carbonitrile;
- 20 1-(1-dimethylamino-2-methyl-propyl)-3-[5-(4-methoxy-phenyl)-pyridin-3-yl]-indole-5-carbonitrile;
- 1-[2-(4-cyano-piperidin-1-yl-ethyl)-3-[5-(4-methoxy-phenyl)-pyridin-3-yl]-indole-5-carbonitrile;
- 3-[5-(4-methoxy-phenyl)-pyridin-3-yl]-indole-4-carboxylic acid methyl ester;
- 25 3-[5-(4-methoxy-phenyl)-pyridin-3-yl]-1-(2-morpholin-4-yl-ethyl)-indole-4-carboxylic acid methyl ester;
- 3-[5-(4-methoxy-phenyl)-pyridin-3-yl]-1-(2-piperidin-1-yl-ethyl)-indole-4-carboxylic acid methyl ester;
- 30 3-[5-(4-methoxy-phenyl)-pyridin-3-yl]-1-(3-piperidin-1-yl-propyl)-indole-4-carboxylic acid methyl ester;

- 1-(3-dimethylamino-propyl)-3-[5-(4-methoxy-phenyl)-pyridin-3-yl]-indole-4-carboxylic acid methyl ester;
- 3-[5-(4-methoxy-phenyl)-pyridin-3-yl]-1-(1-methyl-piperidin-3-ylmethyl)-indole-4-carboxylic acid methyl ester;
- 5 3-[5-(4-methoxy-phenyl)-pyridin-3-yl]-1-[3-(4-methyl-piperazin-1-yl)-propyl]-indole-4-carboxylic acid methyl ester;
- 1-(2-dimethylamino-propyl)-3-[5-(4-methoxy-phenyl)-pyridin-3-yl]-indole-4-carboxylic acid methyl ester;
- 10 1-(1-dimethylamino-2-methyl-propyl)-3-[5-(4-methoxy-phenyl)-pyridin-3-yl]-indole-4-carboxylic acid methyl ester;
- 1-[2-(4-cyano-piperidin-1-yl-ethyl)-3-[5-(4-methoxy-phenyl)-pyridin-3-yl]-indole-4-carboxylic acid methyl ester;
- 3-[5-(4-methoxy-phenyl)-pyridin-3-yl]-pyrrolo[2,3]pyridine;
- 3-[5-(4-methoxy-phenyl)-pyridin-3-yl]-1-(2-morpholin-4-yl-ethyl)-pyrrolo[2,3]pyridine;
- 15 3-[5-(4-methoxy-phenyl)-pyridin-3-yl]-1-(2-piperidin-1-yl-ethyl)-pyrrolo[2,3]pyridine;
- 3-[5-(4-methoxy-phenyl)-pyridin-3-yl]-1-(3-piperidin-1-yl-propyl)-pyrrolo[2,3]pyridine;
- 20 dimethyl-{3-[3-(5-(4-methoxy-phenyl)-pyridin-3-yl)-pyrrolo[2,3]pyridin-1-yl]-propyl}-amine;
- 3-[5-(4-methoxy-phenyl)-pyridin-3-yl]-1-(1-methyl-piperidin-3-ylmethyl)-pyrrolo[2,3]pyridine;
- 3-[5-(4-methoxy-phenyl)-pyridin-3-yl]-1-[3-(4-methyl-piperazin-1-yl)-propyl]-pyrrolo[2,3]pyridine;
- 25 dimethyl-{2-[3-(5-(4-methoxy-phenyl)-1-pyridin-3-yl)-pyrrolo[2,3]pyridin-1-yl]-propyl}-amine;
- dimethyl-{2-methyl-3-[3-(5-(4-methoxy-phenyl)-pyridin-3-yl)-pyrrolo[2,3]pyridin-1-yl]-propyl}-amine;
- 30 1-{2-[3-(5-(4-methoxy-phenyl)-pyridin-3-yl)-pyrrolo[2,3]pyridin-1-yl]-ethyl}-piperidine-4-carbonitrile;

- 3-[5-(3-chloro-phenyl)-pyridin-3-yl]-indole;  
3-[5-(3-chloro-phenyl)-pyridin-3-yl]-1-(2-morpholin-4-yl-ethyl)-indole;  
3-[5-(3-chloro-phenyl)-pyridin-3-yl]-1-(2-piperidin-1-yl-ethyl)-indole;  
3-[5-(3-chloro-phenyl)-pyridin-3-yl]-1-(3-piperidin-1-yl-propyl)-indole;  
5 dimethyl-{3-[3-(5-(3-chloro-phenyl)-pyridin-3-yl)-indol-1-yl]-propyl}-  
amine;  
3-[5-(3-chloro-phenyl)-pyridin-3-yl]-1-(1-methyl-piperidin-3-ylmethyl)-  
indole;  
3-[5-(3-chloro-phenyl)-pyridin-3-yl]-1-[3-(4-methyl-piperazin-1-yl)-propyl]-  
10 indole;  
dimethyl-{2-[3-(5-(3-chloro-phenyl)-l-pyridin-3-yl)-indol-1-yl]-propyl}-  
amine;  
dimethyl-{2-methyl-3-[3-(5-(3-chloro-phenyl)-pyridin-3-yl)-indol-1-yl]-  
propyl}-amine;  
15 1-{2-[3-(5-(3-chloro-phenyl)-pyridin-3-yl)-indol-1-yl]-ethyl}-piperidine-4-  
carbonitrile;  
3-[5-(3-chloro-phenyl)-pyridin-3-yl]-5-methoxy-indole;  
3-[5-(3-chloro-phenyl)-pyridin-3-yl]-5-methoxy-1-(2-morpholin-4-yl-ethyl)-  
indole;  
20 3-[5-(3-chloro-phenyl)-pyridin-3-yl]-5-methoxy-1-(2-piperidin-1-yl-ethyl)-  
indole;  
3-[5-(3-chloro-phenyl)-pyridin-3-yl]-5-methoxy-1-(3-piperidin-1-yl-propyl)-  
indole;  
dimethyl-{3-[3-(5-(3-chloro-phenyl)-pyridin-3-yl)-5-methoxy-indol-1-yl]-  
25 propyl}-amine;  
3-[5-(3-chloro-phenyl)-pyridin-3-yl]-1-(1-methyl-piperidin-3-ylmethyl)-5-  
methoxy-indole;  
3-[5-(3-chloro-phenyl)-pyridin-3-yl]-1-[3-(4-methyl-piperazin-1-yl)-propyl]-  
5-methoxy-indole;  
30 dimethyl-{2-[3-(5-(3-chloro-phenyl)-l-pyridin-3-yl)-5-methoxy-indol-1-yl]-  
propyl}-amine;

- dimethyl-{2-methyl-3-[3-(5-(3-chloro-phenyl)-pyridin-3-yl)-5-methoxy-indol-1-yl]-propyl}-amine;  
1-{2-[3-(5-(3-chloro-phenyl)-pyridin-3-yl)-5-methoxy-indol-1-yl]-ethyl}-piperidine-4-carbonitrile;
- 5 4-chloro-3-[5-(3-chloro-phenyl)-pyridin-3-yl]-indole;  
4-chloro-3-[5-(3-chloro-phenyl)-pyridin-3-yl]-1-(2-morpholin-4-yl-ethyl)-indole;  
4-chloro-3-[5-(3-chloro-phenyl)-pyridin-3-yl]-1-(2-piperidin-1-yl-ethyl)-indole;
- 10 4-chloro-3-[5-(3-chloro-phenyl)-pyridin-3-yl]-1-(3-piperidin-1-yl-propyl)-indole;  
dimethyl-{3-[4-chloro-3-(5-(3-chloro-phenyl)-pyridin-3-yl)-indol-1-yl]-propyl}-amine;  
4-chloro-3-[5-(3-chloro-phenyl)-pyridin-3-yl]-1-(1-methyl-piperidin-3-ylmethyl)-indole;
- 15 4-chloro-3-[5-(3-chloro-phenyl)-pyridin-3-yl]-1-[3-(4-methyl-piperazin-1-yl)-propyl]-indole;  
dimethyl-{2-[4-chloro-3-(5-(3-chloro-phenyl)-1-pyridin-3-yl)-indol-1-yl]-propyl}-amine;
- 20 dimethyl-{2-methyl-3-[4-chloro-3-(5-(3-chloro-phenyl)-pyridin-3-yl)-indol-1-yl]-propyl}-amine;  
1-{2-[4-chloro-3-(5-(3-chloro-phenyl)-pyridin-3-yl)-indol-1-yl]-ethyl}-piperidine-4-carbonitrile;  
5-chloro-3-[5-(3-chloro-phenyl)-pyridin-3-yl]-indole;
- 25 5-chloro-3-[5-(3-chloro-phenyl)-pyridin-3-yl]-1-(2-morpholin-4-yl-ethyl)-indole;  
5-chloro-3-[5-(3-chloro-phenyl)-pyridin-3-yl]-1-(2-piperidin-1-yl-ethyl)-indole;  
5-chloro-3-[5-(3-chloro-phenyl)-pyridin-3-yl]-1-(3-piperidin-1-yl-propyl)-indole;
- 30 indole;

- dimethyl-{3-[5-chloro-3-(5-(3-chloro-phenyl)-pyridin-3-yl)-indol-1-yl]-propyl}-amine;  
5-chloro-3-[5-(3-chloro-phenyl)-pyridin-3-yl]-1-(1-methyl-piperidin-3-ylmethyl)-indole;  
5 5-chloro-3-[5-(3-chloro-phenyl)-pyridin-3-yl]-1-[3-(4-methyl-piperazin-1-yl)-propyl]-indole;  
dimethyl-{2-[5-chloro-3-(5-(3-chloro-phenyl)-1-pyridin-3-yl)-indol-1-yl]-propyl}-amine;  
dimethyl-{2-methyl-3-[5-chloro-3-(5-(3-chloro-phenyl)-pyridin-3-yl)-indol-1-yl]-propyl}-amine;  
10 1-{2-[5-chloro-3-(5-(3-chloro-phenyl)-pyridin-3-yl)-indol-1-yl]-ethyl}-piperidine-4-carbonitrile;  
3-[5-(3-chloro-phenyl)-pyridin-3-yl]-7-methoxy-indole;  
3-[5-(3-chloro-phenyl)-pyridin-3-yl]-7-methoxy-1-(2-morpholin-4-yl-ethyl)-indole;  
15 3-[5-(3-chloro-phenyl)-pyridin-3-yl]-7-methoxy-1-(2-piperidin-1-yl-ethyl)-indole;  
3-[5-(3-chloro-phenyl)-pyridin-3-yl]-7-methoxy-1-(3-piperidin-1-yl-propyl)-indole;  
20 dimethyl-{3-[3-(5-(3-chloro-phenyl)-pyridin-3-yl)-7-methoxy-indol-1-yl]-propyl}-amine;  
3-[5-(3-chloro-phenyl)-pyridin-3-yl]-1-(1-methyl-piperidin-3-ylmethyl)-7-methoxy-indole;  
3-[5-(3-chloro-phenyl)-pyridin-3-yl]-1-[3-(4-methyl-piperazin-1-yl)-propyl]-7-methoxy-indole;  
25 7-methoxy-indole;  
dimethyl-{2-[3-(5-(3-chloro-phenyl)-1-pyridin-3-yl)-7-methoxy-indol-1-yl]-propyl}-amine;  
dimethyl-{2-methyl-3-[3-(5-(3-chloro-phenyl)-pyridin-3-yl)-7-methoxy-indol-1-yl]-propyl}-amine;  
30 1-{2-[3-(5-(3-chloro-phenyl)-pyridin-3-yl)-7-methoxy-indol-1-yl]-ethyl}-piperidine-4-carbonitrile;

- 6-chloro-3-[5-(3-chloro-phenyl)-pyridin-3-yl]-indole;  
6-chloro-3-[5-(3-chloro-phenyl)-pyridin-3-yl]-1-(2-morpholin-4-yl-ethyl)-  
indole;  
6-chloro-3-[5-(3-chloro-phenyl)-pyridin-3-yl]-1-(2-piperidin-1-yl-ethyl)-  
5 indole;  
6-chloro-3-[5-(3-chloro-phenyl)-pyridin-3-yl]-1-(3-piperidin-1-yl-propyl)-  
indole;  
dimethyl-{3-[6-chloro-3-(5-(3-chloro-phenyl)-pyridin-3-yl)-indol-1-yl]-  
propyl}-amine;  
10 6-chloro-3-[5-(3-chloro-phenyl)-pyridin-3-yl]-1-(1-methyl-piperidin-3-  
ylmethyl)-indole;  
6-chloro-3-[5-(3-chloro-phenyl)-pyridin-3-yl]-1-[3-(4-methyl-piperazin-1-  
yl)-propyl]-indole;  
dimethyl-{2-[6-chloro-3-(5-(3-chloro-phenyl)-1-pyridin-3-yl)-indol-1-yl]-  
15 propyl}-amine;  
dimethyl-{2-methyl-3-[6-chloro-3-(5-(3-chloro-phenyl)-pyridin-3-yl)-indol-  
1-yl]-propyl}-amine;  
1-{2-[6-chloro-3-(5-(3-chloro-phenyl)-pyridin-3-yl)-indol-1-yl]-ethyl}-  
piperidine-4-carbonitrile;  
20 3-[5-(3-chloro-phenyl)-pyridin-3-yl]-indole-5-carbonitrile;  
3-[5-(3-chloro-phenyl)-pyridin-3-yl]-1-(2-morpholin-4-yl-ethyl)-indole-5-  
carbonitrile;  
3-[5-(3-chloro-phenyl)-pyridin-3-yl]-1-(2-piperidin-1-yl-ethyl)-indole-5-  
carbonitrile;  
25 3-[5-(3-chloro-phenyl)-pyridin-3-yl]-1-(3-piperidin-1-yl-propyl)-indole-5-  
carbonitrile;  
1-(3-dimethylamino-propyl)-3-[5-(3-chloro-phenyl)-pyridin-3-yl]-indole-5-  
carbonitrile;  
3-[5-(3-chloro-phenyl)-pyridin-3-yl]-1-(1-methyl-piperidin-3-ylmethyl)-  
30 indole-5-carbonitrile;

- 3-[5-(3-chloro-phenyl)-pyridin-3-yl]-1-[3-(4-methyl-piperazin-1-yl)-propyl]-  
indole-5-carbonitrile;  
1-(2-dimethylamino-propyl)-3-[5-(3-chloro-phenyl)-pyridin-3-yl]-indole-5-  
carbonitrile;  
5 1-(1-dimethylamino-2-methyl-propyl)-3-[5-(3-chloro-phenyl)-pyridin-3-yl]-  
indole-5-carbonitrile;  
1-[2-(4-cyano-piperidin-1-yl-ethyl)-3-[5-(3-chloro-phenyl)-pyridin-3-yl]-  
indole-5-carbonitrile;  
3-[5-(3-chloro-phenyl)-pyridin-3-yl]-indole-4-carboxylic acid methyl ester;  
10 3-[5-(3-chloro-phenyl)-pyridin-3-yl]-1-(2-morpholin-4-yl-ethyl)-indole-4-  
carboxylic acid methyl ester;  
3-[5-(3-chloro-phenyl)-pyridin-3-yl]-1-(2-piperidin-1-yl-ethyl)-indole-4-  
carboxylic acid methyl ester;  
3-[5-(3-chloro-phenyl)-pyridin-3-yl]-1-(3-piperidin-1-yl-propyl)-indole-4-  
15 carboxylic acid methyl ester;  
1-(3-dimethylamino-propyl)-3-[5-(3-chloro-phenyl)-pyridin-3-yl]-indole-4-  
carboxylic acid methyl ester;  
3-[5-(3-chloro-phenyl)-pyridin-3-yl]-1-(1-methyl-piperidin-3-ylmethyl)-  
indole-4-carboxylic acid methyl ester;  
20 3-[5-(3-chloro-phenyl)-pyridin-3-yl]-1-[3-(4-methyl-piperazin-1-yl)-propyl]-  
indole-4-carboxylic acid methyl ester;  
1-(2-dimethylamino-propyl)-3-[5-(3-chloro-phenyl)-pyridin-3-yl]-indole-4-  
carboxylic acid methyl ester;  
1-(1-dimethylamino-2-methyl-propyl)-3-[5-(3-chloro-phenyl)-pyridin-3-yl]-  
25 indole-4-carboxylic acid methyl ester;  
1-[2-(4-cyano-piperidin-1-yl-ethyl)-3-[5-(3-chloro-phenyl)-pyridin-3-yl]-  
indole-4-carboxylic acid methyl ester;  
3-[5-(3-chloro-phenyl)-pyridin-3-yl]-pyrrolo[2,3]pyridine;  
3-[5-(3-chloro-phenyl)-pyridin-3-yl]-1-(2-morpholin-4-yl-ethyl)-  
30 pyrrolo[2,3]pyridine;

- 3-[5-(3-chloro-phenyl)-pyridin-3-yl]-1-(2-piperidin-1-yl-ethyl)-  
pyrrolo[2,3]pyridine;  
3-[5-(3-chloro-phenyl)-pyridin-3-yl]-1-(3-piperidin-1-yl-propyl)-pyrrolo[2,3]  
pyridine;  
5 dimethyl-{3-[3-(5-(3-chloro-phenyl)-pyridin-3-yl)-pyrrolo[2,3]pyridin-1-yl]-  
propyl}-amine;  
3-[5-(3-chloro-phenyl)-pyridin-3-yl]-1-(1-methyl-piperidin-3-ylmethyl)-  
pyrrolo[2,3]pyridine;  
3-[5-(3-chloro-phenyl)-pyridin-3-yl]-1-[3-(4-methyl-piperazin-1-yl)-propyl]-  
10 pyrrolo[2,3]pyridine;  
dimethyl-{2-[3-(5-(3-chloro-phenyl)-l-pyridin-3-yl)-pyrrolo[2,3]pyridin-1-  
yl]-propyl}-amine;  
dimethyl-{2-methyl-3-[3-(5-(3-chloro-phenyl)-pyridin-3-yl)-  
pyrrolo[2,3]pyridin-1-yl]-propyl}-amine;  
15 1-(2-[3-(5-(3-chloro-phenyl)-pyridin-3-yl)-pyrrolo[2,3]pyridin-1-yl]-ethyl)-  
piperidine-4-carbonitrile;  
3-[5-(4-chloro-phenyl)-pyridin-3-yl]-indole;  
3-[5-(4-chloro-phenyl)-pyridin-3-yl]-1-(2-morpholin-4-yl-ethyl)-indole;  
3-[5-(4-chloro-phenyl)-pyridin-3-yl]-1-(2-piperidin-1-yl-ethyl)-indole;  
20 3-[5-(4-chloro-phenyl)-pyridin-3-yl]-1-(3-piperidin-1-yl-propyl)-indole;  
dimethyl-{3-[3-(5-(4-chloro-phenyl)-pyridin-3-yl)-indol-1-yl]-propyl}-  
amine;  
3-[5-(4-chloro-phenyl)-pyridin-3-yl]-1-(1-methyl-piperidin-3-ylmethyl)-  
indole;  
25 3-[5-(4-chloro-phenyl)-pyridin-3-yl]-1-[3-(4-methyl-piperazin-1-yl)-propyl]-  
indole;  
dimethyl-{2-[3-(5-(4-chloro-phenyl)-l-pyridin-3-yl)-indol-1-yl]-propyl}-  
amine;  
dimethyl-{2-methyl-3-[3-(5-(4-chloro-phenyl)-pyridin-3-yl)-indol-1-yl]-  
30 propyl}-amine;



- 1-(2-[3-(5-(4-chloro-phenyl)-pyridin-3-yl)-indol-1-yl]-ethyl)-piperidine-4-carbonitrile;
- 3-[5-(4-chloro-phenyl)-pyridin-3-yl]-5-methoxy-indole;
- 3-[5-(4-chloro-phenyl)-pyridin-3-yl]-5-methoxy-1-(2-morpholin-4-yl-ethyl)-
- 5 indole;
- 3-[5-(4-chloro-phenyl)-pyridin-3-yl]-5-methoxy-1-(2-piperidin-1-yl-ethyl)-indole;
- 3-[5-(4-chloro-phenyl)-pyridin-3-yl]-5-methoxy-1-(3-piperidin-1-yl-propyl)-indole;
- 10 dimethyl-{3-[3-(5-(4-chloro-phenyl)-pyridin-3-yl)-5-methoxy-indol-1-yl]-propyl}-amine;
- 3-[5-(4-chloro-phenyl)-pyridin-3-yl]-1-(1-methyl-piperidin-3-ylmethyl)-5-methoxy-indole;
- 3-[5-(4-chloro-phenyl)-pyridin-3-yl]-1-[3-(4-methyl-piperazin-1-yl)-propyl]-
- 15 5-methoxy-indole;
- dimethyl-{2-[3-(5-(4-chloro-phenyl)-1-pyridin-3-yl)-5-methoxy-indol-1-yl]-propyl}-amine;
- dimethyl-{2-methyl-3-[3-(5-(4-chloro-phenyl)-pyridin-3-yl)-5-methoxy-indol-1-yl]-propyl}-amine;
- 20 1-(2-[3-(5-(4-chloro-phenyl)-pyridin-3-yl)-5-methoxy-indol-1-yl]-ethyl)-piperidine-4-carbonitrile;
- 4-chloro-3-[5-(4-chloro-phenyl)-pyridin-3-yl]-indole;
- 4-chloro-3-[5-(4-chloro-phenyl)-pyridin-3-yl]-1-(2-morpholin-4-yl-ethyl)-indole;
- 25 4-chloro-3-[5-(4-chloro-phenyl)-pyridin-3-yl]-1-(2-piperidin-1-yl-ethyl)-indole;
- 4-chloro-3-[5-(4-chloro-phenyl)-pyridin-3-yl]-1-(3-piperidin-1-yl-propyl)-indole;
- dimethyl-{3-[4-chloro-3-(5-(4-chloro-phenyl)-pyridin-3-yl)-indol-1-yl]-
- 30 propyl}-amine;

- 4-chloro-3-[5-(4-chloro-phenyl)-pyridin-3-yl]-1-(1-methyl-piperidin-3-ylmethyl)-indole;  
4-chloro-3-[5-(4-chloro-phenyl)-pyridin-3-yl]-1-[3-(4-methyl-piperazin-1-yl)-propyl]-indole;  
5 dimethyl-{2-[4-chloro-3-(5-(4-chloro-phenyl)-1-pyridin-3-yl)-indol-1-yl]-propyl}-amine;  
dimethyl-{2-methyl-3-[4-chloro-3-(5-(4-chloro-phenyl)-pyridin-3-yl)-indol-1-yl]-propyl}-amine;  
1-{2-[4-chloro-3-(5-(4-chloro-phenyl)-pyridin-3-yl)-indol-1-yl]-ethyl}-  
10 piperidine-4-carbonitrile;  
5-chloro-3-[5-(4-chloro-phenyl)-pyridin-3-yl]-indole;  
5-chloro-3-[5-(4-chloro-phenyl)-pyridin-3-yl]-1-(2-morpholin-4-yl-ethyl)-indole;  
5-chloro-3-[5-(4-chloro-phenyl)-pyridin-3-yl]-1-(2-piperidin-1-yl-ethyl)-  
15 indole;  
5-chloro-3-[5-(4-chloro-phenyl)-pyridin-3-yl]-1-(3-piperidin-1-yl-propyl)-indole;  
dimethyl-{3-[5-chloro-3-(5-(4-chloro-phenyl)-pyridin-3-yl)-indol-1-yl]-propyl}-amine;  
20 5-chloro-3-[5-(4-chloro-phenyl)-pyridin-3-yl]-1-(1-methyl-piperidin-3-ylmethyl)-indole;  
5-chloro-3-[5-(4-chloro-phenyl)-pyridin-3-yl]-1-[3-(4-methyl-piperazin-1-yl)-propyl]-indole;  
dimethyl-{2-[5-chloro-3-(5-(4-chloro-phenyl)-1-pyridin-3-yl)-indol-1-yl]-  
25 propyl}-amine;  
dimethyl-{2-methyl-3-[5-chloro-3-(5-(4-chloro-phenyl)-pyridin-3-yl)-indol-1-yl]-propyl}-amine;  
1-{2-[5-chloro-3-(5-(4-chloro-phenyl)-pyridin-3-yl)-indol-1-yl]-ethyl}-piperidine-4-carbonitrile;  
30 3-[5-(4-chloro-phenyl)-pyridin-3-yl]-7-methoxy-indole;

- 3-[5-(4-chloro-phenyl)-pyridin-3-yl]-7-methoxy-1-(2-morpholin-4-yl-ethyl)-indole;
- 3-[5-(4-chloro-phenyl)-pyridin-3-yl]-7-methoxy-1-(2-piperidin-1-yl-ethyl)-indole;
- 5 3-[5-(4-chloro-phenyl)-pyridin-3-yl]-7-methoxy-1-(3-piperidin-1-yl-propyl)-indole;
- dimethyl-{3-[3-(5-(4-chloro-phenyl)-pyridin-3-yl)-7-methoxy-indol-1-yl]-propyl}-amine;
- 3-[5-(4-chloro-phenyl)-pyridin-3-yl]-1-(1-methyl-piperidin-3-ylmethyl)-7-methoxy-indole;
- 10 3-[5-(4-chloro-phenyl)-pyridin-3-yl]-1-[3-(4-methyl-piperazin-1-yl)-propyl]-7-methoxy-indole;
- dimethyl-{2-[3-(5-(3-chloro-phenyl)-1-pyridin-3-yl)-7-methoxy-indol-1-yl]-propyl}-amine;
- 15 dimethyl-{2-methyl-3-[3-(5-(4-chloro-phenyl)-pyridin-3-yl)-7-methoxy-indol-1-yl]-propyl}-amine;
- 1-{2-[3-(5-(4-chloro-phenyl)-pyridin-3-yl)-7-methoxy-indol-1-yl]-ethyl}-piperidine-4-carbonitrile;
- 6-chloro-3-[5-(4-chloro-phenyl)-pyridin-3-yl]-indole;
- 20 6-chloro-3-[5-(4-chloro-phenyl)-pyridin-3-yl]-1-(2-morpholin-4-yl-ethyl)-indole;
- 6-chloro-3-[5-(4-chloro-phenyl)-pyridin-3-yl]-1-(2-piperidin-1-yl-ethyl)-indole;
- 6-chloro-3-[5-(4-chloro-phenyl)-pyridin-3-yl]-1-(3-piperidin-1-yl-propyl)-indole;
- 25 dimethyl-{3-[6-chloro-3-(5-(4-chloro-phenyl)-pyridin-3-yl)-indol-1-yl]-propyl}-amine;
- 6-chloro-3-[5-(4-chloro-phenyl)-pyridin-3-yl]-1-(1-methyl-piperidin-3-ylmethyl)-indole;
- 30 6-chloro-3-[5-(4-chloro-phenyl)-pyridin-3-yl]-1-[3-(4-methyl-piperazin-1-yl)-propyl]-indole;


- dimethyl-{2-[6-chloro-3-(5-(4-chloro-phenyl)-1-pyridin-3-yl)-indol-1-yl]-propyl}-amine;
- dimethyl-{2-methyl-3-[6-chloro-3-(5-(4-chloro-phenyl)-pyridin-3-yl)-indol-1-yl]-propyl}-amine;
- 5 1-{2-[6-chloro-3-(5-(4-chloro-phenyl)-pyridin-3-yl)-indol-1-yl]-ethyl}-piperidine-4-carbonitrile;
- 3-[5-(4-chloro-phenyl)-pyridin-3-yl]-indole-5-carbonitrile;
- 3-[5-(4-chloro-phenyl)-pyridin-3-yl]-1-(2-morpholin-4-yl-ethyl)-indole-5-carbonitrile;
- 10 3-[5-(4-chloro-phenyl)-pyridin-3-yl]-1-(2-piperidin-1-yl-ethyl)-indole-5-carbonitrile;
- 3-[5-(4-chloro-phenyl)-pyridin-3-yl]-1-(3-piperidin-1-yl-propyl)-indole-5-carbonitrile;
- 1-(3-dimethylamino-propyl)-3-[5-(4-chloro-phenyl)-pyridin-3-yl]-indole-5-
- 15 carbonitrile;
- 3-[5-(4-chloro-phenyl)-pyridin-3-yl]-1-(1-methyl-piperidin-3-ylmethyl)-indole-5-carbonitrile;
- 3-[5-(4-chloro-phenyl)-pyridin-3-yl]-1-[3-(4-methyl-piperazin-1-yl)-propyl]-indole-5-carbonitrile;
- 20 1-(2-dimethylamino-propyl)-3-[5-(4-chloro-phenyl)-pyridin-3-yl]-indole-5-carbonitrile;
- 1-(1-dimethylamino-2-methyl-propyl)-3-[5-(4-chloro-phenyl)-pyridin-3-yl]-indole-5-carbonitrile;
- 1-[2-(4-cyano-piperidin-1-yl-ethyl)-3-[5-(4-chloro-phenyl)-pyridin-3-yl]-
- 25 indole-5-carbonitrile;
- 3-[5-(4-chloro-phenyl)-pyridin-3-yl]-indole-4-carboxylic acid methyl ester;
- 3-[5-(4-chloro-phenyl)-pyridin-3-yl]-1-(2-morpholin-4-yl-ethyl)-indole-4-carboxylic acid methyl ester;
- 3-[5-(4-chloro-phenyl)-pyridin-3-yl]-1-(2-piperidin-1-yl-ethyl)-indole-4-
- 30 carboxylic acid methyl ester;

- 3-[5-(4-chloro-phenyl)-pyridin-3-yl]-1-(3-piperidin-1-yl-propyl)-indole-4-carboxylic acid methyl ester;
- 1-(3-dimethylamino-propyl)-3-[5-(4-chloro-phenyl)-pyridin-3-yl]-indole-4-carboxylic acid methyl ester;
- 5 3-[5-(4-chloro-phenyl)-pyridin-3-yl]-1-(1-methyl-piperidin-3-ylmethyl)-indole-4-carboxylic acid methyl ester;
- 3-[5-(4-chloro-phenyl)-pyridin-3-yl]-1-[3-(4-methyl-piperazin-1-yl)-propyl]-indole-4-carboxylic acid methyl ester;
- 1-(2-dimethylamino-propyl)-3-[5-(4-chloro-phenyl)-pyridin-3-yl]-indole-4-
- 10 carboxylic acid methyl ester;
- 1-(1-dimethylamino-2-methyl-propyl)-3-[5-(4-chloro-phenyl)-pyridin-3-yl]-indole-4-carboxylic acid methyl ester;
- 1-[2-(4-cyano-piperidin-1-yl-ethyl)-3-[5-(4-chloro-phenyl)-pyridin-3-yl]-indole-4-carboxylic acid methyl ester;
- 15 3-[5-(4-chloro-phenyl)-pyridin-3-yl]-pyrrolo[2,3]pyridine;
- 3-[5-(4-chloro-phenyl)-pyridin-3-yl]-1-(2-morpholin-4-yl-ethyl)-pyrrolo[2,3]pyridine;
- 20 3-[5-(4-chloro-phenyl)-pyridin-3-yl]-1-(2-piperidin-1-yl-ethyl)-pyrrolo[2,3]pyridine;
- 3-[5-(4-chloro-phenyl)-pyridin-3-yl]-1-(3-piperidin-1-yl-propyl)-pyrrolo[2,3]pyridine; dimethyl-{3-[3-(5-(4-chloro-phenyl)-pyridin-3-yl)-pyrrolo[2,3]pyridin-1-yl]-propyl}-amine;
- 3-[5-(4-chloro-phenyl)-pyridin-3-yl]-1-(1-methyl-piperidin-3-ylmethyl)-pyrrolo[2,3]pyridine;
- 25 3-[5-(4-chloro-phenyl)-pyridin-3-yl]-1-[3-(4-methyl-piperazin-1-yl)-propyl]-pyrrolo[2,3]pyridine ;
- dimethyl-{2-[3-(5-(4-chloro-phenyl)-1-pyridin-3-yl)-pyrrolo[2,3]pyridin-1-yl]-propyl}-amine;
- dimethyl-{2-methyl-3-[3-(5-(4-chloro-phenyl)-pyridin-3-yl)-pyrrolo[2,3]pyridin-1-yl]-propyl}-amine; and
- 30

1-{2-[3-(5-(4-chloro-phenyl)-pyridin-3-yl)-pyrrolo[2,3]pyridin-1-yl]-ethyl}-piperidine-4-carbonitrile.


10. A compound selected from the group consisting of:

5




1-[3-(4-methyl-piperazin-1-yl)-propyl]-3-(5-thiophen-3-yl-pyridin-3-yl)-1H-indole;

10




5-chloro-1-[3-(4-methyl-piperazin-1-yl)-propyl]-3-(5-thiophen-3-yl-pyridin-3-yl)-1H-indole;

15




1-[3-(4-methyl-piperazin-1-yl)-propyl]-3-(5-thiophen-3-yl-yl-pyridin-3-yl)-1-*H*-indole-5-carbonitrile;

5




5-methoxy-1-[3-(4-methyl-piperazin-1-yl)-propyl]-3-(5-thiophen-3-yl-pyridin-3-yl)-1*H*-indole;

10



1-(3-piperidin-1-yl-propyl)-3-(5-thiophen-3-yl-pyridin-3-yl)-1*H*-indole; and



1-(2-morpholin-4-yl-ethyl)-3-(5-thiophen-3-yl-pyridin-3-yl)-1H-indole.

- 5                    11.    A pharmaceutical composition which is comprised of a compound in accordance with claim 1 and a pharmaceutically acceptable carrier.
- 10                   12.    A method of treating or preventing cancer in a mammalian patient which is comprised of administering to said patient a therapeutically effective amount of a compound of claim 1.
- 15                   13.    A method of treating or preventing cancer in accordance with claim 11 wherein the cancer is selected from cancer of the brain, cancer of the genitourinary tract, cancer of the lymphatic system, cancer of the stomach, cancer of the larynx and cancer of the lung.
- 20                   14.    A method in accordance with claim 12 wherein the cancer is selected from histiocytic lymphoma, lung adenocarcinoma, small cell lung cancers, pancreatic cancer, glioblastomas and breast carcinoma.
- 25                   15.    A method of treating or preventing a disease in which neoangiogenesis is implicated, which is comprised of administering to a



mammalian patient in need of such treatment a therapeutically effective amount of a compound of Claim 1.

16. A method in accordance with claim 15 wherein the  
5 disease is an ocular disease.

17. A method of treating or preventing retinal  
vascularization which is comprised of administering to a mammalian  
patient in need of such treatment a therapeutically effective amount of a  
10 compound of claim 1.

18. A method of treating or preventing diabetic  
retinopathy which is comprised of administering to a mammalian  
patient in need of such treatment a therapeutically effective amount of a  
15 compound of claim 1.

19. A method of treating or preventing age-related  
macular degeneration which is comprised of administering to a  
mammalian patient in need of such treatment a therapeutically effective  
20 amount of a compound of claim 1.

20. A method of treating or preventing inflammatory  
diseases which is comprised of administering to a mammalian patient  
in need of such treatment a therapeutically effective amount of a  
25 compound of claim 1.

21. A method according to claim 20 wherein the  
inflammatory disease is selected from rheumatoid arthritis, psoriasis,  
contact dermatitis and delayed hypersensitivity reactions.  
30

22. A method for inhibiting tyrosine kinase which comprises administering to a mammalian patient in need of such treatment a therapeutically effective amount of a compound of claim 1.

5 23. A process for making a pharmaceutical composition which comprises combining the compound of Claim 1 and a pharmaceutically acceptable carrier.

10 24. A pharmaceutical composition made by combining the compound of Claim 1 and a pharmaceutically acceptable carrier.

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US00/01006

## A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : Please See Extra Sheet.

US CL : Please See Extra Sheet.

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : Please See Extra Sheet.

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

CAS ONLINE structure search

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 98/29408 A1 (NIKKEN CHEMICALS CO., LTD.) 09 July 1998, whole document.	1-4
X	EP 0 643 059 A1 (PFIZER LIMITED) 15 March 1995, whole document.	1-4
X	OHKURA et al. Photo and thermally induced reaction of 3- and 4-fluoropyridines wit the indole 1-anion. Heterocycles. 1990, Vol. 31, No. 10, pages 1833-1836, whole document.	1-4
Y	FRIDERICHs et al. Synthesis of the Isomeric 3-(Pyridyl)-and 3-(Piperidyl)-5-hydroxyindoles. Arch. Pharm. September 1975, Vol. 308, No. 9, pages 663-674, whole document.	5 and 8

☒ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
*A* document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
*E* earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*g* document member of the same patent family
*O* document referring to an oral disclosure, use, exhibition or other means	
*P* document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

06 APRIL 2000

Date of mailing of the international search report

26 APR 2000

Name and mailing address of the ISA/US  
Commissioner of Patents and Trademarks  
Box PCT  
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

HONG LIU

Telephone No. (703) 308-1235

Form PCT/ISA/210 (second sheet) (July 1998)\*

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US00/01006

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	SCHUT et al. 2-Tetrahydropyridylindoles as histamine and serotonin antagonists. J. Med. Chem. 1970, Vol. 13, pages 394-397, see entire document.	1-4

Form PCT/ISA/210 (continuation of second sheet) (July 1998)\*

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US00/01006

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
  
2. ☐ Claims Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
  
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

Please See Extra Sheet.

1. ☒ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
  
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.  
☒ No protest accompanied the payment of additional search fees.

Form PCT/ISA/210 (continuation of first sheet(1)) (July 1998)\*

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US00/01006

A. CLASSIFICATION OF SUBJECT MATTER:  
IPC (7): C07D 471/04, 401/14; A61K 31/4439,  
31/444

A. CLASSIFICATION OF SUBJECT MATTER:  
US CL : 546/13, 277.4; 514/300, 338, 339

B. FIELDS SEARCHED  
Minimum documentation searched  
Classification System:

U.S. 546/13, 277.4; 514/300, 338, 339

## BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING

This ISA found multiple inventions as follows:

This application contains the following inventions or groups of inventions which are not so linked as to form a single inventive concept under PCT Rule 13.1. In order for all inventions to be searched, the appropriate additional search fees must be paid.

Group I, claims 1-22, drawn to the compounds of formula I, the compositions, and methods of use of the compounds wherein one of X, Y, Z is N and W is CH.  
Group II, claims 1-3, 9, and 11-24, drawn to the compounds of formula I, compositions, and methods of use of the compounds wherein one of X, Y, Z is N and W is N.  
Group III, claims 1, 2, and 11-24, drawn to the compounds of formula I, the compositions, and methods of use of the compounds wherein each of X, Y, Z is CH, W is CH.  
Group IV, claims 1, 2, and 11-24, drawn to the compounds of formula I, the compositions, and methods of use of the compounds wherein each of X, Y, Z is CH, W is N.  
Group V, claims 1 and 11-22, drawn to the compounds of formula I, the compositions, and methods of use of the compounds wherein two of X, Y, Z are N.  
Group VI, claims 1 and 11-22, drawn to the compounds of formula I, the compositions, and methods of use of the compounds wherein all of X, Y, Z are N.

The inventions listed as Groups I-VI do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: When one of X, Y, Z is N, the ring structure is a pyridine. When two of X, Y, Z are N, the ring structure is a 1,2-diazine or 1,3-diazine. When all of X, Y, and Z are N, the ring structure is a triazine. Likewise, when W is CH the bicyclic ring is indole. When W is N, the bicyclic ring is pyrrole[2,3]pyridine. Thus Groups I-VI are directed to structurally dissimilar compounds such that the variable core created by varying the definitions of the formula do not belong to a recognized class of chemical compounds in the art, and references anticipating one invention would not render obvious the others. One skilled in the art would not consider such diverse structures as functional equivalents of each other.